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Abstract 
Follicular lymphoma (FL) is an incurable indolent non-Hodgkin’s lymphoma that is both 
biologically and clinically heterogeneous. Despite the loss of one immunoglobulin allele 
through the t14;18 translocation and ongoing somatic hypermutation (SHM) of the 
immunoglobulin heavy chain variable region genes (IGHV), all detectable tumour subclones 
retain functional expression of the surface immunoglobulin throughout disease, resulting in 
thousands of tumour subclones displaying distinct but clonally related IGHV sequences. This 
retention suggests a tumour dependence on signalling through the B cell receptor (BCR). 
 
>90% of FL cases contain N-glycosylation (N-gly) motifs in their IGHV which are acquired 
through SHM. Motifs are rarely found in normal somatically mutated B cells, indicative of a 
pathogenic function. Mannoses attach to motifs and activate BCR signalling pathways 
following engagement with lectins DC-SIGN and MR, expressed by microenvironmental 
immune cells. This novel interaction could represent a critical mechanism by which tumour 
cells survive in the hostile microenvironment.  
 
Utilising a next-generation sequencing approach, we determined using temporal tumour 
samples from a diverse group of patients the behaviour of N-gly motifs during tumour 
evolution and progression to elucidate their importance in lymphomagenesis. Remarkably, 
we observed conservation of N-gly motif sites in >97% of subclone populations within and 
across disease events of all patients, inferring motifs are an early and stable event of 
pathogenesis. Rare motif negative subclones were presumably lost or negligible from 
successive events in contrast to motif positive subclones that were able to migrate between 
anatomical sites. This positive selection suggests an ongoing reliance of N-gly sites during 
disease progression, despite the changing genomic landscape of tumour clones.  
 
Interrogation of the microenvironmental landscape through novel, multiplex phenotyping 
analysis provided new insight into DC-SIGN and MR expression on immune cells of healthy 
and FL derived lymph nodes. A greater population of follicular dendritic cells, macrophages 
and M2 macrophages within tumour lymph nodes expressed a MR+ and DCSIGN+MR+ 
phenotype, indicating a remodelling of the microenvironment in disease that could be 
contributed by the mannose- lectin interaction. Targeting motifs or the inferred mannose-
lectin interaction may lead to therapeutic benefit. 
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Chapter 1: INTRODUCTION 
 
 
1.1 Disease overview 
 
Follicular lymphoma (FL) is the second most common non-Hodgkin’s lymphoma (NHL) in 
Western Europe and the United States following diffuse large B cell lymphoma (DLBCL). 
The disease represents 70% of all indolent lymphomas with an increasing incidence in 
Western countries over the last two decades, rising from 2 in 100,000 people in the 
1950s to 5 in 100,000 people in 2016 (Campo et al., 2011, Mounier et al., 2015). The 
majority of patients are diagnosed at an advanced stage due to lack of symptoms, with 
lymphadenopathy being the first reason for seeking medical assistance. Although there 
is no preponderance regarding sex, there are variations in incidence rates between 
ethnic groups and geographical location, the reason for this remaining unknown. The 
median age at diagnosis is 65 years (Junlen et al., 2015), highlighting FL as a disease 
strongly linked to age. Although rare, FL can manifest in young adults and children which 
is now recognised as a separate disease entity called paediatric-type FL (PTFL) due to 
being both histologically and clinically distinct (Pinto et al., 1990, Winberg et al., 1981, 
Lorsbach et al., 2002, Araf and Fitzgibbon, 2016). 
The clinical course of FL is heterogeneous, with the majority of patients having a high 
response rate to first-line therapy followed by several cycles of relapse and remission 
with each disease free episode becoming progressively shorter. These patients usually 
follow an indolent course, surviving up to twenty years following diagnosis. However, a 
subset of patients (20-25%) follow an aggressive disease course in which progression 
occurs within two years of treatment or the disease transforms to a high-grade 
lymphoma (Casulo et al., 2015, Casulo, 2016). For these patients, the prognostic outlook 
is relatively very poor despite an availability of several immunotherapeutic strategies. 
Predicting which patients would fall into this high-risk group remains an ongoing area of 
research (Huet et al., 2018b) in order to deliver a tailored therapeutic strategy and enrol 
patients most likely to benefit from a clinical trial  (Weigert and Weinstock, 2017). 
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Although we are beginning to unravel the biological processes underpinning the disease 
and targeting them with novel immunomodulatory therapeutic approaches, the disease 
effectively remains incurable.  
 
1.2 Clinical presentation and diagnosis 
 
The majority of patients present with lymphadenopathy in the cervical, axillary, inguinal 
and/or femoral regions. Rarely are tumours localised to one site and therefore 
widespread dissemination of disease is a common finding. Adenopathy waxes and 
wanes spontaneously. Apart from this enlargement, the majority of patients are 
asymptomatic. Less than 20% of patients display ‘B symptoms’ including night sweats, 
fever and/or weight loss. Despite the large tumour burden, increased serum lactate 
dehydrogenase are observed in less than 25% of patients. Extra-nodal involvement is 
common with liver and bone marrow involvement seen in 50% and 80% of cases, 
respectively.  
A biopsy taken from the affected lymph node is preferably used in FL diagnosis, with 
core needle biopsy reserved for cases with difficult to access nodes (e.g. retroperitoneal 
nodes). Histologic analysis typically reveals a nodular growth pattern with abolished 
nodal architecture, including an ill-defined or absent mantle zone. FL is composed of 
follicular centre cells, named centrocytes and centroblasts. Grading, according to WHO 
classification, is based on the number of centroblasts counted per high-powered field 
(hpf), with an higher count indicative of a more aggressive clinical course (Table 1.1). 
Grade 3 is subdivided into group A and B (absence of centrocytes) with 3B resembling 
de novo DLBCL, both histologically and molecularly (Horn et al., 2011, Bosga-Bouwer et 
al., 2003). Because of this marked distinction, grade 3B is likely to be treated similarly to 
DLBCL.  
 
Immunophenotyping of tissue sections is used to identify the disease. Typically, tumour 
cells express pan-B cell markers (IgM, CD19, CD20, CD22 AND CD79a) and germinal 
centre markers, including BCL-6 and CD10. They are negative for CD5 expression which 
is useful in differential diagnosis of low-grade B cell lymphomas (Cossman et al., 1984, 
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Harris et al., 1984, de Leon et al., 1998, Lydyard et al., 1999). Bcl-2 is overexpressed in 
the germinal centres of >90% of patients which is the result of the translocation 
t(14;18)(q32;q21) involving the BCL2 gene and the immunoglobulin heavy chain 
enhancer, discussed in more detail below (Aster and Longtine, 2002). The surface 
immunoglobulin is monoclonal, with malignant cells sharing identical V, D and J genes 
in the variable region of both their heavy and light chains which are readily detected 
through the polymerase chain reaction (PCR). In accordance with their germinal centre 
residence, on-going somatic hypermutation is observed in the variable regions of 
malignant cells, giving rise to a heterogeneous clonal population (Cleary et al., 1986b, 
Bahler et al., 1991). 
 
Grade Definition 
1 0-5 centroblasts/hpf 
2 6-15 centroblasts/hpf 
3A >15 centroblasts/hpf 
  Presence of centrocytes 
3B >15 centroblasts /hpf, sheets of centroblasts 
  Absence of centrocytes 
Table 1.1: WHO classification of FL histological grades. The system is based on the absolute number of 
centroblasts per 40x high powered field (hpf). 
 
 
1.3 Staging and prognostic indicators 
 
Anatomical staging is based on the Ann Arbour classification and describes the number 
of lymph nodes involved, their location and presence of extranodal organ involvement. 
Each stage is subdivided to indicate the absence or presence of B symptoms.  
The clinical outcome for FL patients remains highly variable, with a subset of patients 
having a very poor clinical outcome, associated with histological transformation or 
progression of disease within 2 years of initial therapy (Casulo et al., 2015, Conconi et 
al., 2012). Identifying patients who are in this high-risk group can lead to tailoring of 
therapy and an improved clinical outcome, and therefore developing prognostic tools 
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that stratify patients based on disease-specific features is highly desirable. Follicular 
Lymphoma International Prognostic Index (FLIPI) predicts the outcome of patients 
through five independent adverse prognostic risk factors (9) (Table 1.2). Patients are 
placed into three risk groups, based on the number of risk factors they present. Because 
FLIPI was based on retrospective analysis before the introduction of widespread 
chemotherapy, FLIPI2 (10) was introduced which revised the adverse prognostic risk 
factors (Table 1.2) and is based on a progression-free survival (PFS) endpoint. However, 
the utility of the FLIPI-2 model in a clinical setting remains undetermined, with FLIPI 
continuing to be a useful prognostic model in the Rituximab era. 
M7FLIPI is the first prognostic score in lymphoma to incorporate both genetic and 
clinical factors to identify high risk patients treated with standard therapy. It consists of 
the FLIPI risk factors, Eastern Cooperative Oncology Group performance status, and 
mutations in seven genes involved in epigenetic regulation (EZH2, EP300, and CREBBP), 
transcription (FOXO1, MEF2B), nucleosome remodelling (ARID1A), and BCR signalling 
(CARD11). The risk stratification is more closely associated with outcome compared to 
the clinical or genetic predictors alone. 
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Independent Risk factors Risk group No. of factors Outcome, % 
   
5-y OS 10-y OS 
FLIPI                                                         
Low 0-1 91 71  Age ≥60 y 
 Ann Arbor Stage III/IV 
Intermediate 2 78 51  Haemoglobin <12 g/dL 
 LDH elevated 
High 3-5 53 36  >4 nodal sites 
   
3-y PFS 5-y PFS 
FLIPI-2 
Low 0 91 80  Age ≥60 y 
 B2M elevated 
Intermediate 1-2 69 51  Haemoglobin < 2 g/dL 
 BM involvement 
High 3-5 51 19 Lymph node diameter >6 cm 
Table 1.2: FLIPI and FLIPI-2 prognostic indexes. FLIPI-2 was created in the rituximab therapy era and 
prognosis is based on progression-free survival rather than overall survival. FLIPI-2 also modified the risk 
factors of FLIPI, including beta 2 microglobulin (B2M) level, bone marrow (BM) involvement and lymph 
node diameter of >6cm. 
 
1.4 Management strategies  
 
Therapeutic choices are influenced by a range of factors including stage of disease, 
tumour burden, comorbidities, performance status, age and toxicity concerns. The 
Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria (Brice et al., 1997) can help 
identify patients who are at higher risk for rapid disease progression and therefore 
require immediate therapy. 
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1.4.1 Initial treatment of early stage FL 
 
Less than 10% of patients are diagnosed with Stage I/II disease and due to this low 
number, no randomised studies regarding optimal management exist. However, 
targeted radiotherapy to the disease site has high curative potential and is generally the 
treatment of choice. 10 year overall survival rates based on this treatment modality 
alone is ~ 80% with a median survival of ~19 years (Guadagnolo et al., 2006). The 
recommended dose is currently 24 Gy with higher doses offering no benefit with regards 
to progression-free survival (PFS) or overall survival (OS) (Lowry et al., 2011). 
 
1.4.2 Initial treatment of advanced stage FL 
 
The majority of FL patients have advanced disease at diagnosis with either a low or high 
tumour burden, as assessed through the GELF criteria. For this group, the disease cannot 
be cured by conventional therapies, with the emphasis of treatment being to control 
symptoms and extend remission lengths and OS. Patients can be symptomatic or 
asymptomatic, which influences treatment decisions. 
 
Patients with asymptomatic, low tumour burden generally undergo a watch and wait 
(W/W) approach. The patient is observed for signs of vital organ compromise and 
infiltration, development of cytopenias, B symptoms or rapid disease progression. 
Randomised phase III studies revealed that patients undergoing Rituximab induction 
followed by 2 years of rituximab maintenance had a significantly longer PFS when 
compared to the W/W group. However, there was no difference in OS between the two 
groups, maintaining W/W as a reasonable approach, which shields patients from the 
toxic effects of chemotherapy. However, Rituximab may be beneficial to a subset of 
patients who have coping issues and prefers a longer remission duration with an 
understanding of the efficacy/toxicity trade-off. 
 
Patients with symptomatic, low tumour burden are first examined for alternative 
explanations for their symptoms. If no other cause is ascertained, single agent Rituximab 
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is used, particularly in older patients and those with co-morbidities. Rituximab based 
chemotherapy would likely benefit younger and fitter patients.  
 
Patients with symptomatic, high tumour burden usually require immediate therapy. The 
inclusion of Rituximab to a variety of combination chemotherapy has been a 
considerable therapeutic advance in FL treatment as evidenced by improved response 
rates (RR), PFS, and OS (Hiddemann et al., 2005, Marcus et al., 2008, Herold et al., 2003). 
Rituximab is a chimeric anti-CD20 monoclonal antibody with proposed mechanisms of 
action including elicitation of antibody-dependent cellular cytotoxicity (ADCC) and 
complement mediated cytotoxicity following binding to CD20 on the B cell surface 
(Smith, 2003). Chemotherapy has a less targeted mechanism of action, with the focus 
being on interrupting DNA synthesis and cell division processes (Table 1.3).  To evaluate 
which chemotherapy was optimal for first line treatment of advanced stage FL, R-CHOP 
(rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) treatment was 
compared to R-CVP (rituximab, cyclophosphamide, vincristine, prednisolone) and R-FM 
(rituximab, fludarabine and mitoxantrone) (Federico et al., 2013). R-CHOP and R-FM had 
a better time to treatment failure (TTF) and PFS than R-CVP. However, R-FM was 
associated with a higher toxicity risk profile compared to R-CHOP and R-CVP.  Yet, the 
three year OS rate for all categories was 95%, resulting in a lack of consensus on the 
choice of standard chemotherapy. In a German study group, R-CHOP was compared to 
bendamustine plus rituximab (BR) in a phase III trial in 513 advanced stage FL patients. 
BR had superior toxicity profiles and PFS at 45 months (Rummel et al., 2013). In the 
Bright study, BR was found to be non-inferior to R-CHOP or R-CVP in treatment naïve 
patients, measured by complete response rate (CRR) and overall response rate (ORR) 
(Flinn et al., 2014), establishing BR as a standard frontline therapy for indolent NHLs in 
North America and parts of Europe (Morschhauser et al., 2011, Rummel et al., 2013). 
The use of maintenance rituximab is individualised as although it improves the 2 year 
PFS, there are no benefits regarding OS (Salles et al., 2011). 
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Chemotherapy agent Mechanism of action 
Cyclophosphamide Alkylating agent. Attachment of alkyl groups to DNA bases, 
preventing DNA synthesis 
Doxorubicin Anthracycline. Inhibits topoisomerase II activity 
Vincristine Vinca alkaloid. Binds to microtubular proteins of the mitotic 
spindle causing mitotic arrest at metaphase 
Prednisolone Glucocorticoid. Mediate pro-apoptotic pathways through 
transcriptional activation of the Bim protein 
Fludarabine Inhibits DNA synthesis by  inhibiting DNA polymerase alpha, 
ribonucleotide reductase and DNA primase 
Mitoxantrone DNA intercalating agent causing strand breaks. Inhibitor of 
toposiomerase II 
Bendamustine Alkylating agent. Causes intra- and inter-strand crosslinks 
between DNA bases resulting in cell death 
Table 1.3: Chemotherapy agents used in combination with Rituximab. 
 
1.4.3 Treatment of relapsed FL 
 
Despite the long remission and high response rates to first line treatment, the majority 
of patients inevitably relapse. To determine the extent of disease reoccurrence, a repeat 
biopsy is taken to determine the staging and exclusion of histological transformation.  
Considerations regarding therapy include previous treatments, duration of response, 
health and fitness of the patient and their current symptoms. There are a number of 
options for relapsed FL including radiotherapy for localised disease and for selected 
patients, allogeneic or autologous stem cell transplant. Rituximab with chemotherapy 
was shown to have an enhanced efficacy of treatment of relapsed FL not previously 
treated with rituximab or anthracycline. Patients were randomised to either CHOP or R-
CHOP and those showing response either underwent rituximab maintenance or 
observation (van Oers et al., 2006). The R-CHOP group had an increased overall response 
rate and CR rate compared to CHOP alone with both groups benefiting with an improved 
PFS following rituximab maintenance compared to overall survival. Rituximab added to 
other chemotherapy such as fludarabine, cyclophosphamide, mitoxantrone (R-FCM) 
also showed a clinical benefit in a relapsed setting with superior PFS and OS compared 
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to FCM treatment alone (Forstpointner et al., 2004). Bendamustine as a single agent or 
in combination with rituximab also showed benefit to patients with relapsed FL 
(Friedberg et al., 2008, Robinson et al., 2008, Rummel et al., 2005).  
 
Autologous stem cell transplant (ASCT) has been explored as part of consolidation 
therapy with high dose chemotherapy in high risk and advanced stage FL patients at first 
remission (Benedetti et al., 2013, Gyan et al., 2009, Ladetto et al., 2008, Lenz et al., 2004, 
Sebban et al., 2008) with an improved PFS. However, the lack of advantage regarding OS 
has not merited the use of HSCT as a first line therapy. In a relapsed setting however, 
high dose therapy with ASCT was shown to increase PFS and OS when compared to 
conventional chemotherapy (Schouten et al., 2003) in the pre-rituximab era. Prospective 
studies have indicated the promise of ASCT with rituximab as a treatment in the first 
relapse setting, as indicated by a 90% survival after relapse (SAR) at 5 years (Le Gouill et 
al., 2011, Sebban et al., 2008). Total body irradiation (TBI) as a conditioning regimen is 
not typically used due to a higher incidence of treatment related myelodysplastic 
syndrome/acute myeloid leukaemia compared to chemotherapy based conditioning 
(Montoto et al., 2007a, Darrington et al., 1994), outweighing the benefit of lowered 
relapsed risk. 
 
1.4.4 Novel therapeutics 
 
Targeted therapy exploiting the key mechanisms used by tumour cells has become a 
popular area of research and as a result, a wide range of novel agents are currently in 
development or in a clinical trial. Where available, relapsed/refractory patients requiring 
treatment should be entered into clinical trials evaluating novel therapies. A non-
exhaustive summary of novel agents is provided in Table 1.4. 
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Agent Classification N ORR, % CR, % 
1-y 
PFS, % 
Lenalidomide 
Immunomodulator 
45 53 20 55 
Lenalidomide + 
rituximab 46 76 39 80 
Duvelisib (IPI-145) 
PI3K-δ and PI3K-γ 
inhibitor 13 69 38 80 
Ibrutinib BTK inhibitor 40 28 5 50 
Venetoclax (ABT-
199) BCL-2 inhibitor 29 38 14 40 
Polatuzumab vedotin 
+ rituximab 
Anti-CD79b 
antibody-drug 
conjugate 45 73 33 63 
Obinutuzumab 
Anti-CD20 
monoclonal 
antibody 74 45 12 65 
Table 1.4: Novel agents undergoing evaluation in relapsed FL patients with outcome data provided. N 
(number of patients), ORR (overall response rate), CR (complete remission). Table information taken from 
Kahl & Yang, 2016 (Kahl and Yang, 2016). 
 
1.5 FL variants 
 
Whilst the majority of FL patients display a ‘classical’ nodal FL, less common variants 
occur which are both clinically and pathologically distinct. Below are examples of two 
FL variants. 
 
Paediatric-type FL (PTFL): Typically presents in adolescents and young adults (18-30 
years old), with an occasional presentation in older adults. There is a predominance in 
males (10:1) and the majority of patients present with localised stage one 
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lymphadenopathy. Prognosis is favourable following local excision or minimal 
chemotherapy. The disease has a follicular architecture composed of blastoid cells 
which are larger than centrocytes and centroblasts (Liu et al., 2013). Although having a 
high-grade histological appearance and high proliferation index, the behaviour is 
usually benign.  
 
The genetic landscape of PTFL is also distinct from classical FL. Recurrent mutations in 
epigenetic modifiers including CREBBP and KMT2D are absent (Louissaint et al., 2016, 
Schmidt et al., 2016) in addition to a lack of BCL2, BCL6 and IRF4 rearrangements which 
are typical of classical FL (Louissaint et al., 2012). While the genomic complexity is 
relatively low, mutations in the MEK/ERK pathway and TNFRSF14 were the most 
commonly found with a prevalence of 43% and 29% (Louissaint et al., 2016), 
respectively. Interestingly, TNFRSF14 mutations were associated with deletion or copy 
number–neutral loss of heterozygosity of chromosome 1p, which are lesions typically 
found in TNFRSF14 of classical FL, evidence of at least a degree of genetic semblance 
between the two entities. The lack of epigenetic ‘addiction’ in PTFL along with a low 
genetic complexity and absence of recurrent mutations found in classical FL has 
supported PTFL as being considered a biologically and clinically distinct indolent 
lymphoma.   
 
Duodenal type FL: These are low-grade lesions (grade one or two) localised in the second 
portion of the duodenum without metastasis (Schmatz et al., 2011). Patients have an 
excellent prognosis with a ‘watch and wait’ approach frequently employed. Gene 
expression reveals similarity to extranodal marginal zone lymphoma of mucosa-
associated lymphoid tissue (MALT) lymphoma (Takata et al., 2014). Restricted V gene 
segment usage of immunoglobulins was seen, specifically VH4 and VH5, suggesting an 
antigen-dependent mechanism in lymphomagenesis (Takata et al., 2009), as in the case 
of MALT lymphoma, which develops from chronic inflammation. Genetic changes similar 
to classical FL include the t14;18 translocation and BCL2 and BCL6 expression (Takata et 
al., 2014). Another similarity to FL is that clones have ongoing somatic hypermutation 
(SHM) in their V genes. However, this is in spite of a lack of AID expression (Takata et al., 
2009), suggesting a distinct pathway to facilitating ongoing SHM.  
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1.6 Transformation  
 
A significant disease event that can occur at relapse or progression is the transformation 
of FL into an aggressive lymphoma (t-FL) which is considered one of the most 
unfavourable events in the natural course of FL. t-FL was first described in 1942, in which 
serial biopsies revealed a ‘less differentiated’ appearance compared to the preceding FL 
biopsy (Gall and Mallory, 1942), sharing a more similar histologic appearance to a 
different lymphoma group. However, the clonal relationship between disease events 
can be seen through identical IGH-BCL2 rearrangements (Lossos et al., 2002), 
distinguishing bona fide transformation events from de novo secondary malignancies. 
Unlike FL, t-FL has a high proliferative index which can be visualised through Ki-67 
staining (Natkunam et al., 2004).  The follicular architecture is effaced by the infiltration 
of diffuse large cells within the follicles (Lossos and Gascoyne, 2011). The majority of 
transformations resemble de novo diffuse large B cell lymphoma (DLBCL), with a smaller 
group (7%) resembling Burkitt-like lymphoma (Al-Tourah et al., 2008). The majority of 
patients with a DLBCL-type transformation have a genetic signature that resembles de 
novo germinal centre B cell type DLBCL (GCB-DLBCL), including BCL2 rearrangements 
and mutations in EZH2 and TNFRSF14 (Pasqualucci et al., 2014). Intriguingly, 16% of 
cases are of the activated B –cell subtype (ABC) which are associated with t14;18 
negative FLs (Kridel et al., 2015a).  
Biopsy and immunophenotyping remain the gold standard for t-FL diagnosis although a 
combination of clinical features can offer a reliable diagnosis if biopsy sampling is not an 
option. This includes the sudden onset of B symptoms (fever, night sweats, and weight 
loss), elevated serum LDH, hypercalcaemia, development of extranodal disease and 
rapid tumour growth.  
The rate of transformation is 2-3% per year (Ban-Hoefen et al., 2013, Wagner-Johnston 
et al., 2015, Al-Tourah et al., 2008) with a broad incidence rate ranging from 11-70% 
(Hubbard et al., 1982, Montoto et al., 2007b, Al-Tourah et al., 2008, Garvin et al., 1983, 
Risdall et al., 1979). This variability is likely due to a lack of uniform across studies, 
including the cohort size, method of diagnosis by the clinician (histologic versus clinical 
parameters), variable inclusion of autopsy samples and variable duration of patient 
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follow up and surveillance. Furthermore, lack of clonality determination using a pre-
transformation sample in earlier studies cannot distinguish true transformations from 
de novo secondary malignancies, impacting the frequency of transformation reported. 
Identifying patients who are more at risk of transformation remains an attractive line of 
enquiry for tailored and pre-emptive therapy strategies. Advanced stage disease and a 
high FLIPI score at diagnosis are predictive of patients at a higher risk of transformation 
(Montoto et al., 2007b). Furthermore, transformation rates at 5 years following 
diagnosis were shown to be highest in patients who were observed compared to those 
who underwent rituximab monotherapy (P = 0.21) (Link et al., 2013), suggesting that 
initial management strategies during FL may influence transformation risk. However, 
two different studies contradicted these observations by finding a W&W approach had 
either a lower or similar transformation risk compared to rituximab therapy (Conconi et 
al., 2012, Ardeshna et al., 2014). Several studies have looked into whether 
transformation risk increases over time, with contradicting findings. Montoto et al 
(Montoto et al., 2007b) and Bastion et al (Bastion et al., 1997) found that the risk of 
transformation plateaus after 15 years and 6 years follow up, respectively, suggesting a 
subset of patients who will never undergo a transformation. However, other studies 
found that the risk of transformation continues to increase over time, suggesting 
transformation as an inherent evolution of FL, regardless of treatment versus non-
treatment of FL (Horning and Rosenberg, 1984, Al-Tourah et al., 2008). However, both 
these studies did not include rituximab therapy and therefore the risk of transformation 
in the rituximab era warrants further examination. 
The prognosis of transformed patients was extremely dismal with a median OS of 1-2 
years following diagnosis. However, the introduction of rituximab as part of post 
transformation therapy has seen a considerable improvement with median survival 
reaching up to 5 years post diagnosis (Alonso-Alvarez et al., 2017, Ban-Hoefen et al., 
2013, Link et al., 2013). R-CHOP therapy is used as a treatment option, especially in 
anthracycline naïve patients, with OS of t-FL patients matching that of de novo DLBCL 
patients on the same regimen (Link et al., 2013, Gleeson et al., 2017). Autologous stem 
cell transplant (ASCT) in the rituximab era has also shown benefit to patients. For ASCT 
patients ≤60 years, the 2 year OS was 74% compared to 59% in the non-ASCT patients 
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≤60 years of which 56% were on R-CHOP therapy (Ban-Hoefen et al., 2013). Despite this 
improvement, prognostic parameters are still associated with a poorer outcome. For 
example, patients with a higher FLIPI score, and those who transform less than 18 
months following FL diagnosis are indicated to have a poorer survival (Federico et al., 
2009, Link et al., 2013). Additionally, patients who are chemotherapy naïve prior to 
transformation had a superior 2 year OS following ASCT and non-ASCT compared to 
those exposed to chemotherapy prior to transformation (Ban-Hoefen et al., 2013). 
 
1.7 B cell development 
 
As neoplastic counterparts of normal GC B cells, FL cells are derived from the deviation 
of the normal B cell development pathway. Therefore, we must understand the 
processes governing B cell development, as they are implicit to the manifestation of the 
disease.  
B cells are a critical component of the adaptive immune system as they produce antigen-
specific immunoglobulins that eliminate pathogens. B cell development begins in the 
bone marrow where they originate from lymphoid progenitors, which in turn arise from 
the pluripotent haematopoietic stem cells. The stages of B cell development in the bone 
marrow are marked by the rearrangement and expression of immunoglobulin genes 
which occur in a fixed and regulated sequence, as described below.  
 
1.7.1 Immunoglobulin structure and formation 
 
One feature of normal B cells maintained by all FL cells throughout disease is the 
expression of surface immunoglobulin (sIg). This is in spite of several challenges, 
including the loss of one functional Ig allele as a result of the t(14:18) translocation and 
ongoing SHM of the variable regions that increase the probability of stop codon 
introduction and loss of structural integrity. This selective retention suggests the sIg has 
an important role in FL pathogenesis.  
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There are three immunoglobulin gene loci; the heavy chain (IgH) located on 
chromosome 14q32.3, and two light chains, termed κ and λ, located on chromosome 2p 
and chromosome 22q, respectively. The protein products of these genes form the 
mature Ig molecule initially expressed on the pre B cell surface, which in combination 
with CD79a/b, form the B cell receptor (BCR). The immunoglobulin is made of four 
polypeptide chains comprising of two identical heavy chains (IgH) and two identical light 
chains (either Igκ or Igλ) which are held together by disulphide bonds between cysteine 
residues (Figure 1.1). Heavy and light chains are composed of variable and constant 
regions. The variable region of the heavy chain is encoded by three gene segments; 
variable (VH), diversity (DH) and joining (JH). The variable light chain region is encoded by 
two gene segments; variable (Vκ/λ) and joining (Jκ/λ). The variable region of the heavy 
chains and both regions of the light chains encompass the Fab fragment of the 
immunoglobulin which determines the antigenic specificity. Antigen binds to 3 
complementarity determining regions (CDRs) within this region which are flanked by 
conserved sequences known as framework regions that act as structural support. The 
constant region of the heavy chain makes up the Fc portion which is responsible for the 
effector function of the immunoglobulin dependent on its isotype.  
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Figure 1.1: Production and structure of antibody from heavy and light chain germline DNA locus.  Un-
rearranged immunoglobulin heavy chain locus (top of figure) contains multiple functional V, D and J 
segments (of which only a few are depicted) whereas un-rearranged kappa or lambda light chain locus 
(left of figure) contains multiple V and J segments (of which only a few are depicted). The heavy chain 
locus rearranges first, with the joining of one V gene segment, one D gene segment and one J gene 
segment to generate the DNA encoding the heavy chain variable region. This combination is random, 
contributing to antibody diversity. The light chain V and J segment then combine to generate the light 
chain variable region. Grey bars represent addition of non-templated bases. The positions of the heavy 
and light chain variable regions are depicted on the polypeptide, represented by VH and VL, respectively. 
Complementary determining regions (CDR1-3) are shown, with CDR3 being encoded by all gene segments 
of the respective light and heavy chains. The constant regions of the heavy and light chains (CH and CL) 
are encoded by exons (not shown here) that are joined to the rearranged V(D)J gene by mRNA splicing. 
Disulphide bonds (depicted by black bars) join the heavy and light chains to generate the full antibody 
structure. Image is taken from Boyd and Joshi (Boyd and Joshi, 2014). 
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Immunoglobulin production begins during somatic recombination in which gene 
segments of the variable region are joined together in the bone marrow. The heavy 
chain (IgH) locus undergoes rearrangement first, with the D and JH gene segments 
joining first, followed by the VH segment joining to DJH. This gives rise to μ chains that, 
in complex with surrogate light chains made of VpreB and delta5, form the pre B 
receptor that is transiently expressed on the cell surface of large cycling B cell 
precursors, known as pre-B cells. These cells differentiate into non-dividing small pre B 
cells in which the light chain genes undergo rearrangement to produce immature B cells 
that express IgM and low levels of IgD on the cell surface. If the B cell passes IgM 
autoreactivity testing, it leaves the bone marrow and migrates to secondary lymphoid 
organs. Chemokines produced by follicular dendritic cells attract the naïve B cells into 
follicles that are bordered by T cells (T cell zone) and at this stage, B cells are classified 
as naïve. The B cell receptor binds to a cognate exogenous antigen that enters the follicle 
and then migrates to the T cell zone where it displays the antigen to a T helper cell as 
peptides bound to MHC Class II molecules. This enables full activation of the B cell, with 
some of the B cells differentiating into plasmablasts that produce low affinity antibodies. 
Other B cells migrate back into the follicle and undergo rapid proliferation to form a 
germinal centre (GC). Resting B cells are pushed to the periphery of the follicle and form 
the mantle zone. The germinal centre size continues to increase during proliferation 
with the establishment of a polarised microenvironment referred to as the dark and light 
zone. The dark zone refers to the histological appearance of rapidly proliferating B cells 
being densely packed in contrast to the sparsely populated light zone which also includes 
a number of other cell types, including follicular dendritic cells, macrophages and T 
helper cells. The majority of dark zone B cells are termed centroblasts and light zone B 
cells are termed centrocytes. A majority of B cells undergo apoptosis in the GC with a 
few being selected to undergo differentiation to either memory or plasma B cells that 
exit the germinal centre and provide the individual with effective and long lasting 
protection during chronic or recurring infection. They achieve this by utilising their high 
affinity BCRs, which are produced in the GC reaction through two mechanisms; somatic 
hypermutation (SHM) and class switching (CSR) which are discussed in detail below. 
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1.7.2 Immunoglobulin diversification 
 
To recognise a multitude of antigens and mount an effective immune response requires 
a diverse antibody repertoire which is generated by four main processes. The first 
process of immunoglobulin diversity is achieved in the bone marrow. The variable region 
of each of the immunoglobulin loci contains multiple gene segments. For example, the 
variable region of the human heavy chain germline DNA contains approximately 40 
functional VH gene segments, 25 functional DH gene segments and 6 functional JH gene 
segments. During formation of the heavy and light chains in the B cell progenitor, only 
one gene segment from V, D (only in IGH) and J are selected for combination. As 
selection of gene segments is random, a vast number of gene segment combinations 
can be achieved in different rearrangement events, known as combinatorial diversity. A 
recombination signal sequence (RSS) adjacent to the coding region of V, D and J gene 
segments guides recombination. RSSs are composed of three elements; a conserved 
heptamer contiguous with the coding sequence, followed by a non-conserved spacer 
region composed of either 12 or 23 base pairs, and a conserved nonamer. The RSS of V 
and J gene segments contains 23bp spacers and D gene segments have a 12bp spacer. 
These spacer lengths correspond to approximately one turn (12bp) or two turns (23bp) 
of the DNA helix. A gene flanked by an RSS containing a 12bp spacer can only join to a 
gene with an RSS containing a 23bp spacer, known as the 12/23 rule.  This ensures that 
D genes are able to join to V and J genes but V and J genes aren’t able to directly join.  
Recombinases RAG1 and RAG2 bind to the RSS flanking the coding sequences to be 
joined and through their endonuclease activity, cleaves the RSSs and create a hairpin on 
the coding end. DNA –dependent protein kinase (DNA-PK) and Artemis catalyse a single-
stranded cleavage at a random site near the hairpin, creating a single-stranded tail 
formed of a few nucleotides from the coding sequence plus a few of their 
complementary nucleotides derived from the other DNA strand. This generates 
palindromic or P-nucleotides at the junctions between the V, D and J segments, 
stretches of nucleotides derived from the complementary strand. Terminal 
deoxynucleotidyl transferase (TdT) adds non-template encoded nucleotides, or N-
nucleotides, to the ends of single-stranded DNA, followed by the pairing of strands, 
exonuclease trimming of unpaired nucleotides and DNA repair and ligation processes. 
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This leads to the addition of P- and N-nucleotides at the junctions between gene 
segments and is a significant contributor to the diversity of the CDR3. As P and N 
nucleotide addition is a random and unique process to each B cell clone, the composition 
of the CDR3 region is often employed in clonal analysis studies, including monoclonal B 
cell malignancies. Once rearrangement is accomplished, the promoter located upstream 
of the leader sequence in heavy and light chains is brought closer to an enhancer (~ 2kb 
distance). This close proximity enables the enhancer to activate transcription from the 
promoter, which is not possible in germline DNA in which the promoters and enhancers 
are 250-300 kb apart. This ensures that only rearranged immunoglobulins are 
transcribed to mRNA followed by production of the nascent polypeptide. 
A second major source of diversity is achieved through SHM, a process that introduces 
single point mutations in a step-wise manner throughout the rearranged V region at 
rates that are 106 –fold higher than background mutation rates experienced by other 
genes. SHM occurs during B cell proliferation in the germinal centre with the overall goal 
to produce B cells with high-affinity antibodies following antigen activation. SHM occurs 
during transcription due to the action of the enzyme activation-induced cytidine 
deaminase (AID) which only acts on single-stranded DNA, in which both strands can be 
affected. AID is exclusively expressed upon activation of B cells. It deaminates a cytidine 
to a uridine that has two potential outcomes. Firstly, the uridine can be recognised as a 
thymidine by DNA polymerases leading to transition mutations (c>t or g>a for the 
opposite strand). Secondly, the base-excision repair enzyme uracil-DNA glycosylase 
(UNG) can remove the uridine, generating an abasic site that leads to transition or 
transversion mutations (c>a or g, g>t or c) through repair by error-prone DNA 
polymerases. Transition mutations are more frequent than transversions. SHM hotspots 
exist in the V regions consisting of patterns (a/t)a and g(c/t)(a/t), although SHM can 
occur anywhere within the region. Mutations can lead to amino acid changes that are 
silent or replacement. CDRs, which are critical antigen binding sites, tend to accumulate 
replacement mutations whereas framework regions accumulate silent mutations in 
order to preserve the overall antibody structure.  However, it is important to note that 
SHM does not discriminate between favourable and non-favourable mutations, leading 
to several B cell outcomes including 1) antibodies with higher affinity, 2) antibodies with 
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lower affinity, 3) antibodies with unchanged affinity and 4) antibodies with lost 
functionality due to premature stop codon introduction. The selection process which 
occurs in the light zone selects B cells displaying immunoglobulin with higher antigen 
affinity to undergo more rounds of division and SHM leading to affinity maturation. B 
cells displaying low affinity or non-functional immunoglobulins undergo apoptosis due 
to lack of BCR crosslinking and presentation of a peptide to T helper cells. This Darwinian 
evolution ensures the selection of only B cells displaying high antigen affinity 
immunoglobulin to undergo differentiation into either plasma or memory B cells.  
The third mechanism for antibody diversity is through class switch recombination (CSR). 
This results in a switched isotype of the heavy chain constant region of an 
immunoglobulin, leading to a change in effector function without disrupting antigen 
affinity. Naïve B cells expressing IgM and IgD can change to IgA, IgG, or IgE isotypes, 
diversifying the antibodies response to a shared pathogen. AID mediates CSR and 
deaminates a cytosine to uracil within the switch (S) regions upstream of the constant 
regions (except for IgD). Resulting single-stranded breaks convert into double-stranded 
breaks within the donor S μ/δ and the acceptor S γ/α/ε. The two S regions are 
recombined through non-homologous end-joining (NHEJ) with the subsequent deletion 
of the intervening DNA by loop excision. This results in the replacement of the S μ/δ by 
the new S γ/α/ε with conservation of the VDJ rearrangement upstream. 
 
1.7.3 B cell receptor signalling 
 
The B cell receptor (BCR) is critical to the development and maturation of B cells and 
ongoing expression is critical to the survival of mature B cells. Several B cell 
malignancies, including FL, remain dependent on the expression of the BCR (Kuppers, 
2005), suggesting a role in lymphomagenesis. 
The surface immunoglobulin forms the extracellular antigen-binding domain of the BCR 
which is non-covalently bonded to a heterodimer composed of CD79a and CD79b which 
form the cytoplasmic tail of the BCR. CD79a and CD79b contain conserved peptide 
motifs called Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) which are 
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essential for intracellular signalling. Following antigen recognition and engagement with 
the variable region of the sIg, kinases such as Src family kinases Lyn and spleen tyrosine 
kinase (Syk) are activated which phosphorylate tyrosine residues in the ITAMs 
(Yamamoto et al., 1993, Rolli et al., 2002). This, in turn, results in the recruitment of the 
initial signalling complex composed of Syk, Lyn, Bruton tyrosine kinase (Btk), and 
adaptor proteins Grb2 and B cell linker (BLNK). Lyn provides continued signal 
amplification as well as forming a complex with CD19 and other costimulatory molecules 
that reduce the threshold of B-cell activation and cause BCR aggregation (Fearon and 
Carroll, 2000). Generation of the signalosome results in the production of second 
messengers, including diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3) (Dal 
Porto et al., 2004). DAG activates protein kinase C (PKC) whereas IP3 leads to calcium 
influx from both extracellular compartments and the endoplasmic reticulum (Roos et 
al., 2005).  This, in turn, leads to transcription of NFkB genes which have a broad role in 
B lymphocyte proliferation, class switching (Ruland and Mak, 2003) and survival 
(Stadanlick et al., 2008). PKC also activates the MAPK pathway (Hashimoto et al., 1998) 
which regulates a number of transcription factors which can lead to B cell survival, 
apoptosis or proliferation. To control BCR activation, negative regulators inhibit 
activation. These include phosphatases (Pani et al., 1995) and kinases such as Lyn which 
have both activatory and inhibitory properties (Nishizumi et al., 1998).  
BCR signalling underpins the fate of B cells as activation can lead to various functional 
outcomes including survival, differentiation, proliferation, anergy or apoptosis. This is 
influenced by signal strength and its modulation by negative and positive co-receptors, 
in addition to the stage of B cell development and interaction with the 
microenvironment through secondary signals from non-B cells such as BAFF, CD40, TLRs 
and IL-4 (Niiro and Clark, 2002). Furthermore, signalling strength can regulate which 
mature B cell subsets can develop. Peritoneal B cells require the strongest BCR signal, 
follicular B cells require an intermediate signal and marginal zone B cells require a 
weaker signal (Loder et al., 1999, Martin and Kearney, 2000, Cariappa et al., 2001). This 
flexibility and fine-tuning by the BCR ensures the correct cell fate is determined to 
maintain appropriate populations of different B cell subsets and loss of B cells that are 
functionally obsolete.   
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1.8 Immune cells of the germinal centre 
 
The GC is a critical site for B cell antibody affinity maturation during an immune 
response. This process is dependent on other immune cells in the GC, including follicular 
dendritic cells (FDCs). FDCs develop from perivascular precursors of stromal cell origin. 
Their maturation requires stimulation by lymphotoxin and tumour necrosis factor 
signalling through B cells (Alimzhanov et al., 1997, Pasparakis et al., 1996). FDCs produce 
CXC-chemokine ligand 13 (CXCL13) that guides B cells that have entered the lymph node 
towards follicles by signalling through its receptor, CXCR5 (Allen and Cyster, 2008). 
Therefore, FDCs contribute to maintaining an organised follicular structure. They also 
promote B cell survival in the GC through production of B cell-activating factor (BAFF) 
and interleukin 6 (IL-6) (Wu et al., 2009). FDCs display antigen in immune complexes on 
their surface and are responsible for causing antigen-driven selection of B cells in the 
light zone, with survival of B cells displaying high affinity antibodies that are able to exit 
the GC as a memory B cell or plasma cell.  
B cell clones which have low affinity antibodies and a lack of sufficient survival signalling 
undergo apoptosis. Phagocytic cells such as macrophages and dendritic cells clear these 
apoptotic cells in the GC. Tingible body macrophages are predominantly found in the GC 
and contain many phagocytized, apoptotic cells in various states of degradation (Smith 
et al., 1998). While these macrophages are bone marrow derived, it is unclear whether 
they arise from circulating monocytes or originate during embryonic development as 
indicated from studies looking into the origin of tissue resident macrophages (Jakubzick 
et al., 2013, Epelman et al., 2014).  
 
1.9 Early events in FL pathogenesis 
 
FL pathogenesis is a multi-step process, with the likely earliest event occurring in the 
bone marrow in which an error in VDJ recombination results in the hallmark 
t(14;18)(q32;q21) translocation. Evidence of pre-malignant cells and lesions suggests a 
protracted disease course with the accumulation of several genetic hits required for 
overt disease manifestation.  
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1.9.1 t14;18 translocation 
 
FL is a germinal centre derived B cell lymphoma with tumour cells avoiding programmed 
cell death despite being unable to differentiate into plasma or memory B. However, the 
first considered event in pathogenesis occurs early in B cell development within the bone 
marrow. 90% of FL patients harbour the t(14:18) translocation in which the BCL2 locus 
on chromosome 18q21.3 juxtaposes to the immunoglobulin heavy chain gene (IGH) locus 
on chromosome 14q32.33 (Cleary and Sklar, 1985). The majority of BCL2 breakpoints 
occur within a 150bp region within the 3’ untranslated portion of the third exon (~70%), 
termed the major breakpoint region (mbr). The remainder of breaks occurs 30kb 
downstream of the BCL2 locus, termed the minor cluster region (mcr) (Cleary et al., 
1986a). IGH breakpoints predominantly occur adjacent to the joining elements (JH) or 
adjacent to the regions where the DH region joins the J region.  This suggests that the 
translocation arises during an error in VDJ recombination, resulting in the BCL2 gene 
being under the control of enhancers of the IGH locus. This leads to the disruption of one 
Ig allele and the constitutive expression of the anti-apoptotic protein, bcl2. The t(14:18) 
mature naïve B cell exits the bone marrow and enters the germinal centre reaction, in 
which the translocation is likely to exert its pathogenic function. GC B cells normally 
downregulate bcl2 to enable apoptosis for B cells displaying weak affinity BCRs. Those 
with high affinity found in the light zone then re-express bcl2 and undergo 
differentiation. In FL, there is bcl2-driven rescue from apoptosis of B cells with low-
affinity BCRs, bypassing a critical mechanism used in normal B cell selection.  
 
1.9.2 t14;18 translocation insufficient for lymphomagenesis 
 
Despite offering apoptotic rescue, the t(14;18) translocation is insufficient to inducing 
lymphomagenesis. This has been established through the failure of recapitulating the 
disease in transgenic mouse models overexpressing bcl2. The original model, in which 
the BCL2 gene was placed under the control of heavy chain enhancers, developed 
follicular hyperplasia and after a long period, a high grade lymphoma which was not 
reminiscent of the indolent nature of FL (McDonnell and Korsmeyer, 1991). The 
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subsequent mouse model, VavP-BCL2, in which the BCL2 gene was placed under the 
control of the pan-haematopoietic promoter VavP, was able to develop FL disease (Egle 
et al., 2004). Yet the overexpression of BCL2 in T cells is not found in FL and therefore 
the molecular features of the disease were not accurately reflected. Around 10% of FL 
cases are t14;18 negative with the majority not expressing BCL2. Whilst sharing many 
morphologic and genetic features with t14;18 positive FLs which has maintained their 
‘classical’ FL classification by WHO,  there are differences between the two groups. Some 
negative cases harbour BCL6 translocations (Horsman et al., 2003) and have micro-RNA 
expression profiles reminiscent of late GC B cell phenotype (Leich et al., 2011). 
Furthermore, low frequencies (0.1–10 cells/million) of t(14:18) positive cells are found 
in peripheral blood mononuclear cells of ~50% of healthy individuals, termed FL-like cells 
(FLLCs) (Limpens et al., 1995, Dolken et al., 1996, Schuler et al., 2009), without 
individuals being at an increased risk of FL development. These translocations contain 
the same breakpoints conserved in FL and results in the overexpression of BCL2, 
suggesting a similar apoptotic rescue of cells in the GC (Roulland et al., 2006a, Agopian 
et al., 2009). Interestingly, the number of t14;18 positive cells increase with age and 
exposure to pesticides (Roulland et al., 2004, Baccarelli et al., 2006, Schuler et al., 2009, 
Liu et al., 1994), which may support epidemiological findings of a median FL onset at 65 
years and increased risk of t14;18 positive NHLs in those with increased use of 
insecticides (Chiu et al., 2006).  
 
1.9.3 Disease evolution- common progenitor cell compartment 
 
Disease progression had previously been thought of as a linear process, in which the 
dominant clone of the subsequent disease episode originates directly from the 
preceding event following the acquisition of additional mutations. This theory was 
investigated in genetic data gathered from sequential FL biopsies and paired FL/t-FL 
pairs which offers invaluable insight into FL evolution during progression (e.g. relapse) 
and transformation. Single nucleotide variants (SNVs) and copy number aberrations 
(CNAs) from FL-relapse and FL-tFL samples revealed that whilst cases of direct evolution 
did exist, a greater proportion of patients displayed a non-stepwise evolution pattern, 
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with the preceding disease event having a set of distinct mutations absent from the 
subsequent event, suggesting a divergence between the two populations at an earlier 
time point (Pasqualucci et al., 2014, Eide et al., 2010). A number of shared mutations 
evidenced a clonal relationship between events. Analysis of the SHM patterns of the 
variable heavy chain gene in FL-relapse and FL-tFL paired samples revealed relatedness 
between the two disease events through shared point mutations. However, not all point 
mutations found in FL were present in the relapse and t-FL samples. This was visualised 
in genealogic trees composed of IgH-VH sequences, highlighting a complex, non-linear 
SHM pattern in support of divergent evolution predominance in FL cases (Carlotti et al., 
2009, Aarts et al., 2001, Eide et al., 2010). Collectively, these studies imply that 
successive disease episodes arise from a putative common ancestral cell pool, referred 
to as the common progenitor cell (CPC) following the acquisition of distinct genetic 
aberrations (Figure 1.2).  
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Figure 1.2: Models of FL evolution as suggested through genomic analysis of sequential FL biopsies and 
paired FL-tFL samples. The left-hand panel describes two scenarios of the linear model of evolution, 
whereas the right-hand panel describes two scenarios of divergent evolution from a CPC. Regarding the 
linear model, the dominant tFL clone can arise directly from the preceding dominant FL clone following 
the acquisition of distinct mutations. In the divergent model, both FL and t-FL clones arise from a less 
mutated, ancestral cell (CPC) following the acquirement of distinct mutations. In both models, the tFL 
dominant clone may exist as a minor subclone in the preceding FL event which following favourable 
selection pressures, expand to become dominant. Image is taken from Pasqualucci et al (Pasqualucci et 
al., 2014).  
 
Studies on two cases of donor derived FL following stem cell transplant has given us 
insight into the features of this population. In the first case, a son received an allogeneic 
stem cell transplant from his father for the treatment of acute myeloid leukaemia (AML) 
(2009). Both father and son developed clonally related FL with transformation 3 and 10 
years after transplantation, respectively. Evidence of a CPC was indicated through the 
IGHV sequence of the major clones from the two tumours, with shared and distinct point 
mutations between the father and son (Carlotti et al., 2009). The long latency between 
a transfer of the CPC in the stem cell transplant and disease manifestation (up to ten 
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years) reveals the CPC population has a self-renewal capacity and can remain dormant 
for years. This long dormancy was further supported by a second case of donor derived 
FL. Siblings who had underwent allogeneic SCT and donor leukocyte infusions (DLI) for 
the treatment of chronic myeloid leukaemia (CML) developed FL seven years after 
treatment (Weigert et al., 2012). The same t14;18 breakpoint and VDJ rearrangement 
were found in the FL tumours of the siblings, evidencing their clonal relationship. 
Interestingly one in two thousand cells in the DLI also harboured these features. 
Additionally and rather remarkably, ultra-deep sequencing of the DLIs identified 
fourteen of the fifteen shared somatic mutations identified in the tumours. As DLIs were 
taken at the time of transplant, we can infer that the CPC population existed at least 
seven years before overt disease manifestation. It also suggests that the CPC is able to 
circulate in the peripheral blood, taking up residence in different anatomical sites.  The 
pattern of evolution from this putative CPC was investigated through whole genome and 
exome sequencing of paired FL-t-FL samples and the analysis of non-synonymous 
mutations across events (Okosun et al., 2014). All cases had shared somatic mutations 
between disease episodes, indicating the existence of a CPC. Yet the degree of clonal 
semblance varied between cases, revealing two distinct evolutionary patterns. A high 
number of shared mutations between disease episodes indicated evolution through a 
‘rich’ CPC whereas a low number of shared mutations indicated a ‘sparse’ CPC in which 
disease events diverge at an earlier time point (Figure 1.3). The majority of cases were 
classified as having a ‘rich’ CPC, with mutations occurring in histone-modifying genes 
(CREBBP, KMT2D) and immune modulating genes (B2M, CD58, TNFRSF14), suggesting 
that these aberrations are early events in pathogenesis. Over 70% of cases had 
concurrent mutations in at least two chromatin modifying genes. Several other studies 
have implied chromatin-modifying genes as an early event in FL (Pasqualucci et al., 
2011a, Pasqualucci et al., 2014, Li et al., 2014, Green et al., 2015). The functional 
consequence of CREBBP mutations was shown to result in the decrease of MHC class II 
expression on tumour cells, leading to immune evasion (Green et al., 2015). Intriguingly, 
Okosun et al observed that different mutations occurred within the KMT2D, TNFRSF14 
and CREBBP genes of ‘sparse’ serial biopsies (Okosun et al., 2014). This indicates a 
convergent evolution in which similar genetic alterations occur independently within 
episode-specific clones. The observation of alterations in these genes across both 
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evolutionary patterns suggests they have an important role in lymphomagenesis and 
progression.   
Due to the high relapse rates seen across FL patients, the CPC population is believed to 
be resistant to current therapies. Targeting early events may lead to the disruption of 
this reservoir pool improving remission rates and progression free survival. Epigenetic-
based therapies are conceptually attractive and would move towards a precision 
medicine approach to FL treatment that is currently based on a ‘one size fits all’ 
approach. However, several trials using epigenetic modifying agents, such as histone 
deacetylase (HDAC) inhibitors and EZH2 inhibitors as single agent therapies, have shown 
disappointing complete response rates (Evens et al., 2016, Morschhauser et al., 2017, 
Kirschbaum et al., 2011, Ogura et al., 2014). Future research should focus on the 
functional implications of these therapies and exploration of how to improve efficacy, 
for example through combination regimens.  
While sequential biopsies and donor derived FL cases has provided a ‘proof of principle’ 
of the CPC compartment, little is known regarding its phenotypic and biologic features 
as well as its location (in either tissue or peripheral circulation) and stage of 
differentiation (e.g. ranging from cancer stem cell to an already malignant subclone). 
Characterising this compartment represents a significant scientific challenge yet one 
that would provide invaluable insight into disease evolution and opportunities for 
therapeutic intervention. 
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Figure 1.3: Phylogenetic trees based on non-synonymous mutations of paired FL-tFL biopsies. Upper and 
lower panels highlight distinct evolutionary patterns The branches represent individual disease events 
(blue circles indicative of FL and relapsed FL, red circles indicative of transformation), with the number of 
event specific mutations indicated on each branch. Trees on the top panel reveal two cases of evolution 
from a ‘rich’ CPC population (indicated by grey circles) in which serial samples share a high number of 
mutations. Trees on the bottom panel reveal two cases of evolution from a ‘sparse’ CPC, with events 
having few shared mutations (only 4 in both examples). Image is taken from Okosun et al (Okosun et al., 
2014).  
 
1.9.4 Intermediate steps in FL development 
 
The long latency period to disease presentation seen in allo-HSCT derived FL cases, 
suggests FL development is protracted, taking years to develop the disease. This ties in 
with the multi-step pathway to lymphomagenesis, requiring several genetic hits in 
addition to the t14;18 translocation. Whilst studies have suggested epigenetic 
alterations to be early events in disease evolution, the exact steps and time points at 
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which they are acquired is still unknown. However, now we have begun to identify 
potential precursor cells and lesions in which such genetic mutations may arise and 
accumulate in to develop overt disease. The current model of FL pathogenesis from 
these presumed precursor lesions is summarised in Figure 1.4.   
 
Although circulating t14;18 positive cells termed follicular lymphoma-like B cells (FLLCs) 
are found in healthy individuals who never go on to develop the disease, they harbour 
features  which are reminiscent of FL cells including expression of the GC B cell marker 
CD10, and upregulation of BCL2. Furthermore, FLLCs have intraclonal diversity (Agopian 
et al., 2009), suggestive of repetitive GC entry where they can undergo AID-mediated 
SHM and/or CSR. Indeed, FLLCs have been shown to have a GC-experienced memory B 
cell phenotype (Roulland et al., 2006b, Hirt et al., 2007), supporting their increased 
exposure to AID. One study also found that some FLLCs have aberrant ongoing AID 
activity which is normally downregulated following GC exit (Agopian et al., 2009). As AID 
introduces aberrant mutations in non-Ig genes which are usually proto-oncogenes, such 
as BCL6, PIM1, MYC and PAX5 (Rossi et al., 2005, Pasqualucci et al., 2001, Liso et al., 
2006) increased exposure may increase genomic instability, leading to accumulation of 
mutations in FLLCs and their eventual transformation to overt FL. 
 
The direct relationship between FLLCs and FL was established in a study which found 
that the frequency of FLLCs can be used as a predictive marker for FL development. Pre-
diagnostic blood samples were available for 100 FL patients (Roulland et al., 2014). 
Samples were available due to the patients being involved in an earlier study before the 
occurrence of overt disease. t14;18 positive cells were screened using sensitive PCR 
assays and clonal relationships between FLLCs and tumour samples were assessed by 
analysing the t14;18 breakpoints. All FLs and identified t14;18 positive cells in the paired 
pre-diagnostic blood sample were clonally related, establishing the FLLCs as the disease 
precursor cell. Furthermore, pre-diagnostic blood samples from these patients had a 
higher frequency of t14;18 positive cells when compared to samples taken from a 
control group who didn’t go on to develop the disease (n=218). They concluded that 
individuals with t(14;18) frequency reaching 1 in every 10,000 blood cells had a 23-fold 
greater risk of progression to FL. This predictive value did not change depending on 
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whether FLLCs were harvested close to disease onset or many years before. This 
highlights the long latency period between pre-malignancy to diagnosis, suggesting the 
overt disease is preceded by a preclinical, asymptomatic phase of clonal growth and 
establishment of a precursor clone that takes years, if not decades to manifest. This 
supports the hypothesis of a long-lived and dormant CPC population. This was also seen 
in cases of donor-derived FL, in which t14;18 positive cells detected at transplantation 
within DLIs contained the same BCL2:IGH rearrangement as that found in the FL clone 
of the donor and recipient years later (Weigert et al., 2012).  
 
t14;18 positive cells are also found incidentally in GCs of 2-3% of reactive lymph nodes 
of healthy adults, forming unconventional foci within a background of BCL2 negative B 
cell follicles (Cong et al., 2002, Henopp et al., 2011). They are monoclonally derived and 
colonise several GCs. They are termed in situ follicular neoplasia (ISFN), formerly known 
as FL in situ. In a study of 21 patients with FLIS, <5% progressed to a clonally related FL 
(Jegalian et al., 2011). However, the study was limited by the small cohort size and a 
restricted median follow up 118 months. A study by Mamessier et al utilised high-
resolution comparative genomic hybridization microarrays on laser-capture micro-
dissected ISFN cases to reveal that there is a degree of genetic instability in these lesions, 
albeit at a much lower number when compared to overt FL (Mamessier et al., 2014). A 
study by Schmidt utilised paired FL-ISFN samples to analyse the genetic relationship 
between FL and its pre-malignant lesion (Schmidt et al., 2014). ISFN samples showed 
little to no secondary genetic changes. Only one case had an EZH2 mutation shared 
between biopsies. The low genetic complexity and semblance of ISFN with clonally 
related FL highlights that several intermediate steps are necessary for disease 
manifestation from precursor cells. 
As FLLCs and ISFN are considered precursors in lymphomagenesis and express t14;18, 
we can infer that the survival advantage offered by constitutive expression of BCL2 
enables the B cell to acquire and accumulate genetic aberrations over the years, if not 
decades, to enable malignant transformation. The relationship between FLLCs and ISFN 
remains undetermined, however, Cheung et al found that in one ISFN case, a paired 
blood sample contained B cells with an identical t14;18 rearrangement to the ISFN cells 
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(Cheung et al., 2009b). This supports the hypothesis that FLLCs represent the circulating 
counterpart of ISFNs. The selection and commitment of some ISFN to develop into FL 
whilst others do not suggest a diverse number of unknown factors at play in contributing 
to lymphomagenesis.  
Whilst in ISFN the lymph node architecture is preserved, in partial involvement by FL 
(PFL), the affected follicles are larger with ill-defined marginal zones and attenuated 
mantle cuffs. Therefore, histologically, PFL has a greater semblance to FL. This is 
supported in a follow-up study that found that 53% of untreated PFL patients went on 
to develop overt FL over a fourteen year period (Jegalian et al., 2011) compared to only 
5% of FLIS patients. PFL also has significantly more genetic alterations compared to FLIS 
as evidenced in array comparative genomic hybridization studies (Mamessier et al., 
2014). Some of the amplified genes were also found to be amplified in low-grade FL, 
indicating a selective pressure for the high malignant transformation of PFL patients. 
These recurrent mutations included TNFRSF14, EZH2, and MLL2. However it’s important 
to note that genomic alterations and gains/losses within the PFL cases was still low 
compared to overt FL and that most cases present with low stage disease, suggesting 
that PFL does not simply represent a partial colonisation of the lymph node by FL, but is 
rather a precursor lesion (Adam et al., 2005).  
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Figure 1.4: Model of FL pathogenesis based on presumed t14;18 positive precursor cells. In the bone 
marrow (BM), naïve B cells acquire the t(14:18) translocation as a result of defective VDJ recombination. 
Cells exit the BM and enter peripheral circulation in which cells are termed FLLC. Cells colonise secondary 
lymphoid tissues where they undergo the GC reaction, characterised by somatic hypermutation (SHM) 
and class switch recombination (CSR). Constitutive expression of BCL2 protein provides a survival 
advantage, rescuing cells from apoptosis regardless of BCR affinity. ISFN is believed to represent this pre 
malignant precursor stage. Cells undergo clonal expansion within the GC and can exit into peripheral 
circulation. They are able to re-enter the GC multiple times as seen by FLLCs presenting a GC-experienced 
memory B cell phenotype (Roulland et al., 2006b, Hirt et al., 2007), where they have opportunity to 
increase their genomic instability through repeated exposure to AID. As PFL has a greater genomic 
complexity than ISFN (Mamessier et al., 2014), they are believed to represent a more differentiated 
precursor cell. The gain of specific genetic and epigenetic hits (   ) then leads to overt disease and t-FL. 
 
1.10 Immunoglobulin in FL 
 
One feature of normal B cells maintained by all FL cells throughout disease is the 
expression of surface immunoglobulin (sIg). This is in spite of several major challenges, 
including the loss of one functional Ig allele as a result of the t(14:18) translocation and 
ongoing SHM of the variable regions that increase the probability of stop codon 
introduction and loss of structural integrity (Zuckerman et al., 2010). This selective 
retention suggests the sIg has an important role in FL pathogenesis. Further evidence of 
a conferred selective advantage came from the observation that resistance to anti-
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idiotypic antibody therapy directed against the Ig variable region resulted in the 
outgrowth of tumour cells with amino acid substitutions in the targeted region rather 
than the outgrowth of Ig negative variants (Cleary et al., 1986b).  
As a monoclonal disorder, FL cells can be identified through identical V, D and J genes 
within their variable region, established during somatic recombination in the bone 
marrow. The usage of IGHV genes resembles the repertoire of normal peripheral B cells 
with IGHV3-23 the most commonly used gene (Berget et al., 2015, Brezinschek et al., 
1997, Aarts et al., 2001). IGHD3–10 and IGHJ4 are the most commonly used D and J 
genes used, respectively. As IGHV3 is the largest subgroup family, it is unsurprising that 
the majority of FL patients belong to this group, suggesting an unbiased usage of IGHV 
in FL. This is in contrast to chronic lymphocytic leukaemia (CLL) which unlike normal B 
cells, has a notable over-representation of genes, including IGHV1-69 and IGHV4-34 
(Schroeder and Dighiero, 1994, Fais et al., 1998) indicative of a superantigen 
contributing to disease pathogenesis. The usage of IGHV genes has also been shown to 
be a prognostic marker in disease. For example in CLL, V3-21 is associated with an 
unfavourable prognosis (Ghia et al., 2008, Oscier et al., 2010). A novel finding by Berget 
et al found that FL patients with IGHV5 usage had an unfavourable prognosis with an 
estimated survival at five years of 62.5% compared to patients in all other subgroups 
who had a combined five year survival of 95.1% (Berget et al., 2015). However, validation 
in a larger series is warranted for validity of IGHV sequence analysis in a prognostic 
setting.  
In accordance to their derivation from GC B cells, FL cells accumulate mutations in their 
variable region genes through SHM. Ongoing somatic hypermutation, compatible with 
their prolonged expansion in the GC (Kuppers et al., 1999), results in intraclonal 
sequence heterogeneity of malignant clones (Aarts et al., 2000) which can be used to 
trace the clonal evolution of the tumour (Bognar et al., 2005). In normal GC cells, SHM 
results in modifying the affinity of the BCR for its cognate antigen, resulting in either the 
proliferation/expansion of the B cell clone through strong antigen engagement, or its 
clonal deletion due to loss of survival signalling (Klein and Dalla-Favera, 2008, De Silva 
and Klein, 2015). Early reports of the tumour IGHV genes having a similar SHM pattern 
to those of normal antigen-selected B cells (77, 78), supported an antigen-driven 
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selection and expansion in malignancy. This included replacement mutations in the CDRs 
of the BCR, and an underrepresentation of replacement mutations in the framework 
regions (Jacobs and Bross, 2001, Bognar et al., 2005). However, findings that are more 
recent are proving contradictory, with no positive selection in the CDRs of FL Ig variable 
regions but a strong negative selection against replacement mutations in the FWRs 
(Hershberg et al., 2008, Zuckerman et al., 2010). This suggests that based on SHM 
patterns, FL clones are selected for their ability to express a functional BCR and not for 
antigen recognition. 
The majority of FL cases express sIgM, with ~40% having undergone isotype switch to 
IgG (Scherer et al., 2016, Vaandrager et al., 1998). Intriguingly, CSR frequently occurs in 
the translocated non-functional IGH allele of IgM cases (Vaandrager et al., 1998, Akasaka 
et al., 1998). In normal memory B cells, CSR only occurs on the functional allele, making 
this observation a hallmark feature of FL cells.  In FL, CSR occurs as frequently on both 
alleles, but “downstream switch” (e.g., Sγ-to-Sα) happens at unusually high frequency 
on the productive allele, sparing the Cμ region from deletion and allowing sIgM 
expression (Figure 1.5) (Vaandrager et al., 1998). Consequently, despite CSR occurring 
on both alleles in >80% of cases, most FL cases still express a sIgM. This ‘allelic paradox’ 
indicates the presence of a selective pressure in favour of sIgM expression on a B cell 
population that is at the same time permanently driven to switch. This could be due to 
favourable downstream effector functions offered by the cytoplasmic tail of IgM. 
Interestingly, t14;18 positive cells in healthy individuals also display this ‘allelic paradox’ 
(Roulland et al., 2006b), highlighting a possible shared functional feature between 
malignant cells and their precursors. 
  
Figure 1.5: CSR processes in translocated and functional IGH allele. A high frequency of CSR are observed 
in the translocated allele. In contrast, the C μ region is usually spared from deletion in the coding IGH 
allele, while “downstream switching” is observed at high frequency (left panel). Image adapted from 
Kishimoto and Nishikori, 2014 (Kishimoto and Nishikori, 2014) 
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1.11 B cell receptor signalling in FL  
 
Due to evidence of retention of the Ig, as described above, it is likely that BCR signalling 
is important to tumour survival. Krysiak et al found that ~40% of FLs had recurrent 
mutations affecting the BCR signalling pathway including CD79B, CARD11, CXCR4, and 
BTK mutations in the tyrosine kinase domain (Krysiak et al., 2017). Lower level mutations 
were also found in BLNK, PLCγ2, BCL10, and NFκB2. 
The investigation into BCR kinetics and activation in normal B cells and FL B cells can help 
provide insight into potentially important signalling differences which may contribute to 
pathogenesis. An interesting study by Irish et al investigated phosphorylation of BCR 
effector proteins in malignant B cells and non-malignant B cells derived from both 
healthy individuals and those within the FL tumours. Basal phosphorylation of Btk, Syk 
Erk1/2 and p38 did not differ between malignant and non-malignant B cells, disproving 
the hypothesis of constitutive activation of BCR signalling in FL (Irish et al., 2006). 
Another unexpected finding was that following BCR cross-linking, phosphorylation was 
lower in FL cells although Erk1/2 phosphorylation was variable between patients with 
some having increased phosphorylation and others having reduced phosphorylation. As 
this was independent of Syk and Btk phosphorylation, it suggests a novel signalling route 
activated between BCR and Erk1/2 in FL.  When BCR cross-linking was repeated in the 
presence of hydrogen peroxide (H2O2), a phosphatase inhibitor, there was increased 
phosphorylation amongst all four phosphoproteins, suggesting BCR signalling in FL has 
a strong negative regulation by protein tyrosine phosphatases (PTPs). Compared to 
infiltrating non-tumour B cells, BCR-mediated signalling via phosphorylation of Btk, Syk, 
Erk1/2, and p38 occurred more rapidly in tumour B cells and sustained greater levels of 
per-cell signalling which was sustained for hours. There was strong inter-individual 
variability in both the magnitude and kinetics of the signal, highlighting the 
heterogeneity in BCR signalling in FL disease. Heterogeneity was further supported by a 
later study by Irish et al which identified an FL cell subset with impaired BCR signalling 
that was associated with an unfavourable prognosis (Irish et al., 2010). Phosphatase 
inactivation reversed BCR signalling inhibition in these cells, suggesting increased 
negative regulation as a cause of impaired signalling rather than an abrogation of the 
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BCR signalling pathway. As the disease progressed following therapy, the subset 
expanded, highlighting the changes to BCR signalling as the disease evolves and different 
subclone populations gain dominance. This expansion could support the notion of intra-
tumour signalling heterogeneity contributing to therapy failure and relapse.  
Amin et al also compared BCR signalling in FL cells, looking specifically at IgM+ and IgG+ 
FL cases. They compared findings to healthy IgM+ or IgG+ GC B cells. IgM+ FL cells were 
shown to be effectively stimulated through cross-linking alone when compared to their 
normal GC B cell counterpart, despite having significant phosphatase activity (Amin et 
al., 2015). However, IgG+ FL cells did not exhibit an increased BCR response following 
cross-linking alone compared with normal IgG+ GC B cells and was even shown to have 
reduced signalling which was corrected following phosphatase addition. This 
heterogeneity in signalling could be due to reduced BCR expression on IgG+ FL cells and 
different phosphatase activity between the two isotype groups.  
Regarding the source of BCR stimulation, two scenarios have been hypothesised. The 
first is through antigen stimulation.  A study in which tumour derived Ig was tested 
against tissue antigens revealed that 26% of FLs were self-reactive (Sachen et al., 2012). 
Myloferin was identified as a self-antigen for one patient and despite ongoing SHM, self-
reactivity of the BCR remained constant in tumour subclones, suggesting a positive 
selection of a BCR that recognises the antigen. Building on this, Cha et al found that a 
subgroup of patients (19.35%) had immunoglobulins that were reactive to vimentin, 
indicating it as a shared autoantigen (Cha et al., 2013). Interestingly, these cases were 
more commonly IgG+ than IgM+, suggesting that IgG+ FLs are more commonly self-
reactive than IgM+ cases. This observation, in addition to only a subset of FL cases being 
self-reactive, suggests there is heterogeneity regarding the source of BCR stimulation. 
The second inferred source of BCR activation stems from the observation that the 
majority of FLs carry high mannose glycans in their Ig variable region (Radcliffe et al., 
2007). These bulky oligosaccharides impair BCR affinity to its cognate antigen (Schneider 
et al., 2015), however, activate BCR signalling through binding to calcium-dependent (C-
type) lectins which are found in the tumour microenvironment (Coelho et al., 2010, 
Linley et al., 2015). This antigen-independent BCR activation pathway will be discussed 
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in depth in the chapters below. Figure 1.6 summarises the two proposed sources for BCR 
stimulation. 
 
 
Figure 1.6: Model of BCR stimulation in FL. The left-hand panel highlights FL cases which are capable of 
recognising self-antigen. Two identified antigens, myloferin and vimentin, are shown. The right-hand 
panel depicts the scenario of high mannose glycans in the variable region of the immunoglobulin that are 
able to interact with lectins expressed on immune cells, such as dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN) and activate BCR signalling through an antigen-
independent pathway.  
 
1.12 Genetics of FL 
 
Next-generation sequencing (NGS) platforms have begun to unravel the genetic 
landscape of FL tumours by identifying several recurrent somatic mutations in genes 
involved in a variety of cellular pathways, including immune surveillance and signalling 
pathways associated with BCR, NFKB and JAK-STAT. Table 5 gives a non-exhaustive list 
of genes recurrently mutated in patients. Mutations can arise through loss or gain of 
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chromosomal segments, with certain alterations being more frequently found in FL, as 
described below.  
Aberrations in histone modifying genes are present in nearly all FL patients, indicating 
epigenetic deregulation as a hallmark of FL. Epigenetics, which means ‘outside 
conventional genetics’ is used to describe modifications of gene expression and activity 
without affecting the DNA sequence (Felsenfeld, 2014). This includes DNA methylation 
and histone modification. 
 
Pathway Gene Frequency 
(%) 
Function Oncogenic 
alteration 
Epigenetic 
regulation 
KMT2D  70-90 Histone H3K4 
methyltransferase 
Loss of function 
CREBBP 50-79 Histone H3K27 and 
H3K18 acetyltransferase 
Loss of function 
EZH2 20-30 Histone H3K27 
methyltransferase 
Gain of function 
EP300 10-20 Histone H3K27 and 
H3K18 acetyltransferase 
Loss of function 
Transcription 
factors 
STAT6 10-15 JAK-STAT signalling Gain of function 
FOXO1 10 Downstream of BCR 
signalling 
Gain of function 
MEF2B 10-20 Regulator of BCL6 Gain of function 
Signalling RRAGC 15-20 Guanine nucleotide-
binding protein 
Gain of function 
TNFRSF14 30-40 Inhibit HVEM signalling Loss of function 
CARD11 10-15 BCR–NF-κB signalling 
pathway 
Gain of function 
Nucleosome 
remodelling 
ARID1A 10-15 Alter chromatin 
structure 
Unknown 
BCL7A 10 Alter chromatin 
structure 
Unknown 
Table 1.5: Recurrent mutations in FL with frequencies of 10% and above. Information was adapted from 
Kuppers and Stevenson (Kuppers and Stevenson, 2018) and Huet et al (Huet et al., 2018a).  
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1.12.1 Chromosomal alterations: 1p36 and 6q deletions 
 
In addition to the t14;18 translocation, FL is characterised by additional chromosomal 
aberrations, with the most common being non-random losses of 1p36 and 6q and gains 
of 7, 18, and X (Schwaenen et al., 2009, Johnson et al., 2008, Cheung et al., 2009a, 
Horsman et al., 2001). 1p36 region alterations (deletions and acquired uniparental 
disomy) were described as one of the most frequent secondary genetic abnormality in 
FL (Cheung et al., 2010a), with 6q deletions found in 10-15% of cases (Cheung et al., 
2009a). NGS has begun to identify genes affected by these aberrations.  The tumour 
necrosis factor receptor superfamily 14 (TNFRSF14) gene is located on 1p36, and 
following a ~12kb deletion of the region, is inactivated (Cheung et al., 2010a, Launay et 
al., 2012). Mutations in TNFRSF14 occur at high frequencies in FL patients (30-40%) and 
in PTFL patients (>25%) (Martin-Guerrero et al., 2013, Louissaint et al., 2016, Schmidt et 
al., 2016) which otherwise have very contrasting genetic landscapes. TNFRSF14 lesions 
are similar between the two variants, including deletion or copy number–neutral loss of 
heterozygosity of chromosome 1p. TNFRSF14 encodes for the herpes virus entry 
mediator (HVEM), a transmembrane receptor expressed on B cells that attenuates T cell 
proliferation and effector response following engagement with T cell expressed B- and 
T-lymphocyte attenuator (BTLA) (Sedy et al., 2005, Gavrieli et al., 2003, Krieg et al., 2005, 
Watanabe et al., 2003). The HVEM-BTLA axis was also shown to inhibit BCR signalling by 
reducing Syk activity and in turn reduced activation of downstream signalling molecules 
(Vendel et al., 2009). Knockdown of HVEM or BTLA in the VavP-BCL2 mouse model 
resulted in accelerated progression of FL development and additionally resulted in a 
tumour supportive microenvironment, through an increase in TNF family cytokines and 
follicular T helper cells (TFH) which secrete IL-4 and IL-21 (Boice et al., 2016, Crotty, 2014). 
This highlights HVEM as having a tumour suppressor function, which is supported by its 
ability to inhibit proliferation of adenocarcinoma cells (Harrop et al., 1998) and enhance 
Fas-induced apoptosis in non-Hogkin’s lymphoma cells (Costello et al., 2003). However, 
how TNFRSF14 mutations translate to clinical outcome is unclear. A study by Cheung et 
al found that TNFRSF14 mutations correlated with an inferior OS and disease-specific 
survival (DSS) (Cheung et al., 2010b). In contrast, Launay et al found mutated patients 
had a better overall survival than non-mutated (Launay et al., 2012). However, HVEM 
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can mediate several costimulatory and co-inhibitory pathways (Shui et al., 2011) and 
therefore further studies are necessary to determine the global functional 
consequences of TNFRSF14 mutations in FL. 
 
The second most common chromosome alteration is the deletion of 6q. Several studies 
have shown that 6q deletions are linked to patient survival suggesting the presence of 
tumour suppressor genes within this region (Offit et al., 1993, Nanjangud et al., 2007). 
A seminal study by Oricchio et al used a pooled shRNA library specific for genes located 
in the different 6q common regions of deletion and then tested their ability to rescue 
BCL2 overexpressing pro B-lymphocytes following growth factor withdrawal (Oricchio et 
al., 2011). This study provided the first evidence for Ephrin receptor A7 (EPHA7) as a 
tumour suppressor gene. The knockdown of EPHA7 in the FL mouse model, vavPBcl2, 
resulted in accelerated lymphomagenesis, similar to the effects of MYC. FL histology was 
unchanged and lymphomas had a low Ki-67, resembling the slow proliferation seen in 
human FL. When recombinant EPHA7 ectodomain (EPHA7FC) was administered to 
lymphoma cell lines, the proliferation of cells was dramatically reduced, highlighting 
EPHA7’s role as a tumour suppressor in FL pathogenesis. This was in part the result of 
EPHA7 inhibiting another Ephrin receptor, EPHA2, from forming a homodimer and its 
subsequent oncogenic signalling through ERK and STAT3.  When FL TMAs were 
examined for EPHA7 expression, 72% were completely absent for the protein in contrast 
to the clear expression seen in healthy tonsil controls.   
 
The impact of chromosomal alterations on clinical outcome, by themselves or in 
combination, has been investigated (Cheung et al., 2009a, Horsman et al., 2001, Viardot 
et al., 2003). While these studies have suggested a correlation between aberrations and 
inferior survival, findings were highly variable likely due to a lack of experimental 
reproducibility and patient variability. A later study by Johnson et al (Johnson et al., 
2008) performed on diagnostic samples exclusively found that an additional X 
chromosome in males was the only aberration to correlate with prognosis, indicating an 
inferior overall survival. 
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1.12.2 Epigenome 
 
While epigenetic modifications are essential to mammalian development (Reik, 2007), 
its deregulation can result in altered transcription states, contributing to a malignant 
transformation in both solid and hematologic tumours. This is expressed through global 
DNA hypomethylation and silencing of tumour suppressor genes through 
hypermethylation, resulting in genomic instability (Esteller, 2008, Feinberg and 
Vogelstein, 1983, Merlo et al., 1995). Epigenetic deregulation is considered a hallmark 
of FL pathogenesis, given that mutations in chromatin-modifying genes occur with high 
frequency and often occur concurrently with other epigenetic modifiers within 
individual cases, suggesting that promotion of lymphomagenesis through epigenetic 
deregulation is the result of a culminated effect. Mutations affect the function of several 
histone methyltransferases and histone acetyltransferases, including KMT2D (also 
known as MLL2) and CREBBP, respectively. Truncating and missense mutations in 
KMT2D are found in 60-90% of FL patients whereas loss of function mutations in CREBBP 
are found in up to 70% of patients (Green et al., 2013, Morin et al., 2011, Okosun et al., 
2014, Pasqualucci et al., 2011a, Pasqualucci et al., 2014). Alterations promote GC 
proliferation and block differentiation through their effects on tumour suppressor genes 
regulating B cell development. Normal KMT2D targets the following lymphoid tumour 
suppressor genes; TNFAIP3, SOCS3, and TNFRSF14 (Molavi et al., 2013, Cheung et al., 
2010b, Compagno et al., 2009). However following its inactivation, loss of methylation 
at lysine 4 on histone 3 (H3K4) in the enhancers and promoters of these genes, likely 
lead to transcriptional repression and deregulated GC B cell proliferation. CREBBP 
acetylates two non-histone proteins tp53 and bcl6, leading to activation of tp53 
mediated apoptosis and inactivation of bcl6 function (Pasqualucci et al., 2011a). 
Therefore, loss of function results in inhibition of TP53 mediated apoptosis and 
enhanced bcl6 activity. Bcl6 is a transcription repressor with its expression carefully 
modulated during B cell development. It is highly expressed in GC B cells and prevents 
premature activation and differentiation of GC B cells while also allowing a tolerance to 
DNA breaks required for SHM and CSR of the immunoglobulin genes (Basso and Dalla-
Favera, 2012). The enhanced activity of BCL6 may in part be responsible for GC 
expansion and maturation block. BCL6 is also recurrently altered by chromosomal 
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translocations and somatic hypermutation in FL (Akasaka et al., 2003, Bastard et al., 
1994, Otsuki et al., 1995), with a higher prevalence of translocation frequencies found 
in patients who go on to transform to aggressive DLBCL (Akasaka et al., 2003).  
 
EZH2, a methyltransferase that catalyses methylation at histone 3 lysine 27, is mutated 
in up to 30% of FL cases (Sneeringer et al., 2010). Mutations result in a gain of function, 
and as EZH2 is a transcriptional repressor, mutations lead to a permanent silencing of 
genes involved in cell cycle checkpoints and B cell differentiation, enabling rapid B cell 
proliferation within the GC. Individually, KMT2D, CREBBP and EZH2 mutations were 
shown to promote lymphomagenesis in presence of BCL2 overexpression, as evidenced 
in the VavP-BCL2 mouse model (Zhang et al., 2015, Zhang et al., 2017, Beguelin et al., 
2013, Berg et al., 2014).  
 
The reversible nature of epigenetic modifications makes them an attractive drug target. 
To date, the FDA had licenced several epigenetic therapies in the treatment of 
haematological malignancies, including myelodysplastic syndrome and multiple 
myeloma (MM) (Garcia-Manero and Fenaux, 2011, Laubach et al., 2015). However, in 
FL, several trials using epigenetic modifying agents including histone deacetylase (HDAC) 
and EZH2 inhibitors as single agent therapies have shown disappointing complete 
response rates (Evens et al., 2016, Morschhauser et al., 2017, Kirschbaum et al., 2011, 
Ogura et al., 2014). 
 
1.12.3 Genetics of transformed FL 
 
As previously mentioned, tFL is clonally related to the previous FL disease, sharing an 
identical t14;18 translocation. Therefore, the genomic profile of tFL consists of 
alterations both shared and distinct from the paired FL, which was illustrated in studies 
using paired FL-tFL samples. Recurrently shared mutations, occur in the following genes; 
CREBBP, KMT2D, EZH2, TNFRSF14 and FAS (Okosun et al., 2014, Pasqualucci et al., 2014), 
indicating histone modification, apoptosis resistance and immune modulation as 
pathways affected in the CPC. Recurrent mutations specifically gained at transformation 
include CDKN2A deletions and/or loss of heterozygosity (Pasqualucci et al., 2014), 
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deletions and loss of heterozygosity affecting TP53 and deregulation of MYC through 
point mutations, chromosomal translocations or copy number amplification (Lo Coco et 
al., 1993, Sander et al., 1993, Yano et al., 1992, Lossos et al., 2002). As these aberrations 
impact on cell proliferation and DNA damage pathways, it is likely that these processes 
contribute to transformation. Deletions in genes involved in immune recognition control 
such as B2M and CD58 were also found at higher frequencies in tFL, suggestive of 
immune surveillance escape being a contributor. Several gene mutations found in both 
FL and t-FL but which could not be assigned to either shared or phase-specific due to 
their variability, included STAT6, FOXO1 and CARD11 (Pasqualucci et al., 2014), 
suggesting a heterogeneous contribution of multiple signalling pathways to both FL and 
tFL pathogenesis. In comparison to FL, tFL has a more complex genetic profile with 
distinguishing alterations in genes such as MYC and TP53 (Lossos and Gascoyne, 2011, 
Davies et al., 2007). As the majority of DLBCL-like tFL resembles de novo GCB, a 
comparison between thirty nine tFL and one hundred and two de novo GCB-DLBCL cases 
revealed similar genetic alterations in REL, EZH2, GNA13, and TNFRSF14 mutations 
(Morin et al., 2010, Morin et al., 2011, Pasqualucci et al., 2011b). Additionally, t-FL also 
has specific aberrations rarely seen in de novo DLBCL including loss of CDKN2A/B, STAT6 
mutations, ARID1A mutations and FAS mutations/deletions (Pasqualucci et al., 2014). It 
is unlikely that a single driving oncogenic event exists for transformation due to the lack 
of uniformity across cases (Pasqualucci et al., 2014, Bouska et al., 2014, Davies et al., 
2007) and instead requires a specific sequence of genetic ‘hits’ to confer an aggressive 
phenotype. 
 
1.12.4 Genetic heterogeneity in FL 
 
Recurrent genetic and epigenetic mutations in patients give us an indication into key 
pathways perturbed in the disease. Yet there is significant genetic heterogeneity in 
disease, reflecting the complex biology of disease. This has complicated identifying 
further hallmark mutations of disease, in addition to the t14;18 translocation. 
Furthermore, heterogeneity is not only restricted between patients but also in different 
subclonal populations within an individual. Araf et al performed profiling on spatially 
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separated, synchronous biopsies and found spatial discordance in several genes 
including TNFAIP3, TNFRSF14 and EP300 (Araf et al., 2018). This was in part due to 
differences in clonal dominance between sites, in which a mutation in a subclonal 
population at one site becomes clonally dominant at another site. The intra-tumour 
heterogeneity highlights the shortfalls of genetic landscape profiling in FL from single 
site biopsies and compromises the precision medicine approach so sought after in FL 
treatment, with Darwinian selection most likely to result in treatment failure. However, 
CREBBP and KMT2D mutations were found to be clonally maintained in spatially 
separated biopsies, reaffirming them as early events in pathogenesis and therefore a 
more robust target for therapeutic intervention.  
 
1.13 Microenvironment     
 
In addition to intrinsic genetic aberrations, cross-talk between lymphoma cells and their 
microenvironment is considered critical to tumour pathogenesis and survival.  Similar to 
their normal counterparts, FL cells are admixed with immune cells, including stromal 
cells, macrophages and follicular helper CD4+ T cells in invaded follicles (Carbone et al., 
2009). The difficulty of growing FL cells in vitro without stimulation through CD40 
engagement (Ghia et al., 1998), a main signalling pathway of B and T cell interactions, 
supports a direct tumour-immune cell interaction. A pivotal study by Dave et al in which 
the gene expression of non-malignant immune cells was analysed elucidated how 
important the immune system, irrespective of tumour genetics, is in determining the 
clinical outcome (Dave et al., 2004). Enrichment for genes expressed in T cells was found 
to be associated with a favourable prognosis, whereas genes expressed in macrophages 
and follicular dendritic cells are strongly associated with poor clinical prognosis. 
However, results from subsequent immunohistochemistry (IHC) studies investigating 
how the number and arrangement of immune cells impacts on prognosis has been highly 
variable due to the heterogeneity of treatment and patient selection criteria (Carreras 
et al., 2009, de Jong et al., 2009, Lee et al., 2006). 
In general, the germinal centre is a hostile microenvironment for B cells, in which those 
displaying low affinity BCRs for their cognate antigens are deprived of survival signal and 
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undergo apoptosis. One way in which FL cells subvert this Darwinian selection process 
is through constitutive expression of the anti-apoptotic protein, bcl2. However, there 
are additional mechanisms which support tumour survival. FL cells expressing high levels 
of CXCR4 and CXCR5 are recruited into follicles by chemokines secreted from follicular 
helper T cells (TFH) and dendritic cells, including CXCL13 and CXCL12/SDF-1 (Lopez-Giral 
et al., 2004, Ame-Thomas et al., 2007, Husson et al., 2002). FL cells also promote the 
secretion of CCL2 from stromal cells which although having no direct effect on B cell 
survival, leads to monocyte recruitment and therefore modulation of the 
microenvironment (68). Mesenchymal stromal cells (MSC) were also found to drive 
monocyte differentiation towards a pro-angiogenic and anti-inflammatory tumour 
associated macrophage (TAM)-like phenotype, with up-regulation of IL-10, IL-6 and 
VEGF (Guilloton et al., 2012).  
IL-4 is up-regulated within the FL microenvironment and is predominantly produced by 
TFH cells (Pangault et al., 2010). IL-4 binds to its receptor on tumour cells and activates 
STAT6 responsive genes that may promote survival of the tumour cells (Lu et al., 2005). 
It also stimulates the production of CCL17 (Rawal et al., 2013), which facilitate 
recruitment of regulatory T cells (TRegs) that may generate an immunosuppressive 
tumour microenvironment and promote immune evasion (Zou, 2005).  In addition, the 
gene expression profile of tumour infiltrating lymphocytes were also shown to have an 
altered gene expression profile that corresponds to impaired actin polymerization and 
immune synapse formation, leading to T-cell exhaustion that can be repaired with the 
immunomodulatory drug lenalidomide (Ramsay and Gribben, 2011, Ramsay et al., 
2009). 
Therefore, the FL cell niche both promotes tumour growth and organises the 
microenvironment through cell recruitment, polarisation and survival signalling to 
provide a pro-tumour environment. Mechanisms for how this is achieved remains to be 
fully elucidated.  
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1.13.1 N-linked glycosylation of follicular lymphoma surface immunoglobulin 
 
N-linked glycosylation (N-gly) is a common protein modification that occurs co-
translationally within the endoplasmic reticulum (ER) of eukaryotic cells (Aebi, 2013). A 
fourteen sugar precursor is covalently bound to the carbamino nitrogen on asparagine 
residues within the specific glycosylation amino acid motif N-X-S/T (where N stands for 
asparagine, X could be any amino acid except proline, S stands for serine and T stands 
for threonine) on the nascent protein. The glycan then undergoes trimming and 
maturation in the Golgi to transform from a high mannose oligosaccharide to a complex 
glycan, as summarised in Figure 1.7. Complex glycoproteins can be transported to the 
cell surface, where they can take part in cell–cell interactions required for adhesion, 
migration and signalling (Varki, 1993, Saxon and Bertozzi, 2001). 
 
 
Figure 1.7: N-glycosylation trimming and maturation in the Golgi. The fourteen sugar precursor glycan 
attached to the asparagine (Asn) reside of the N-X-S/T amino acid motif undergoes trimming in the ER 
through the action of glycosidases. This results in the removal of 3 terminal glucose residues (not shown 
here). The glycoprotein is then trafficked to the Golgi where Mannosidase I removes terminal mannose 
residues, leaving a high mannose glycan. N-acetylglucosamine transferase (GlcNAc transferase) transfers 
the monosaccharide N- acetylglucosamine to the glycan chain, followed by more trimming and addition 
of different sugar molecules. This results in the production of branched, complex oligosaccharides. 
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N-gly motifs are found within the immunoglobulin, mainly confined to the constant 
regions (Radcliffe et al., 2007). During B-cell development, an N-linked glycosylation site 
in the first constant region of the μ-chain is essential for a functional pre-B cell receptor 
(Ubelhart et al., 2010). A few germline encoded variable genes also carry sites, including 
IGHV1–08, IGHV4–34 and IGHV-5a (Radcliffe et al., 2007). Interestingly, during the SHM 
process of FL Ig, the number of N-gly motifs in the variable region increases significantly, 
with the majority occurring in the heavy chain compared to the light chain (Zhu et al., 
2002, Zabalegui et al., 2004). Motifs are most prevalent within the CDR regions (McCann 
et al., 2008), which are associated with antigen binding. The acquisition of at least one 
motif occurs in >90% of FL cases (McCann et al., 2008). Interestingly, this phenomenon 
also occurs at high frequencies in other GC centre B cell lymphomas including DLBCL and 
Burkitt’s lymphoma (Zhu et al., 2002). Acquisition in non-GC B cell lymphoproliferative 
disorders, including multiple myeloma and CLL, is considerably lower, with an incidence 
range of 3-18%, similar to the value  seen in normal somatically mutated B cells (~9%) 
(Alcoceba et al., 2012). Importantly, acquired sites in FL are conserved during ongoing 
mutation, in contrast to germline-derived sites (McCann et al., 2008).   
To determine the glycosylation profile at these introduced sites, IgM proteins derived 
from the B cells of FL patients were exposed to specific glycosidases. Analysis revealed 
high mannose-terminating glycans (Coelho et al., 2010) (Figure 1.8), an unusual finding 
as surface proteins normally display branched and complex oligosaccharides that have 
undergone processing in the ER and Golgi (Aebi, 2013, Varki, 1993, Saxon and Bertozzi, 
2001). Interestingly, N-glycosylation sites in the constant region are fully processed 
(Radcliffe et al., 2007), suggesting that normal Golgi transit is maintained and sugar 
processing enzymes remain functional. This infers that the added oligomannose have a 
tumour related function. This is supported by the observation that all somatically 
mutated N-gly sites in FL are oligomannosylated (McCann et al., 2008). Interestingly, 
germline-encoded N-gly sites such as that found in the CDR2 region of V4-34 are not 
glycosylated (McCann et al., 2008), suggesting introduced sites have a biological 
significance in FL.  
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Figure 1.8: Mannosylation of sIg derived from two FL patients with known N-gly sites. Endoglycosidase H 
(Endo-H) and Peptide:N-Glycosidase F (PNGase) cleave either mannosylated or all N-glycans, respectively. 
FL proteins contain additional mannosylated glycans as seen through increased mobility of protein 
following Endo-H treatment. The distance of migration correlates to the number of N-gly sites in the heavy 
chain variable region (indicated in brackets), suggesting all sites are mannosylated. Image is taken from 
Coelho et al (Coelho et al., 2010). 
 
N-glycans were found to severely impair cognate antigen binding in the CDRs and 
antigen-induced BCR stimulation (Radcliffe et al., 2007, Schneider et al., 2015). This was 
indirectly supported by Sabouri et al discovering how N-glycans block self-antigen 
binding on anergic B cells, modulating antibody avidity and redeeming autoantibodies 
from self-reactivity (Sabouri et al., 2014). The prevalence of sites within the antigen 
binding CDRs, suggests that oligomannoses interact with their microenvironment 
through an antigen-independent mechanism, enabling FL residence and proliferation 
within the GC. 
 
1.13.2 Interaction between oligomannosylated Ig and C-type lectins 
 
Binding studies using oligomannosylated FL sIg and mannose-binding lectin (MBL), 
confirmed that glycans were accessible for binding to calcium-dependent (C-type) 
lectins (McCann et al., 2008), suggesting a novel interaction between tumour cells and 
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their microenvironment through oligomannose engagement. C-type lectins are pattern 
recognition receptors (PRR) that bind to glycans through their carbohydrate binding 
domains (2009). They have a wide variety of roles including phagocytosis/antigen 
presentation of pathogens and mediation of endogenous cell-cell interaction during the 
immune response (Dambuza and Brown, 2015, Geijtenbeek and Gringhuis, 2009). As 
genes associated with macrophages and dendritic cells are predictive of poor prognosis 
(Dave et al., 2004), it was hypothesised that lectins expressed on these immune cells 
were candidate molecules for interaction with sIg mannoses. Two major C-type lectins 
were proposed which have specificity for high mannose structures and are expressed by 
macrophages and dendritic cells; mannose receptor (MR) and DC-SIGN (DC-specific 
intercellular adhesion molecule-3–grabbing non-integrin). In vitro studies revealed that 
mannosylated sIgM from primary FL cells interacted with both lectins and induced sIgM-
associated intracellular calcium fluxes, highlighting a functional interaction (Coelho et 
al., 2010). In addition, recombinant human DC-SIGN incubation with IgM positive FL cells 
led to phosphorylation of BCR signalling kinases, including ERK1/2 and AKT, and 
increased expression of MYC (Linley et al., 2015, Amin et al., 2015). This highlights the 
activation of the BCR pathway (and its associated targets) through an antigen-
independent mechanism. Although phosphorylation of kinases was delayed and 
reduced in comparison to control anti-IgM treatment, the duration of response was 
longer (Linley et al., 2015). Furthermore, the sIg failed to undergo endocytosis, 
suggesting that constitutive activation of the BCR signalling pathway through DC-SIGN 
engagement is enough to maintain FL survival. These effects were lost with the 
treatment of Btk and Syk inhibitors, providing support to BCR activation via the lectin-
mannose interaction (Linley et al., 2015). The proposed mechanism is summarised in 
Figure 1.9. DC-SIGN was found to be strongly expressed on M2 macrophages and 
dendritic cells derived from FL samples (Amin et al., 2015) which may have relevance to 
the poor prognosis associated with a high CD68+ macrophage count (Dave et al., 2004). 
It was also found to be in direct contact with FL cells in situ, indicating the feasibility of 
DC-SIGN as a FL specific BCR ligand within the disease niche (Amin et al., 2015). Bacterial 
lectins Pseudomonas aeruginosa and Burkholderia cenocepacia were also shown to bind 
to FL sIg and induce sIg-associated intracellular calcium fluxes (Schneider et al., 2015), 
indicating the vast array of potential lectin candidates that may be utilised in disease 
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pathogenesis. There is a dispute regarding the Ig isotype able to bind DC-SIGN. Linley et 
al found both IgM+ and IgG+ FL cell were able to bind to DC-SIGN and activate signalling 
(Linley et al., 2015). However, Amin et al found that IgG+ FL cells were poorly activated 
by DC-SIGN (Amin et al., 2015). These discrepancies may be due to technical and 
IgG+/IgM+ case variation between the two studies. However, as IgG+ FLs are more 
commonly self-reactive (Sachen et al., 2012), the lowered affinity to lectins may be due 
to alternative stimulation (via autoantigen) of the BCR within this isotype subgroup. This 
warrants further investigation. 
While DC-SIGN and MR are well described in innate immunity (Engering et al., 1997, 
Geijtenbeek et al., 2000), the evidence is accumulating regarding their role in tumour 
immunity. Cross-linking of MR on immature dendritic cells with anti-MR antibody was 
shown to activate DC maturation and induce the secretion of anti-inflammatory 
cytokines and Th2 attracting chemokines, leading to negative regulation of Th1 polarised 
responses (Chieppa et al., 2003). Interestingly, similar responses are seen when the 
receptor is engaged with cancer-derived glycoproteins. For example, ligation of MR with 
the ovarian cancer derived glycoprotein TAG-72 on TAMs lead to increased IL-10 
production and decreased CCL3 (Allavena et al., 2010), the Th1 attracting chemokine. 
This immune dampening response is also seen when DC-SIGN is engaged with colon 
cancer derived glycoproteins, leading to an increased IL-10 expression (Nonaka et al., 
2008). IL-10 production promotes polarisation of M2 macrophages (Allavena et al., 
2010), the phenotype displayed by FL derived TAMs. MR and DC-SIGN are highly 
expressed on TAMs (Amin et al., 2015), suggesting that these lectins play a role in 
polarising the immune cells to create a pro tumour, immune suppressive 
microenvironment. This suggests another dimension to the lectin-mannose interaction 
in the support of tumourigenesis. 
Mannose-lectin interactions motifs could enable FL cells to survive and accumulate 
mutations within the hostile GC through both stimulating the BCR and creating a tumour 
supportive microenvironment. Determining how N-gly motifs influence disease 
evolution could provide validation for targeting this tumour-microenvironment 
interaction. Promising evidence has been seen in a case study in which ISFN cells 
gathered from several lymph nodes of a 69 year old male contained a conserved N-gly 
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motif (NCS) in the CDR3 region of the IGHV, suggesting N-gly motifs can be acquired 
within malignant precursor cells, perhaps in parallel with the t(14:18) translocation 
(Kosmidis et al., 2017). This was supported in another case study of a 35 year old male 
in which clonally related ISFN and FL cells shared an acquired motif within the CDR2 
region of the IGHV (Mamessier et al., 2015). Having a functional mannose-lectin 
interaction at this early stage in disease development may explain how precursor cells 
are able to survive in the hostile germinal centre without the need for high affinity BCRs 
enabling accumulation of genetic hits required for malignant transformation.  
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Figure 1.9: Model highlighting the inferred interaction between FL cells and the microenvironment via the 
mannose-lectin interaction. N-glycosylation motifs located in the variable region of the sIg on FL cells is 
an acceptor site for high mannose glycans. C type lectins including DC-SIGN are expressed on macrophages 
and dendritic cells. These selectively bind to the high mannose structures, leading to the organisation of 
the BCR and CD19 co-receptor signalling platforms and downstream phosphorylation of signalling kinases, 
including SYK, BTK, ERK and AKT (10). How this interaction may affect the partnering immune cell 
expressing DC-SIGN/MR in the context of FL has not been investigated. Image adapted from Strout, 2015 
(Strout, 2015). 
 
1.14 Current challenges in FL 
 
Despite improvements to patient survival following the introduction of Rituximab, FL 
remains an incurable disease with a relapse-remitting pattern. The varying clinical 
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outcomes of patients, with some having durable responses to first-line treatment whilst 
others progress or transform suggest an underlying intrinsic biological heterogeneity in 
the disease. This has been exemplified by NGS that has revealed a complex and variable 
genetic landscape. Recurrent mutations in specific genes have been identified, 
indicating biological pathways perturbed in disease, including epigenetic regulation. 
However, these mutations are not found within all patients and vary in clonal 
dominance, not just between patients but also in spatially separated biopsies from 
individual cases (Araf et al., 2018). Heterogeneity is also illustrated by the vast number 
of minor subclones identified from IGHV sequences (Carlotti et al., 2015). Targeting a 
mutation in a clonal population may therefore enable a minor subclone to gain 
dominance, leading to relapse. This heterogeneity of subclones and their genetics 
compromises the approach of precision medicine. Targeting early events in 
pathogenesis which are conserved clonally would likely have the most beneficial impact 
on sustained remission, which is why characterising events of the putative CPC 
compartment is an important area of research in FL. Genetic changes in the CPC are 
being investigated and characterised (Okosun et al., 2014), yet CPC-microenvironment 
interactions remain unexplored despite our extensive knowledge on the importance of 
microenvironment-tumour cell interactions in pathogenesis.  
 
1.15 Aims of this thesis 
 
Acquired N-gly motifs in the variable region of the IGH are believed to possess a 
pathogenic function due to their high frequency in FL cases and rarity in healthy 
somatically mutated B cells. This is likely conferred by their attachment to high 
mannoses and subsequent interaction with lectins, which activate the BCR signalling 
pathway. Determining at what stage of tumour evolution these motifs are acquired will 
validate their role in disease development.  
The primary aim of this thesis was to determine whether N-gly motifs are acquired 
within the putative CPC population by investigating the behaviour of N-gly sites during 
ongoing SHM and disease progression. To do this we analysed the incidence and 
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maintenance of sites within the heterogeneous clonal repertoire of several patients 
taken at different time points of disease, ranging from diagnosis to transformation. 
Temporal samples were either taken from the same or different anatomical sites. Clones 
were derived through targeted sequencing of the IGHV and subclonal relationships were 
visualised through lineage trees. To our knowledge, this is the first study that has 
analysed the relationship between FL progression and N-gly sites in a variable patient 
cohort who have undergone different lines of therapy and presented with different 
clinical courses, reflecting the heterogeneous nature of the disease. 
The second aim was to use a unique, in-depth multiplex phenotyping method to 
investigate the tumour microenvironment with regards to expression of the C-type 
lectins, DC-SIGN and MR. Using digital image analysis software, the in situ frequency, 
distribution and spatial arrangement of lectin-expressing immune cells was analysed in 
tissue sections derived from a heterogeneous FL patient cohort. Patients had an overall 
survival of less than five years or greater than fifteen years, enabling us to compare the 
microenvironmental landscape in extreme survival cases and investigate the prognostic 
value of lectin expression in FL disease. 
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Chapter 2: MATERIALS AND METHODS 
 
 
2.1 Patient samples and ethics 
 
For sequencing studies, readily available genomic DNA samples were previously 
extracted from lymph node biopsies of patients affected with FL at different time points 
of disease including diagnosis, relapse and tFL. Written consent was obtained for 
collection and use of specimens for research purposes with ethical approval obtained 
from the Institutional Review Board under the following submissions: 10/H0704/65 and 
06/Q0605/69. Clinical information was available through the database maintained 
within the Centre for Haemato-Oncology at Barts Cancer Institute. 
For immunohistochemistry studies, whole section slides were prepared from diagnostic 
paraffin-embedded lymph node blocks from patients diagnosed with FL at St 
Bartholomew’s Hospital (London, United Kingdom). Ten slides were prepared for 
patients whose survival was less than five years and ten slides were prepared for 
patients whose survival was greater than fifteen years following diagnosis. Whole 
sections from reactive lymph nodes of ten healthy subjects were used as a control. 
Ethical approval for this study was obtained from East London and the City HA Local 
Research Ethics Committee under the submission 05/Q0605/140. 
All tumour biopsies were reviewed by a panel of haemato-pathologists to confirm the 
diagnosis. Further description of samples can be found within the relevant results 
chapters of this thesis.  
 
2.2 Cell lines 
 
Germinal centre derived B-NHL cell lines (SU-DHL4 and SU-DHL6) were previously 
obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ). 
Both cell lines were t(14:18) positive. SU-DHL4 expresses IgG whereas SU-DHL4 
expresses IgM, the two immunoglobulins dominantly expressed on FL cells. Cryovials 
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containing cells  passaged four times (stored in 10% DSMO, 10% foetal calf serum (FCS) 
and RPMI 1640 medium) were removed from liquid nitrogen storage (-196⁰C) and 
thawed in a water bath set to 37⁰C. 1ml of 37⁰C RPMI 1640 medium supplemented with 
1% penicillin/streptomycin and 10% FCS were added to the vial and transferred to 15ml 
falcon tubes containing 9ml of medium before spinning at 1000rpm for 5 minutes at 
room temperature (20⁰C). Supernatant was discarded and the cell pellet was 
resuspended in 10ml of medium before transfer to a sterile T75 tissue culture flask and 
incubated in a humidified 5% CO2 incubator at 37⁰C. Following an initial slow cell growth 
due to acclimatizing to new conditions, cells were passaged approximately every three 
days to maintain optimal cell density and viability as indicated from cell line profiles on 
the DSMZ website. Morphology and density of cells was assessed under light microscope 
as well as to check for contamination signs. Mycoplasma testing was carried out 
regularly.  
Cell viability and density measurements were carried out using the LUNA-II™ Automated 
Cell Counter (Logos Biosystems). Measured viabilities were determined by a dye 
exclusion method, using Trypan blue staining. Live cells do not take up the dye due to 
their intact cell membrane leaving the cytoplasm unstained. Therefore, cells stained 
blue are considered dead. Following thorough resuspension of cells, 10µl of cell sample 
was mixed with 10µl of Trypan blue dye before being loaded into a cell-counting 
chamber on the Luna slide. Similar to normal haematocytometers, the Luna performs 
multiple cell counts in a known area and outputs a mean value. >85% viability 
highlighted adequate growth conditions, in terms of cell density and nutrient supply.  
 
2.3 DNA extraction from cell lines 
 
Total DNA extraction was carried out using the DNeasy Blood and Tissue kit (Qiagen, Cat 
No. 69504). 5 x 106 cells were taken from the cell suspension, and centrifuged for 5 
minutes at 300 x g at room temperature. Supernatant was discarded and cell pellet 
resuspended in 200µl of phosphate buffered saline (PBS). 20µl of proteinase K was 
added to the pellet along with 200µl of Buffer AL. Sample was pulse vortexed briefly and 
mixed to ensure effective lysis. Proteinase K is a serine protease that eliminates proteins 
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and DNases that may affect DNA. Buffer AL contains a chaotropic salt, which has an 
additive effect to protein destabilisation by disrupting hydrogen bonds in water, which 
denatures biomacromolecules. Furthermore, chaotropic salts disrupt the interaction of 
DNA with water and enable it to bind to silica. Samples were incubated at 56⁰C for 10 
minutes. 200µl of 100% ethanol was added to samples and pulse vortexed. Ethanol 
precipitates nucleic acids out of solution. The mixture was transferred to a QIAmp Mini 
Spin Column placed inside a 2ml Eppendorf. The column was centrifuged at 6000 x g for 
one minute. Precipitation by ethanol enables the separation of nucleic acids from the 
rest of the solution with the DNA binding to the silica membrane and contaminants 
passing through. 500µl of Buffer AW1 was added followed by a centrifuge at 6000 x g 
for 1 minute. Flow through was discarded. 500µl of buffer AW2 was added and sample 
was centrifuged at 20000 x g for 3 minutes. These washing steps are essential for 
removing residual contaminants from the DNA including chaotropic salts. A dry spin of 
two minutes ensures removal of ethanol. Finally, 200µl of Buffer AE is added to the spin 
column followed by a five minute stand period. The column is centrifuged at 6000 x g 
for 1 minute, resulting in the elution of DNA from the silica into a 1.5ml eppendorf. 
Purified DNA was stored at 4⁰C. 
 
2.4 IGHV amplification 
 
We sought to amplify the IGHV from FL samples. Due to the vast number of V, D and J 
segments, we used the widely validated Biomed consortium’s multiplex PCR approach 
in which all functional VH family members were able to be recognised by one of 6 VH 
consensus primers, targeting the Framework 1 region (van Dongen et al., 2003). This is 
due to 6-7 oligonucleotides in each primer binding to its corresponding VH family 
member with no mismatch. These primers were used in conjunction with a single JH 
consensus primer designed to anneal to the 3’ end of all six known JH gene segments 
(Figure 2.1). Taq polymerase lacks a proofreading 3’-5’ exonuclease domain and 
therefore cannot remove a misincorporated nucleotide. As single nucleotide 
polymorphism (SNP) analysis is critical to identifying acquired N-glycosylation motifs and 
analysing SHM-based evolutionary pathways, minimising SNPs generated by polymerase 
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reading errors required using a high fidelity polymerase. This was achieved by using the 
Phusion Green Hot Start II High-Fidelity PCR Master Mix, comprising of the Phusion Hot 
Start II High-Fidelity DNA Polymerase, nucleotides, a reaction buffer containing MgCl2, a 
density reagent that permits direct loading of the PCR products to the gel, and two 
tracking dyes. The tracking dyes were bromophenol blue and xylene cyanol FF that 
comigrates with approximately 300bp fragments and approximately 4000bp fragments, 
respectively, enabling the rate of migration of DNA molecules to be monitored. The 
master mix reduces the amount of pipetting steps and therefore lessens the risk of 
contamination during the reaction set up. A 10µl reaction consisting of 5µl of master 
mix, 0.5µl of FR1 primer mix (each individual primer at 10µM, 0.5µl of JH primer (10µM), 
2µl of nuclease-free water and 2µl of genomic DNA (20ng/µl). The polymerase activity 
is inhibited at ambient temperature and therefore reaction setup can be done at room 
temperature, without the risk of primer dimer formation and non-specific amplification 
products. A no template control (NTC) consisting of all components apart from DNA was 
included in all experimental runs to exclude contamination with exogenous DNA. The 
cycling conditions consisted of an initial denaturation step at 95⁰C for 30 seconds, 
followed by 40 cycles of DNA denaturation at 95⁰C for 30 seconds, then primer annealing 
at 58⁰C for 30 seconds, then primer extension at 72⁰C for 30 seconds and a final 
extension step of 72⁰C for 7 minutes. Following heteroduplex analysis and Sanger 
sequencing of the homoduplex band (described below), the PCR was repeated using a 
single FR1 primer corresponding to the IMGT-VQUEST identified VH family.  
 
Figure 2.1: Molecular organisation of an IGH VH-JH rearranged sequence in genomic DNA. VH family FR1 
primers and a single consensus JH primer were used to target and amplify this region during multiplex 
PCR. Primer sequences (indicated) were taken from the BIOMED2 protocol (van Dongen et al., 2003). 
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2.5 Heteroduplex analysis 
 
A drawback of the PCR technique in lymphoma-based IGHV studies is the risk of false 
positive results generated by amplification of IGHV from polyclonal B cells, especially 
when there is a high background of polyclonal B cells existing in the tumour sample. To 
discriminate between monoclonal and polyclonal PCR products, heteroduplex analysis 
is used. In heteroduplex analysis, PCR products are denatured at high temperatures and 
then reannealed by rapid cooling to create duplexes. Homoduplexes are formed by 
monoclonal PCR products (with identical junction regions) whereas heteroduplexes are 
formed by polyclonal PCR products (with heterogeneous junction regions), resulting in 
a smear of slow migrating fragments on a polyacrylamide gel (Figure 2.2).  
 
 
Figure 2.2: Schematic diagram of the heteroduplex analysis technique. PCR products are heat denatured 
and quickly cooled to induce duplex formation. In cell samples consisting of clonal B cells (left panel), PCR 
products give rise to homoduplexes whereas samples with clonal and polyclonal B cells present give rise 
to homo- and heteroduplexes (middle panel). Polyclonal samples will mainly form heteroduplexes (right 
panel). Homoduplexes have matched junctional regions and therefore migrate more rapidly through the 
polyacrylamide gel. Heteroduplexes have mismatched junctional regions and therefore have an open 
conformation at these sites, causing them to migrate slowly through the gel, enabling distinction between 
monoclonal and polyclonal samples. 
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The clonal gene rearrangements in lymphoma cells were distinguished from polyclonal 
normal cells using heteroduplex analysis. PCR products were incubated at 95⁰C for 
denaturation and then rapidly cooled to 50⁰C for 1 hour for reannealing. Samples were 
then promptly put on ice and 1x gel loading dye was added. Samples were added to 
wells of non-denaturing 10% polyacrylamide gel (Novex) with one additional well 
containing a 100bp DNA ladder as a size reference. Electrophoresis was performed with 
20mA applied to the gel in 1x TBE running buffer for 14 hours at 4⁰C. The gel was then 
submerged in 1x TBE buffer containing 3x GelRed (Biotium) and gently agitated at room 
temperature for 30 minutes. Bands were then viewed under ultraviolet (UV) light. 
Prominent homoduplex bands located at the 300-400bp mark represented the 
sequence of the IGHV region of the major clone (highest count number) whereas faint 
bands located nearer to the top of the gel represent non-malignant polyclonal PCR 
products (Figure 2.2). Homo-duplex bands were extracted, and DNA recovered using 
QIAquick® Gel Extraction Kit, followed by re-amplification by PCR. Following 
visualisation by agarose gel and UV light, PCR products underwent clean up and Sanger 
sequencing.  
 
2.6 Gel extraction 
 
Bands located at the 300-400bp mark which corresponds to the amplified IGHV were 
excised from the gel. DNA was extracted using the QIAquick® Gel Extraction Kit (Qiagen) 
following the manufacturer’s instructions.  
 
2.7 Agarose gel electrophoresis 
 
IGHV PCR products were visualised on agarose gels. 2% agarose gels were prepared 
using 2g of agarose in 100ml of 1x TBE buffer. Agarose was melted in the buffer by 
heating. 5µl of GelRed (Biotium) was promptly added to the gel. GelRed is a fluorophore 
that intercalates with nucleic acids resulting in DNA visualisation under UV light. The gel 
mix was poured into an appropriate sized gel cast tray and combs applied to create wells 
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for sample loading. Once the gel was set following a twenty minute period, the gel was 
placed in 1x TBE running buffer. 15µl of PCR product was added to each well with an 
additional well containing a 100bp DNA ladder (exACTGene™, Fisher Scientific) used to 
identify amplicons of the appropriate size. Electrophoresis was performed for one hour 
at 100V. As DNA is negatively charged, it migrates towards the positive electrode 
through the agarose pores with small fragments migrating faster and large fragments 
migrating slower. DNA bands were visualised by transillumination under UV light that 
excites the fluorophore, producing a bright orange colour. Images were collected 
digitally.  
   
2.8 PCR product clean-up 
 
To remove any unincorporated nucleotides and primers, enzymatic clean up preceded 
sequencing to minimise interference. The ExoSAP-IT kit (Thermofisher) was used 
following manufacturers guidelines. The minimal pipetting steps reduce contamination 
of the product. 2µl of ExoSAP-IT reagent was added to 5µl of PCR sample, followed by 
an incubation step of fifteen minutes at 37⁰C. This activates two enzymes, Exonuclease 
I and Shrimp alkaline phosphatase in the ExoSAP-IT reagent. Shrimp alkaline 
phosphatase removes 5’ phosphates from unincorporated nucleotides whilst 
Exonuclease I specifically digests single-stranded DNA containing a 3’ OH group in the 3’ 
to 5’ direction. This selectivity ensures that the double-stranded PCR product is not 
affected by these enzymes and only residual primers and unincorporated nucleotides 
are removed. An incubation step at 80⁰C for fifteen minutes inactivates the enzymes. 
PCR products were stored at -20⁰C or proceed directly to sequencing.  
 
2.9 Nucleic acid assessment: Nanodrop   
 
DNA quality and quantity were assessed by spectrophotometry using the NanoDrop ND-
1000 Spectrophotometer (ThermoFisher). Nucleic acids absorb at a wavelength of 
260nm. The amount of absorbance of a sample generates an optical density (OD) value 
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(OD260) which is multiplied by a factor of 50 to determine DNA concentration (ng/µl), 
which multiplied by the total volume, gives the overall DNA quantity of the sample. The 
TE buffer used to resuspend the DNA was used to create a baseline value to calculate 
DNA concentration. The OD value at 280nm is used to create the 260nm/280nm ratio 
which indicates the purity of DNA. Abnormalities in the 260/280nm ratio can indicate 
contamination of the sample with protein or reagents such as phenol which are used in 
DNA gel extraction methods. The OD value at 260nm is used to establish the 
260nm/230nm ratio, a further assessment of purity. As many contaminants associated 
with the DNA extraction process absorb at 260nm and 230nm, a low ratio indicates a 
low DNA purity. A ratio of ~1.8 and ~2-2.2 for the 260nm/280nm and 260nm/230nm 
ratios, respectively, is indicative of contaminant-free DNA. 
 
2.10 Nucleic acid assessment: Qubit 
 
DNA destined for NGS platforms was quantitated using the Qubit® 2.0 Fluorometer 
(Invitrogen, Life Technologies), an approach that uses fluorescent dyes to selectively 
bind to either double or single-stranded DNA, RNA or protein, making it a more sensitive 
approach than UV absorbance by the Nanodrop. To quantify double-stranded DNA, the 
Qubit® dsDNA BR Assay Kit was employed. A range of standards was made up using 
190µl of Qubit working solution and 10µl of the appropriate Qubit standard. Standards 
were used to calibrate the machine. 2µl of sample was added to 198µl of Qubit working 
solution and mixed by a pulse vortex. Samples and standards were incubated at room 
temperature for 2 minutes. Following calibration with the standards, samples were read 
on the machine and concentrations given in µg/µl. To gain the real concentration of the 
sample before its 2:200 dilution, the following equation was used;        
                                             Concentration of sample = QF value × (200/2)  
                                                  where: QF value = the value given by the Qubit® 2.0 Fluorometer  
                                                              2 = the number of microliters of sample added to the assay 
tube. 
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2.11 Sanger sequencing 
 
5µl of purified PCR product (~20ng/µl) mixed with 2.5µl of 10µM JH primer were sent to 
the Eurofins Genomics Sanger sequencing services (Germany) for bidirectional capillary 
electrophoresis using the ABI PRISM 3730XL Genetic Analyser. Sanger sequencing is 
based on synthesising DNA strands complementary to a single-stranded DNA template, 
therefore, a denaturation step of ~95⁰C is required. In addition to the template DNA, it 
requires DNA polymerase, complementary DNA primer, the four deoxynucleotide 
triphosphates (dNTPs) and four modified nucleotides (ddNTPs), each labelled with a 
distinct fluorescent dye and lacking a 3’ hydroxyl group. When ddNTPs are incorporated 
into the DNA strand, they prevent further extension by DNA polymerase as the absence 
of a hydroxyl group inhibits phosphodiester bond formation between two nucleotides. 
As a result, fragments of different sizes are produced which then undergo capillary 
electrophoresis. The exciting of the fluorophore generates a fluorescent signal, 
identifying the nucleotide in the original DNA template. Fragments of every possible 
length are generated through stoichiometric manipulation of the reaction components, 
revealing the entire reverse sequence of the template strand.  
 
2.12 Analysis of sequencing results: IMGT/V-QUEST 
 
AB1 and .seq files provided by Eurofins Genomics were analysed and interpreted by 
BioEdit Sequence Alignment Editor and Lasergene EditSeq. Electropherograms were 
checked by eye to ensure sequences were of good quality and base calls reliable for 
further analysis. This included ensuring peaks were evenly spaced and minimal baseline 
noise was present. The beginning and end sequences of the chromatogram were 
discarded due to lack of reliability. The FASTA format of sequences was submitted to 
IMGT/V-QUEST, a human Ig reference database that aligns nucleotide sequences to the 
V, D and J genes with the closest sequence homology (www.imgt.com). It also identifies 
the number and location of P- and N-nucleotides insertions at the junctional regions 
which occur during the somatic recombination process.  As the tool can identify 
sequences in the reverse orientation and perform complementary reverse, no data 
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manipulation is required with the sequence generated by JH primer. Once the V gene 
was identified, the Sanger sequencing process was repeated with the JH primer being 
replaced by the appropriate VH Framework 1 primer. This was to accurately sequence 
the CDR3 region so that all variable region gene segments were identified, including the 
D and J segments. Furthermore, this ensured that identified mutations in the first Sanger 
sequencing were accurate.  
 
2.13 Identification of acquired N-glycosylation sites 
 
To determine the N-gly sites, the NetN-glyc 1.0 online server was used 
(www.cbs.dtu.dk/services/NetNGlyc/). Nucleic acid sequences were first translated 
using Transeq (EMBOSS) and entered in FASTA format. The server screens for consensus 
N-linked glycosylation motifs, consisting of asparagine (N), any amino acid except 
proline (X) and either serine or threonine (S/T). It also predicts which N-gly motifs are in 
fact glycosylated, a useful tool as we did not have access to primary FL cells from our 
paired FL-tFL samples to carry out glycosidase treatment of sIg (McCann et al., 2008, 
Coelho et al., 2010). To do this, nine neural networks interrogated each input sequence 
for N-X-S/T motifs, generating an average glycosylation potential score at the motif site. 
When a potential of >0.5 is reached and ≥7/9 networks are in agreement, the motif site 
is considered glycosylated. Motifs with proline as the middle amino acid are not 
considered glycosylated by the server, due to the amino acid causing steric hindrance of 
the asparagine residue (Gavel and von Heijne, 1990). To determine whether N-gly motifs 
were naturally occurring (germline-encoded) or acquired through SHM, sequences were 
aligned to germline immunoglobulin sequences in IMGT/V-QUEST.  
 
2.14 Analysis of selection pressures 
 
Normal B cells are selected based on their immunoglobulin’s affinity for antigen, which 
can be visualised through the analysis of somatic mutation patterns in the IGHV 
(replacement versus silent). An increased frequency of replacement mutations in the 
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CDRs and a reduced frequency of replacement mutations in the framework regions 
which provide the structural backbone to the receptor, is indicative of antigen-driven 
selection. To determine whether our NGS derived sequences showed signs of antigen-
driven selection, I used the online program BASELINe version 1.3 (Yaari et al., 2012). 
BASELINe is a statistical computational framework that quantifies selection from large-
scale Ig sequence data by analysing the distribution of silent and replacement mutations 
in the CDRs and FWRs and comparing it to an expected frequency (Yaari et al., 2012, 
Uduman et al., 2011). The V gene sequences derived from the experimental data were 
inputted into the program in a single FASTA formatted file. This included the germline 
sequence which was placed above the sequences and contained an additional ‘>’ in its 
title as an identifier to the program. The analysis output included identification of point 
mutations for each sequence, describing whether they were silent or replacement, and 
indicating their location in the variable region (CDRs or FWRs). This is compared against 
the expected frequency. P-values were also generated for both CDRs and FRWs 
indicating the selection strength which could be either positive or negative. The results 
from the multiple sequences were combined and gave a graphical output of the 
BASELINe analysis. An example is given below (Figure 2.3). The narrower the curve, the 
more confident the selection.                                      
 
Figure 2.3: Graphical output from BASELINe. A value on the left-hand side of 0 (indicated by a dotted 
line) indicates a negative selection and a value on the right-hand side indicates a positive selection. This 
selection pressure profile graph is characteristic for antigen driven clonal expansion, with positive 
selection in the CDRs and negative selection in the FWRs. A negative PCDR/FWR indicates a more positive 
selection in CDRs compared to FWRs in clonally related sequences. 
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2.15 BCL2-IGH breakpoint analysis 
 
As the t14;18 translocation occurs during the precursor B cell stage of development and 
is retained in tumour cells, the t14;18 breakpoint, which is unique to the clone, is often 
used to determine clonality between serial samples. This was to ensure that all 
successive events had arisen from a shared B cell precursor and were not de novo 
events. A qualitative analysis of the breakpoint was investigated through PCR and Sanger 
sequencing. The majority of breakpoints occur in the major breakpoint region (MBR), 
therefore a primer targeting a region of the BCL2 gene which is upstream of this site was 
employed (Gribben et al., 1993). A consensus JH primer targeting the six germline JH 
segments was also utilised. The 5’ to 3’ sequence of primers is given below (Table 2.1). 
The PCR was performed using the HotStarTaq Master mix (Qiagen) with the PCR reaction 
detailed below (Table 2.2 and Table 2.3). A NTC was used in addition to a positive control 
(SU-DHL6) to evaluate sensitivity. Amplified PCR products were visualised on a 2% 
agarose gel, followed by clean-up and then sequenced using MBR and JH primers. The 
size of DNA bands differed between patients depending on the breakpoint location.  
 
Primer 5’-3’ sequence 
MBR CTATGGTGGTTTGACCTTTAGAGAG 
JH  ACCTGAGGAGACGGTGACC 
Table 2.1: Primers used to amplify the BCL2-IGH gene rearrangements in temporal FL samples. Primer 
sequences flank the major breakpoint region (MBR) of BCL2 and JH region in the immunoglobulin heavy 
chain gene 
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Component Volume (µl) 
HotStarTaq Master Mix 5 
Coral Red Dye 1 
Forward Primer (10mM)-MBR 1 
Reverse Primer (10mM)-JH 1 
Nuclease-free water 1 
DNA (50ng/µl) 2 
Final Volume 11 
Table 2.2: BCL2-IGH breakpoint analyses PCR master mix 
 
Step Temperature (⁰C) Time  
Initial denaturation 95 5 minutes  
Denaturation 95 30 seconds  
40 cycles Annealing 63 30 seconds 
Extension 72 30 seconds 
Final extension 72 7 minutes 
Hold 4 -  
Table 2.3: PCR cycling conditions used to amplify the BCL2-IGH gene rearrangements 
 
The sequences were entered into BLAST (https://blast.ncbi.nlm.nih.gov/), a web 
alignment tool that finds regions of similarities between query nucleotide sequences 
and genomic databases. The top two hits included BCL2 (Accession No. NC_000018.10) 
and IGH (Accession No. NC_000014.9). The fusion site was identified as the nucleotides 
at the interface of the BCL2 and IGH sequences which was unique to each patient.  
 
2.16 Cloning 
 
To analyse tumour subclones with differing IGHV sequences, IGHV PCR products were 
cloned using the TOPO TA cloning kit (Thermofisher). As the PCR products generated 
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using the proofreading enzyme are blunt-ended, 3’ adenine overhangs were added for 
insertion into the plasmid vector. This was necessary as blunt-end cloning is ~100X less 
efficient than overhang cloning (Yao et al., 2016), resulting in fewer colonies in addition 
to the PCR product being inserted into the vector in the incorrect orientation. Following 
amplification of the IGHV, the PCR product was purified to ensure removal of 
proofreading DNA polymerase. A 10µl reaction mixture was set up in a standard PCR 
tube (Table 2.4). 
 
Component Volume (µl) 
Purified blunt-ended PCR product (100ng) 2 
dATP (1mM) 1 
GoTaq Flexi DNA polymerase (5u/µl) 0.2 
5 X GoTaq Reaction buffer (colourless) 2 
Nuclease-free H2O 4.8 
Table 2.4: Reaction mixture for adding 3’ adenine overhangs to blunt-ended PCR product. 
 
The reaction mixture was incubated at 72°C for 30 minutes in a thermal cycler to add 3 
A’ overhangs to PCR products. The reaction mixture was placed on ice before directly 
proceeding to cloning.  
TOPO cloning utilises the Vaccinia virus topoisomerase I which functions as both a 
restriction enzyme and a ligase. Topoisomerase recognises the sequence 5´-(C/T)CCTT-
3´ which are found in the TOPO vectors and cuts at these sites, generating 3’ overhangs 
of  thymidine residues which then allows a single PCR amplicon with 3’ adenine 
overhangs to ligate with the vector using ligation activity of topoisomerase I. These 
vectors are then transformed into E-coli which then replicate the recombinant DNA 
along with the host DNA, giving rise to bacterial colonies containing multiple copies of 
the DNA sequence, established from a single PCR amplicon. Different colonies contain 
different PCR amplicons which can then undergo sequencing to determine 
heterogeneity within the initial PCR product.  
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2µl of the reaction mixture described above containing the 3 A’ overhang PCR product 
was added to 1µl salt solution (200 mM NaCl and 10mM MgCl2), 1µl of pCR®2.1-TOPO® 
vector (Figure 2.4) and 2µl of water. The cloning reaction was incubated for 5 minutes 
at room temperature to enable insertion of the PCR product into the vector. 2µl of the 
cloning reaction mix was added to one vial of One Shot® Chemically Competent E. coli 
and mixed gently before incubation on ice for 30 minutes. Cells were pre-treated with 
calcium chloride which enables close contact between the plasmid and the cells and 
facilitates plasmid uptake. The cells were then ‘heat shocked’ for 30 seconds at 42°C to 
enable plasmid entry by creating pores in the cell membrane. Immediate transfer of the 
tubes to ice results in restoration of the cell membrane potential. 250µl of room 
temperature S.O.C medium was added and tubes were shaken for 1 hour (200rpm) at 
37°C to enable the recovery of E coli cells following the transformation process. 50µl and 
100µl of medium were spread on two separate, pre-warmed LB agar plates containing 
ampicillin (50µg/ml) and X-gal (40mg/ml). Two plates at different volumes ensured that 
at least one plate would have well-spaced colonies which would be easy to pick. The 
pCR®2.1-TOPO® vector contains an ampicillin resistance gene (Figure 2.4) and therefore 
only E.coli which have been successfully transformed with the vector will survive on the 
ampicillin-coated plate.  
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Figure 2.4: pCR™2.1 TOPO® TA vector. The vector has several restriction enzyme sites within the MCS 
including sequences that are recognised by topoisomerase I, which creates thymidine overhangs that are 
complementary to the adenine overhangs of the PCR product (highlighted), enabling successful 
incorporation of the DNA into the vector. The vector has ampicillin and kanamycin resistant genes and 
either of these antibiotics can be used in selection of E.coli transformed cells. 
 
The vector also contains a LacZα gene that encodes for β-galactosidase, an enzyme that 
metabolises lactose. As the PCR product is inserted into a multiple cloning site (MCS) 
within the LacZα gene, the production of a functional β-galactosidase is inhibited (Figure 
2.4). As X-gal is a substrate for β-galactosidase, and forms an insoluble blue pigment 
upon its hydrolysis (Figure 2.5), we were able to differentiate which vectors have 
successfully taken up the PCR product by the colours of the colonies. Blue colonies have 
no insert as the LacZα gene had not been disrupted whereas white colonies indicated 
successful incorporation of the insert as X-gal has not been hydrolysed by β-
galactosidase (Figure 2.5).  
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Individual white colonies representing different PCR amplicons were picked. The vector 
also contains M13 sequences within the multiple cloning site (Figure 2.4), enabling direct 
sequencing of individual colonies using either using M13 forward (CATTTTGCTGCCGGTC) 
or M13 reverse (GTCCTTTGTCGATACTG) primers. PCR amplification of the colonies was 
carried out to ensure enough sample for sequencing. Each colony was individually 
resuspended in 48μl of Platinum™ SuperFi™ PCR Master Mix (Thermofisher) and 1μl of 
both forward and reverse M13 primer. The reaction was incubated for ten minutes at 
94⁰C before amplification for 35 cycles of denaturation, reannealing and extension at 
95⁰C, 56⁰C and 72⁰C, respectively. This was followed by a final extension of seven 
minutes at 72⁰C before a 4⁰C hold.  1x gel loading dye was added to the PCR product 
before sample underwent agarose gel electrophoresis. Bands were visualised under UV 
light and purified before sending for sequencing (Germany). 
 
 
Figure 2.5: Visualisation of successful incorporation of the DNA in the plasmid vector. X-gal is hydrolysed 
by β-galactosidase, an enzyme encoded by the LacZα gene, to produce galactose and 5-bromo-4-chloro-
3-hydroxyindole. 5-bromo-4-chloro-3-hydroxyindole undergoes oxidation and dimerisation to produce 
the insoluble blue pigmented precipitate, 5,5’-dibromo-4,4’-dichloro. When the LacZα gene is disrupted 
by DNA insert, β-glactosidase is not produced and therefore cannot catalyse hydrolysation of X-gal. 
Determing which plasmids have taken up the DNA insert and which haven’t can be visualised by blue-
white screening of colonies on an agar plate which contains X-gal.  
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2.17 Targeted amplicon sequencing  
 
Amplicon sequencing enables ultra-deep sequencing of PCR products to enable variant 
identification at a much higher sequence depth and lower cost than WGS. This is 
advantageous in the detection of clonal and importantly, subclonal variants.  
Following PCR amplification of the IGHV, 100ng of purified DNA was sent to Genewiz 
(UK) for paired end 2x250bp sequencing using the Illumina Miseq platform. Additional 
quality control (QC) was performed using the D1000 ScreenTape assay to determine 
suitability of the DNA for the NGS platform. This required 1-2 µl of DNA sample to 
undergo automated electrophoresis and gel imaging to assess the quantity, size and 
integrity of DNA using TapeStation analysis software. This step verified the insert size 
was as expected (250-350bp) and there was no contamination by larger or smaller DNA 
fragments.   
 
2.17.1 Preparation of libraries 
 
Samples underwent multiplexed sequencing in which DNA libraries are tagged with 
unique indexes made of eight nucleotides enabling multiple samples to be pooled onto 
a single flow cell and sequenced simultaneously. This offers the benefit of increased 
experimental throughput whilst maintaining low error rates due to tag identification. 
Indexes are added to DNA fragments during adapter ligation, carried out using TruSeq 
DNA Library Preparation Kit (version 2). Firstly, the 3’ ends of the DNA fragments were 
adenylated (addition of a single adenine nucleotide), a process known as A-tailing, to 
prevent fragments from ligating to each other. The 5’ ends of the DNA fragments are 
phosphorylated, which enables successful ligation. Adapters are partial double-stranded 
molecules containing the full complement of sequencing hybridization sites, including 
read 1 and read 2 specific sequencing primer sites, index primer site and complementary 
sequences to the flow cell (Figure 2.6). The 3’ end of the adapter contains a thymidine 
nucleotide overhang which is complementary to the adenine overhang on the DNA 
fragment, resulting in ligation of the adapter to the DNA. PCR was used to selectively 
enrich DNA fragments with adapters ligated to both ends. The PCR primers anneal to 
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the ends of the adapters and amplify the amount of DNA in the library. Final indexed 
DNA libraries are normalised to 10nM and pooled in equal volumes in preparation for 
cluster generation.    
 
 
Figure 2.6: DNA library preparation. Single adenines were added to the 3’ ends of amplicons. A 
corresponding single thymidine nucleotide on the 3’ end of the adapter provides a complementary 
overhang for ligating the adapter to the fragment. The adapter consists of the Read 1 sequencing primer 
site (Rd1 SP), Read 2 sequencing primer site (Rd2 SP), an index sequencing primer site, and two sequences 
(P5 and P7) that are complementary to the two types of primer attached to the surface of the flow cell 
used for cluster generation through bridge amplification. Only DNA fragments which have adapters 
incorporated on both ends are able to form clusters on the flow cell. 
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2.17.2 Cluster generation and sequencing by synthesis 
 
Single-stranded DNA libraries are applied to a flow cell coated with oligonucleotides that 
are complementary to those found on the adapter region of the DNA, specifically P5 and 
P7 oligonucleotides. When DNA binds to the complement oligonucleotides on the flow 
cell, cluster generation occurs in which approximately a million copies of the template 
strand are created through bridge amplification. Reverse strands are then washed away 
and the 3’ end of the forward strands are blocked before they undergo sequencing. The 
sequencing primer binds to it complementary sequence near the 3’end followed by 
incorporation of fluorescently labelled ddNTPs by a polymerase. Only one fluorescently 
tagged ddNTP is added to the growing chain per cycle based on the sequence of the 
template. All identical strands in a cluster are sequenced simultaneously. A light source 
excites the fluorophore, resulting in an emittance of a fluorescent signal in the cluster 
after each round. The fluorophore is then cleaved and the 3’ hydroxyl group is 
regenerated with a reducing agent, enabling the next ddNTP to be added and the 
process is repeated. This is known as sequencing by synthesis (SBS). After the Read 1 
product is produced, it is washed away. The index primer is then introduced and anneals 
to the same strand to produce the 8-bp index read which is used to identify samples 
during downstream analysis (Figure 2.7). To produce a paired-end read, the 3’ end of 
the strand is unblocked and the template folds over and bind the second oligonucleotide 
on the flow cell surface, resulting in the regeneration of the complementary (reverse) 
strand (Figure 2.7). Following linearization of the DNA, the forward strands are removed 
and the complementary strands are sequenced following binding of the read 2 
sequencing primer to its site on the strand to generate the paired read 2 product. 
Sequences were de-multiplexed according to their index read sequences to identify 
sample origin.  
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Figure 2.7: Multiplexed paired-end sequencing process. (A) Forward strands attached to the flow cell are 
used to create Read 1 products. Complementary primers to the Rd1 SP sequence bind and polymerases 
add fluorescently labelled ddNTPs through SBS. (B) The Read 1 product is then removed and an index 
primer then binds to the index sequence to produce an 8bp index read. This read is then removed, 
followed by the forward strand forming a bridge with the second set of oligonucleotides on the flow cell 
(not shown) and producing a complementary (reverse) strand (C). The forward strands are removed, 
leaving the reverse strand to undergo sequencing following primer binding to the Rd2 SP site. 
 
2.17.3 Phasing  
 
An issue of the Illumina is that as the number of cycles increases, the quality of base calls 
decrease, resulting in the end of reads being less accurate than the beginning of reads. 
This is because the SBS process relies on sequencing millions of identical molecules (a 
cluster) simultaneously, with each cycle adding one nucleotide at a time. However, a 
small proportion of molecules in the cluster will not undergo extension and remain on 
the base of the previous cycle, becoming out-of-sync to the rest of the cluster. These 
molecules will pollute the light signal emitted from the fluorophores coupled to the 
newly incorporated nucleotide in the majority of molecules. This is known as phasing 
(Figure 2.8). The proportion of molecules affected by phasing increases with cycle 
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number, hindering the correct identification of bases in longer reads (Erlich et al., 2008, 
Kircher et al., 2009). To reduce base inaccuracy in the CDR3 region of the IGHV, paired-
end sequencing was employed, in which the forward and reverse strands were 
sequenced (Figure 2.9). The reads generated were 250bp in length. Based on a 300bp 
IGHV fragment, the reads overlapped by 200bp, a sufficient amount to enable merging 
of reads, yielding sequences of higher quality that accounted for sequencing errors.  
 
Figure 2.8:  Reduced base quality during ongoing cycling using Illumina technology. a) During one cycle, 
clusters incorporate a single fluorescently labelled nucleotide (left panel). When molecules of a cluster do 
not incorporate a new nucleotide during the next cycle (right panel), they are one base behind the rest of 
the cluster (e.g. out of phase), resulting in pollution of the light signal used to generate base calls. b) 
Typical range of quality scores (y-axis) across all bases at each position in the read (x-axis). Yellow boxes 
represent the inter-quartile range (25-75%), the red line represents the median value, and the blue line 
represents the mean quality.  
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Figure 2.9: Paired-end read length in relation to target DNA fragment length. The reads overlap by 200bp 
based on a 300bp fragment.  
 
2.17.4 PhiX Spike-in 
 
Because the B cell clones carry a highly similar sequence and therefore low base 
diversity, a 30% PhiX Spike-in was included to allow accurate base calling and ensure the 
complexity of the run.  The PhiX genome library has a diverse base composition with all 
four nucleotides present in similar quantities (45% GC, 55% AT), compensating for the 
low base diversity in the samples, and therefore assisting with template registration on 
flow cells and as a calibration control for phasing and pre-phasing calculations in 
addition to registering the overall performance of the sequencing run.   
 
2.18 NGS data processing  
 
Data processing was carried out by Genewiz including de-multiplexing, adaptor 
trimming and removal of low quality bases located at read ends. Paired reads were 
merged using the BBMerge script with the default setting requiring a minimum insert of 
35bp and a minimum identical overlap of 12bp to allow merging. Reads that were not 
merged were discarded. Unique sequences (excluding primer sequences) were 
identified and their abundance was quantified as a count number.  
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2.19 NGS processing: IMGT/HIGHV-Quest 
 
Sequences with counts of ≥10 were selected for analysis using IMGT/HIGHV-Quest 
(Alamyar et al., 2012), the high-throughput version of IMGT which is capable of analysing 
up to 500,000 immunoglobulin sequences in a single run. Sequences were first 
converted to the FASTA format and entered into the search page as a text file. Output 
files included the Summary file which contained information for each sequence in 
relation to its functionality, V, D and J genes and alleles with closest homology, junction 
analysis and FR-IMGT and CDR-IMGT lengths, all according to IMGT ontology and 
classification. Because healthy B cells also display immunoglobulins of the IgH-V3 family, 
there was a heterogeneous level of contaminating sequences from normal B cells in our 
sequencing data. However, as we previously identified the major clone for each sample 
through heteroduplex analysis, tumour related sequences were identified as having 
identical V, D, J genes and CDR3 length to the major clone. Following their selection, 
tumour related reads underwent further filtering regarding functionality and CDR 
lengths (Figure 2.10). 
 
 
Figure 2.10: Parameters used in selection and filtering of unique sequences. 
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2.22 NGS processing: Editing 
 
To ensure sequences covered an identical region, multiple sequence alignment program 
(MAFFT) was used (usegalaxy.org) to compare regions of similarity. Sequences with 
deletions or insertions were omitted due to our focus being on single nucleotide 
polymorphisms (SNPs) related to the SHM process. Sequences were trimmed to the 
length represented by the majority of sequences to retain diversity. Duplicate sequences 
were found and omitted, resulting in unique sequences differing from each other by ≥1 
nucleotide. This provided us with our final clonal repertoire of IGHV sequences which 
were used for lineage tree construction below.  
 
2.20 IGHV NGS data for serial FL samples 
 
To validate findings from our IGHV sequencing platform, raw IGHV sequencing data files 
deposited in databases were utilised and underwent processing.  
Tumour-related reads covering the IGHV gene for three patients over different disease 
events were downloaded from the European Nucleotide Archive (ENA) using the 
accession numbers PRJEB9334 and PRJNA240336 (Jiang et al., 2014, Carlotti et al., 
2015). Reads were generated using the Roche 454 Life Sciences Genome Sequencer FLX 
or Illumina Miseq platform. Temporal biopsies were taken either from the same lymph 
node or distinct lymph nodes, which will be detailed in the relevant results chapter. 
 
2.21 IGHV sequences for composite HL and NHL lymphomas 
 
IGHV sequences for Reed Sternberg and FL cells in composite Hodgkin’s lymphoma (HL) 
and FL disease from three patients were downloaded from the ENA using the following 
accession numbers; AJ409171, AJ409173-AJ409186 (Kuppers et al., 2001), AJ011134 and 
AJ011135 (Brauninger et al., 1999). HL and FL cells were derived from the same biopsy 
site, which will be detailed in the section 3.4.17. 
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2.23 Statistical Analysis 
 
Statistical analyses were performed using GraphPad Prism version 5.4 (GraphPad 
Software Inc., La Jolla, CA, USA). Two way ANOVA was used to determine if the 
differences between the number of N-gly positive subclones and N-gly negative 
subclones within each disease event was greater than you would expect to see by 
chance. Statistic tests were considered significant at P ≤ 0.05 (*). A p-value of ≤0.01 was 
identified by two asterisks (**) and a p-value of ≤0.001 was identified by three asterisks 
(***). 
 
2.24 Lineage trees 
 
To visualise clonal expansion and the relationship between individual subclones, lineage 
trees were constructed using the algorithm of the IgTree program (Barak et al., 2008). 
IgTree is specifically designed for Ig sequences, calculating the distance between each 
pair of input sequences to find possible ancestor–progeny relationships, with the 
putative germline sequence being the root of the tree.  
To ensure lineage trees accurate represented the evolutionary hierarchy of lymphoma-
derived clones, the V, D and J gene sequences need to be included as SHM can occur 
across the entire variable region. However, the CDR3 region poses a challenge; during 
somatic recombination, P- and N-nucleotides are added at the junctions between the 
gene segments and are therefore not encoded by genes. The lack of an experimentally 
derived germline IGHV sequence means the original P- and N- nucleotides inserted 
during somatic recombination cannot be identified and therefore within this region we 
cannot determine which nucleotides are present because of SHM or somatic 
recombination, resulting in inaccurate lineage trees. Therefore, P- and N- nucleotide 
regions identified by IMGT/V-QUEST in experimentally derived sequences were changed 
to ‘N’ whilst nucleotides assigned to V, D or J genes were retained. The IgTree program 
ignores these ‘N’ regions, generating lineage trees based only on mutational profiles of 
V, D and J derived sequences. N was also inserted into corresponding sites in the 
putative germline sequence.  
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Following editing and alignment of experimental IGHV sequences and the putative 
germline sequence using MAFFT (usegalaxy.org), the output FASTA file was converted 
to a .PIR file. This file type was used as the input file for the IgTree program.  
The output tree file created is a .vsdot file which is visualised by Graphviz 2.38 (Figure 
2.11). Every distinct sequence is set as a node within the tree, separated from its 
ancestor by one mutation, unless otherwise stated on the connecting branch (Figure 
2.11). If a node has no descendants, it is set as a leaf. White nodes represent subclones 
which are artificially added by the IgTree program to connect experimental subclones. 
The program traces the minimal steps separating experimental sequences from each 
other and the putative germline, with the assumption that this is the naturally occurring 
scenario. It can also account for reversion mutations (point mutation that restores the 
original nucleotide). The program uses a heuristic algorithm to reduce the running time 
of the program and therefore short sequences (~300bp) and closely related sequences 
are best suited to this program. One advantage is that trees are non-binary, reflecting Ig 
evolution in which several B clones can arise from one cell.  
 
Figure 2.11:  Example of a lineage tree created using IgTree and Graphviz. The root of the tree marks the 
known Ig germline (G.L) sequence to which experimental Ig sequences are compared.  Each node 
represents a unique sequence and therefore a subclone. Clear nodes represent clones that have not been 
found from the sequencing data but are implied to exist. Nodes are separated by at least one mutation, 
unless indicated on the branches. Internal nodes give rise to other subclones whereas nodes, which do 
not daughter clones, are set as leaves. The tree enables the visualisation of evolution of 
mutations/subclones within the Ig variable region, making it a useful tool for identifying tumour 
populations and progression. 
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2.25 Immunohistochemistry 
 
Immunohistochemistry (IHC) is able to determine the tissue distribution of a specific 
antigen in situ based on a chromogenic signal. Briefly, the indirect method of IHC utilises 
a primary and secondary antibody to amplify detection of an antigen. The primary 
antibody binds to the target antigen on the tissue via the Fab regions, forming the first 
layer. The secondary antibody which is labelled with an enzyme binds to the primary 
antibody. Following addition of the enzyme substrate, a coloured precipitate is 
deposited at the site of antigen (Figure 2.12).  
 
As DC-SIGN and MR are expressed on macrophages and dendritic cells, we included 
markers to identify these cell types. For macrophages, the pan-marker CD68 and M2 
macrophage marker CD163 were used. CD21 was used to identify follicular dendritic 
cells to determine whether expression of lectins occurred in this germinal centre-based 
dendritic cell type. CD21 is also a marker for mature B cells, however as these lectins are 
not expressed on B cells, CD21+DC-SIGN+/MR+ staining was considered to be restricted 
to follicular dendritic cells.  
 
3µm thick whole sections were cut from tissue blocks and mounted onto glass slides. 
Slides were incubated in a 60⁰C oven overnight to ensure effective adhesion of the tissue 
to the surface and to soften the wax. Slides were prepared for immunostaining by 
complete removal of the paraffin using xylene. Slides were immersed in two rounds of 
xylene for five minutes each. Xylene was then removed and the section re-hydrated 
through graded washes with industrial methylated spirit (IMS) and water. Endogenous 
peroxidase activity was blocked by incubating slides in 2% H₂O₂ in IMS solution for two 
rounds of five minutes. This was to minimise non-specific background staining as 
horseradish peroxidase-conjugated secondary antibodies were later used as the 
substrate for colour precipitation and positive staining. Formaldehyde fixation results in 
cross-linking between proteins, resulting in a change to the tertiary structure and 
potential hindrance of epitope recognition by the primary antibody. To remove 
methylene bridges between proteins, heat-induced epitope retrieval (HIER) was used. 
HIER was performed for ten minutes in a pressure cooker (400⁰C) containing three litres 
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of citrate based antigen unmasking solution (Vector Laboratories H3300) at a 1:100 
dilution in water. Slides were then rinsed in running water for five minutes to remove 
residual unmasking solution and placed in wash buffer (DAKO), a tris-buffered saline 
with tween (TBS-T). From this point on, slides were kept wet to avoid non-specific 
binding of antibody. The area around the section was dried and drawn around using a 
hydrophobic pen. Wash buffer was quickly applied to the section to prevent drying out 
of the tissue. Optimal primary antibody dilutions (using Zytomed Antibody diluent) were 
determined by titration around the dilution recommended from the datasheet (Table 
2.5). Primary antibody directed against the antigen of interest was applied to the section 
for a forty minute incubation.  
 
Antibody (company, catalogue number, clone) Validated working 
dilution 
CD10 (Novocastra, NCL-CD10-270, mouse monoclonal IgM, clone 
56C6) 
1/100 
CD68 (Dako, M0814, mouse monoclonal IgM, clone KP1) 1/8000 
CD21 (Novocastra, NCL-CD21-2G9, mouse monoclonal IgM, clone 
2G9) 
1/100 
CD163 (Novacastra, NCL-L-CD163, mouse monoclonal, clone 10D6) 1/250 
DC-SIGN (LSBio, LS-B479, Rabbit IgG polyclonal) 1/3500 
MMR (R&D, MAB25341, mouse monoclonal IgG, clone 685645) 1/200 
Table 2.5: Primary antibodies and dilution factors. 
 
To visualise antibody-antigen interactions a peroxidase-labelled VIP system (Super 
Sensitive Polymer-Horseradish Peroxidase IHC Detection System; BioGenex) was used. 
A secondary antibody, directed against the species in which the primary antibody was 
raised in, was conjugated to horseradish peroxidase (HRP)-polymers. Following a 30 
minute incubation with the secondary antibody, hydrogen peroxide and the chromogen 
VIP (Vector Laboratories) are incubated with the section which react with the HRP 
polymer to form a purple precipitate. Tissue sections were counterstained in Mayer 
Haematoxylin (Gill’s II) which binds to lysine residues on nuclear histones, resulting in a 
blue stain of the nuclei. Slides were then dehydrated in IMS and xylene before mounting 
with DPX xylene based mountant and left to dry overnight in the fume cupboard. Slides 
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were scanned using the Pannoramic 250 High Throughput scanner to produce high 
quality brightfield images. Quality of scanned slides were checked on the Pannoramic 
Viewer program (Version 1.15.4). 
 
 
Figure 2.12:  Indirect IHC. A primary antibody which recognises epitopes on the antigen of interest binds 
to the surface via its Fab domains. A secondary antibody (conjugated to HRP) which has been raised 
against the host species of the primary antibody then binds to the unlabelled primary antibody. The 
addition of VIP and hydrogen peroxide act as substrates for the HRP enzyme, resulting in precipitation 
of an insoluble purple colour deposit at the site of the antigen. Although not shown here, two or more 
secondary antibodies can bind to a single primary antibody, resulting in signal amplification and 
detection of weakly expressed antigens. 
 
2.26 Principles of multiplex IHC 
 
Analysing the distribution of specific antigens within a tissue enables an important 
insight into the tumour microenvironment and biology of disease. Historically, this was 
performed on serial tissue sections, each stained with a different marker. Yet due to the 
three dimensional structure of the tissue, serial sections do not capture an identical 
array of cells leading to a lack of information regarding cellular co-expression and spatial 
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relationships between cells. Multiplex IHC offers simultaneous visualisation of multiple 
antigens on the same tissue section resulting in a more comprehensive characterisation 
of the microenvironment. This can be performed simultaneously, in which sections are 
stained with a variety of antibody-chromogen pairs that are visualised by either HRP or 
alkaline phosphatase (AP) (Table 2.6). To avoid secondary antibody cross-reactivity, 
primary antibodies must be from different host species (e.g. rabbit, mouse). 
Furthermore, while this method can be useful for different cell types, the co-localisation 
of antigens may be difficult to interpret by overlapping chromogens at a specific site. 
This limits multiplexing capacity and usually no more than three antigens are visualised 
this way. These issues can be overcome by sequential multiplex staining, in which the 
stain is stripped from the section and then re-probed with a different primary antibody. 
A technique developed and validated in our department by Andrew Clear (Ball et al., 
2017) enables up to six repeated re-probes on whole tissue sections with very little 
amendment to the protocol described in section 2.25.  
 
Chromogen Catalytic agent Deposition colour 
DAB HRP Brown 
DAB + Ni HRP Black 
AEC HRP Red 
VIP HRP Purple 
NBT/BCIP AP Deep blue 
Vulcan Fast Red AP Red 
Vector Black AP Black 
Nova Red HRP Deep red 
TMB HRP Blue 
Table 2.6: Chromogens used in multiplex IHC (brightfield). DAB (3,3′-Diaminobenzidine), Ni (Nickel), AEC 
(3-Amino-9-ethylcarbazole), NBT/BCIP(Nitroblue tetrazolium and 5-Bromo-4-chloro-3-indolyl 
phosphate), TMB (3,3',5,5'-Tetramethylbenzidine), HRP (Horseradish peroxidase), AP (Alkaline 
phosphatase). Table taken from Stack et al, 2014 (Stack et al., 2014). 
 
 
103 
 
2.27 Sequential multiplex IHC: stripping and re-probing 
 
Following high-resolution scanning, slides were placed overnight in xylene, until 
coverslips could be easily removed without damaging the section. As the slides were 
dehydrated and mounted with a xylene based solution (DPX mountant, Sigma), 
rehydration was required before stripping, using graded IMS and water washes.  
Following a five minute incubation in running water, slides were placed in a pressure 
cooker for ten minutes containing 3L of citrate based antigen unmasking solution 
(Vector Laboratories H3300) at a 1:100 dilution in water for HIER. After cooling and 
rinsing in water, slides were checked by eye against a white background to detect any 
colour, indicative of residual staining. If no colour was detected, slides were kept in wash 
buffer and underwent the same protocol as above (Section 2.25) to detect the next 
antigen. This process was repeated until all six stains were scanned. To minimise tissue 
degradation with repeat rounds of stripping, boiling time was optimised to 
sevenminutes, which was found to be the shortest incubation time necessary to 
effectively strip the tissue.  
To verify that primary antibodies could be stripped from the tissue, whole tonsil sections 
were used to test each antibody (Figure 2.13). Following stain and strip, the slide was 
analysed for any residual antibody by using the peroxidase-labelled VIP system (Super 
Sensitive Polymer-Horseradish Peroxidase IHC Detection System; BioGenex) (Figure 
2.13). Residual staining indicated incomplete removal of the antibody. This is exampled 
for CD21. This helped decide the optimal sequence of re-probing, with CD21 being the 
last stain and therefore issues regarding effective stripping were addressed and 
minimised.  To ensure that antigen stability was conserved through several rounds of 
repeated stain/strip cycles, two lymph node sections were subjected to the five rounds 
of cycles, in the following antibody order; DC-SIGN, CD10, CD163, MMR, CD68, CD21.  
104 
 
 
Figure 2.13: Antibody test to determine the stripping efficacy. Tonsil sections were stained with a primary 
antibody (CD10,CD21, CD68, CD163, DC-SIGN, and MMR) following the protocol in Section 2.25 (left 
columns of both panels). Following scanning, slides underwent HIER stripping (described above) and were 
exposed to a secondary antibody conjugated to HRP. Hydrogen peroxide and VIP were added to the slide 
and any deposit of chromogen on the tissue was indicative of residual primary antibody and ineffective 
stripping. This was seen for CD21, with residual chromogen indicated by the red arrow. CD21 was 
therefore decided to not be stripped from the tissue and therefore was the last antibody deposit in the 
stain/strip cycle. Magnification is indicated for each antibody image. 
 
2.28 Digital image analysis 
 
To determine the identification of DC-SIGN/MR-expressing cells required analysing the 
co-localisation of such biomarkers with cell specific biomarkers (CD68, CD21 and 
CD163). To achieve this, the Tissuealign™ analysis module in the digital image analysis 
software Visiopharm (Hoersholm, Denmark) was used to perform automated alignment 
of the six sequentially stained images. Correct alignment was critical to accurate 
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downstream quantitative analysis and therefore the alignment was checked by eye to 
ensure correct mapping of cells. Any misalignments were manually corrected.  
 
 
Figure 2.14: Normal histology of lymph node. Left panel) All germinal centre B cells express CD10 (brown 
stain indicated by arrow), with mantle zone B cells being CD10 negative (arrowhead). Right panel) H&E 
stain showing germinal centre (GC) surrounded by outer rings of mantle (Mantle Z) and marginal zone 
(Marginal Z) B cells. The interfollicular zone (IFZ) is indicated. Images adapted from www.pathpedia.com. 
Magnification and size unknown.  
 
To identify the location of DC-SIGN/MR-expressing cells within the tumour 
microenvironment, an analysis protocol package (APP) was designed in Visiopharm to 
recognise and annotate GC and non-GC regions in all patient and control samples. 
Germinal centres are normally surrounded by a ring of small, dark, tightly packed B cells 
which comprise the mantle zone, followed by the marginal zone (Figure 2.14). In FL, 
neoplastic follicles can be back to back with the mantle zone usually attenuated or 
absent, making germinal centre identification difficult from the interfollicular zone. 
Therefore, CD10 staining was used to train the APP to identify GC regions as the 
biomarker is specifically expressed on both normal and neoplastic germinal centre B 
cells. Non-CD10 regions were allocated ‘Tissue’ and regions of no cells were designated 
‘Background’ to exclude their analysis downstream (Figure 2.15).  
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Figure 2.15: Examples of Visiopharm APP identifying distinct regions following training based on CD10 
staining. GCs are in red, tissue in green and background outlined in blue, which were discarded from 
downstream analysis. Magnification for both FL and Reactive LN: x11.5. 
The APP was run on all samples and checked manually to ensure correct region 
identification.  
The phenotype of cells in both the GC and tissue were identified using another APP, with 
cell type biomarkers (CD68, CD21, CD163) used to quantify the cells expressing DC-SIGN 
and MR (Table 2.7). The threshold values for each stain were individually optimised to 
take into account the different staining intensities of each antibody.  
DC-SIGN+ cells MR+ cells 
GC Tissue GC Tissue 
                           CD163+CD68+ 
                           CD163+CD68- 
                           CD163-CD68+ 
                           CD163-CD68- 
                           CD21+ 
                           MR+ 
                           CD163+CD68+ 
                           CD163+CD68- 
                           CD163-CD68+ 
                           CD163-CD68- 
                           CD21+ 
                           DC-SIGN+ 
Table 2.7: Cell types defined by Visiopharm APP analysed for DC-SIGN and MR positivity.  
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The APP analyses staining in the six channels (representing the six stains) and 
determines whether a specific cell is either unstained, single stained, or multi-stained 
for several cell markers through multiplexing the individual stains for each tissue section 
following the alignment described above. Figure 2.16 shows identification of single 
stained CD68+ and CD21+ cells whereas Figure 2.17 highlights identification of MR and 
DC-SIGN positivity in CD68+ and CD163+ cells. The APP identifies positive stains while 
excluding weaker, less specific stains across all six channels. 
 
 
Figure 2.16: Identification of CD68 and CD21 positive cells through staining intensity. All six channels were 
analysed and depending on whether the staining threshold value is reached, the APP will identify a cell 
positive or negative for a single stain that will be compared to other markers in the section, determining 
whether a cell expresses one or multiple markers. For these cells, only CD68 or CD21 were identified as 
positive markers. Magnification of top panel images: x85.45. Magnification of bottom panel images: x19.9. 
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Figure 2.17: Identification of MR and DC-SIGN positivity in CD163+ and CD68+ cells. Magnification of top 
panel images: x212.62. Magnification of bottom panel images: x102.54. 
 
Quantitative output included mean intensity of staining of positive cells, their actual 
numbers, and their location within the tissue (e.g. GC or non-GC). Advantages of 
automated scoring compared to manual pathologist scoring includes avoiding bias in 
staining interpretation (Varghese et al., 2014, Choudhury et al., 2010) along with its high 
throughput capability which would otherwise be time-consuming by manual analysis.  
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Chapter 3: ACQUIRED N-GLYCOSYLATION MOTIFS 
AND THEIR ROLE IN FL EVOLUTION 
 
 
3.1 Introduction 
 
As mentioned previously, FL is a clinically heterogeneous disease with some patients 
responding extremely well to first-line therapy whilst others progress or transform 
within two years of treatment. The course of disease is characterised by several 
remitting-relapse cycles, with patients becoming increasingly refractory to treatment. 
Transformation of FL to a high grade, aggressive lymphoma is a critical event in disease 
evolution, commonly associated with poorer clinical outcomes. Genomic analysis of 
temporal FL biopsies including cytogenetic and CNV analysis has indicated that disease 
progression is not a step-wise process with the accumulation of mutations in major 
clones, but instead occurs through a divergent pathway, founding from a putative CPC 
population (Fitzgibbon et al., 2007, Johnson et al., 2008, Martinez-Climent et al., 2003). 
Shared mutations between disease episodes is indicative of mutations harboured within 
the CPC, and based on the degree of genetic semblance between episodes, the CPC for 
a patient can either be ‘rich’ or ‘sparse’ (Okosun et al., 2014). Sparse indicates an early 
divergence of event specific clones from the CPC, with their evolution occurring through 
pathways that are more independent.  As this CPC reservoir pool is believed to give rise 
to successive disease events, uncovering key pathogenic events within this population 
may lead to the development of therapeutic interventions that abrogate the remitting-
relapse cycle of disease and improve the outcome for patients. Recurrent mutations that 
are clonally maintained over temporal FL/tFL samples occur in histone modifying genes, 
including CREBBP and KMT2D, indicating epigenetic ‘addiction’ as a feature of both the 
‘rich’ and ‘sparse’ CPC (Okosun et al., 2014).  
However, to our knowledge, no studies have explored the microenvironmental 
interactions of the CPC, despite FL cells being highly dependent on cross-talk with 
immune cells of the GC (Ame-Thomas and Tarte, 2014) . A basic demonstration of this is 
seen by the difficulty of growing FL cells in vitro without stimulation through CD40 (Ghia 
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et al., 1998) engagement, a main signalling pathway of B and T cell interaction. The 
selective retention of the BCR throughout disease highlights another critical survival-
signalling pathway used by FL cells.  
Newly discovered replacement mutations caused by SHM introduces amino acid 
sequence motifs into the IGHV of the BCR, consisting of Asparagine (Asn)-X-
Serine/Threonine (S/T), where X can be any amino acid except proline. These N-
glycosylation (N-gly) motifs are found in ~90% and 73.5% of surface IgM and IgG positive 
FL cases, respectively (McCann et al., 2006, Kuppers and Stevenson, 2018). These motifs 
occur in the heavy chain IGV of only 9% of healthy B cells (Alcoceba et al., 2012), 
indicative of a pathogenic function. Oligosaccharides of the high mannose type are 
added to motifs and are retained on the Ig, despite being an unusual feature of cell 
surface proteins (McCann et al., 2008). Oligomannoses can interact with calcium-
dependent lectins associated with cells of the microenvironment, activating the BCR 
signalling pathway and likely contributes to the survival and retention of tumour cells in 
the GC (Coelho et al., 2010). This retention may enable the accumulation of recurrent 
mutations characteristic of FL, including those involved in epigenetic modification.  
The behaviour of N-gly motifs during disease evolution and progression has been 
investigated through IGHV cloning in a number of FL cases. Studies have indicated a 
conservation of acquired N-gly sites within identified molecular clones (McCann et al., 
2006). However, clone numbers have been limited in such studies and do not truly 
reflect the extent of intraclonal diversity that exists in disease as a result of ongoing 
SHM. Furthermore, as the analysis has been restricted to a single disease event, 
behaviour over time has not been addressed and therefore no conclusions regarding 
their role in the putative CPC has been determined. To address this requires 
comprehensive IGV analysis of the clonal repertoire taken from temporal biopsies, 
ranging from a relatively early time point in disease manifestation (e.g. diagnosis) to a 
time point at which the disease has become genetically and clinically distinct (e.g. 
relapse and transformation). As SHM continues during disease progression and 
transformation, the stepwise process can be visualised through lineage trees rooted to 
a putative non-malignant germline IGV sequence, making them an important tool in B 
cell evolutionary studies. 
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3.2 Objectives 
 
By implementing an NGS approach, this study set out to identify and catalogue N-gly 
motifs in the IGHV gene of a patient’s lymphoma as it progressed from an indolent form 
to an aggressive form of the disease, tFL. A longitudinal profiling strategy enabled the 
delineation of the clonal IGHV repertoire throughout a patient’s disease course, giving 
insight into the importance of motifs during disease evolution, expanding our views on 
the ontogeny and pathogenesis of FL. The inclusion of a clinically and biologically 
variable patient cohort ensured findings were representative of the heterogeneous 
disease.  
 
3.3 Methods 
 
N.B The term ‘clone’ mentioned throughout this chapter is solely based on IGHV 
sequencing data and does not reflect mutational status/mutational burden. The ‘major 
clone’ refers to the IGHV sequence identified through Sanger sequencing of the 
homoduplex. We can infer this is representative of the major clone as successful 
sequencing indicates a high copy number of the sequence in the sample which has 
outcompeted minor clone sequences. In NGS data, the major clone was identified by 
having the highest count number. 
 
3.3.1 Patient samples 
 
Genomic DNA for all FL samples used in this study were readily available from our 
department (Haemato-Oncology). This included 30 diagnostic FL samples, twelve  paired 
FL-tFL samples and three additional paired FL-tFL samples which were used in NGS. DNA 
was previously extracted from biopsies that were histologically reviewed to confirm the 
diagnosis. IGHV sequencing files for three temporal FL samples were available from the 
European Nucleotide Archive (ENA) using the accession numbers PRJEB9334 and 
PRJNA240336 (Jiang et al., 2014, Carlotti et al., 2015) to validate findings.  
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3.3.2 BCL2-IGH breakpoint analysis 
 
Clonality between paired samples was confirmed by identical BCL2-IGH breakpoints, 
which is detailed in Section 2.15.  
 
3.3.3 IGHV amplification 
 
Amplification of IGHV was performed by multiplex PCR using Biomed consensus primers 
targeting the Framework 1 and JH  regions, as detailed in Chapter 2. A high fidelity 
polymerase with a proofreading 3’-5’ exonuclease domain was used to minimise 
polymerase reading errors thus ensuring that observed SNPs were generated by the 
SHM process. Details of PCR reaction mixture and cycling conditions are detailed in 
Section 2.4.  
 
3.3.4 Heteroduplex analysis 
 
To distinguish monoclonal products from polyclonal products, PCR products underwent 
heteroduplex analysis. The PCR product was denatured and renatured at 95⁰C and 50⁰C, 
respectively. Products were run on a polyacrylamide gel to distinguish homoduplexes 
from heteroduplexes, with full details found in Section 2.5. Homoduplexes representing 
the major tumour clones were extracted and underwent further PCR amplification. The 
PCR product was then purified before undergoing sequencing or cloning. 
 
3.3.5 Cloning 
 
To identify tumour subclones, PCR products were cloned using the TOPO TA Cloning® 
system, described in detail in Section 2.16. Up to ten colonies were selected for PCR 
amplification and Sanger sequencing.  
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3.3.6 Sanger sequencing  
 
Purified PCR product was sent to Eurofins Genomics Sanger sequencing services 
(Germany) for bidirectional capillary electrophoresis using the ABI PRISM 3730XL 
Genetic Analyser, as detailed in Section 2.11. PCR products were sequenced in both the 
5’ and 3’ direction to ensure accurate sequencing of the entire V gene.  
 
3.3.7 VDJ assignment and SHM analysis 
 
The IGHV sequences produced by Sanger sequencing were entered into the IMGT/V-
QUEST programme available at http://www.imgt.org, which compares sequences to all 
known germline immunoglobulins, identifying the V, D and J gene segments of closest 
homology. SHM sites were identified through discordance between nucleotides of 
experimental and germline sequences. The sites of SHM were compared between the 
major clones of each paired FL-tFL sample in addition to the multiple disease-specific 
subclones derived from cloning. SHM events gave rise to either synonymous (e.g. no 
change to the amino acid encoded by the affected codon) or non-synonymous (e.g. 
change to the amino acid sequence) mutations which were identified by the IMGT/V-
QUEST programme. Full details of IMGT/V-QUEST are found in Section 2.12. For 
sequencing data generated from next-generation sequencing platforms, the IMGT-
HighV-QUEST program was used (Section 2.19). 
 
3.3.8 N-gly motif identification 
 
The NetN-glyc 1.0 online server (www.cbs.dtu.dk/services/NetNGlyc/) was used to 
identify N-gly motifs in IGHV sequences, as detailed in Section 2.13.  
 
3.3.9 Amplicon sequencing 
 
Re-amplified homoduplex PCR products were sent to Genewiz (United Kingdom) for 
paired-end 2x250bp sequencing using the Illumina Miseq platform, as detailed in 
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Section 2.17. The full pipeline regarding processing and subclone identification based on 
IGHV reads are also detailed in Section 2.18 and 2.19. 
 
3.3.10 Lineage tree 
 
To visualise clonal expansion and the relationship between individual subclones, lineage 
trees were constructed using the IgTree program algorithm (Barak et al., 2008). Full 
details of this process can be found in Section 2.24.  
 
3.4 Results 
 
3.4.1 N-gly detection in a diagnostic FL cohort 
 
Diagnostic FL samples were used to optimise IGHV amplification and validate previous 
findings regarding N-gly motif frequency in disease.  
Homoduplex IGHV bands located at the 300-400bp region were identified for ten 
diagnostic samples (Figure 3.1). The variation in migration through the gel was indicative 
of unique VDJ rearrangements between cases.  
 
 
Figure 3.1: IGHV bands visualised on agarose gel following amplification of homoduplexes. Homoduplexes 
were amplified by FR1 and JH consensus primers, with primer sequences listed in Figure 2.1. Bands were 
extracted followed by DNA gel extraction before being sequenced. The faint lower band for Patient 9 was 
also sequenced and had no results, suggesting an artefact. 
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Patient Germline IGHV  
Homology (%) No. of sites 
Region aa Motif 
1 V4-59, J4, D5-18 90.75 1 CDR2 NIS 
2 V4-39, J5, D2-21 94.32 2 CDR2, FR3 NIS, NAS 
3 V4-61, J6, D4-17 92.44 1 CDR1 NWT 
4 V3-48, J4, D4-11 89.13 2 CDR1, CDR2 NMT, NIS 
5 V3-48, J6, D5-18 85 3 
CDR1, CDR2, 
FR3 
NMT, NIT, 
NIS 
6 V3-48, J4, D3-10 86.11 3 
CDR1, CDR2, 
CDR3 
NMT, NIS, 
NYS 
7 V4-59, J5, D5-24 93.64 1 CDR2  NVS 
8 V3-48, J4, D2-2 85.42 1 CDR2 NIT 
9 V4-38, J4, D3-10 89.86 1 CDR2 NIS 
10 V4-31, J4, D3-10 88.97 0 - - 
Table 3.1: Incidence of novel N-glycosylation sites in diagnostic FL samples. CDR-complementarity 
determining regions, FR-framework region. Homology indicates degree of similarity between the 
experimental sequence and the germline of closest homology. 
 
In 90% of cases, motifs were identified giving support to the high prevalence seen in 
other studies (Zhu et al., 2002) (Table 3.1). Patients either had one or multiple sites. As 
none of the motifs were found in the corresponding germline sequences of the IGHV 
gene and arose from base substitution (Figure 3.2), SHM is the cause for acquisition. 
Without a germline DNA sample, it is difficult to determine the nature of the CDR3-
associated N-gly motif of patient 6 as theoretically, nucleotides could have been added 
to junctional regions during the somatic recombination. However, the lack of motifs in 
CDR3 regions of normal somatically mutated B cells is strong evidence that motifs are 
acquired through SHM and are positively selected in FL. 
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Figure 3.2: Acquired N-gly motif of patient 1. The electropherogram identifies the sequence encoding the 
N-gly motif. The germline nucleotide sequence of V4-59 was compared to the experimental sequence, 
highlighting that point mutations lead to motif acquirement (YIY>NIS), as indicated by red letters. AA-
amino acid. 
 
Analysis of the acquired asparagine residue of the N-gly motif revealed that in all cases, 
the amino acid was dissimilar or highly dissimilar to its germline counterpart (Table 3.2), 
based on three values; hydropathy, volume and physiochemical properties.  
 
Patient SHM hotspot (Y/N) Comparison between asparagine and G.L aa 
1 N Dissimilar 
2 N, N Very dissimilar, dissimilar 
3 N Very dissimilar, dissimilar 
4 Y, N Very dissimilar, very dissimilar 
5 N, N, Y Dissimilar, dissimilar, very dissimilar 
6 Y, N, N/A Dissimilar, very dissimilar, N/A 
7 N Dissimilar 
8 N Dissimilar 
9 N Dissimilar 
Table 3.2: Location of N-gly motifs in relation to known SHM hotspots. Known SHM consist of rgyw 
(a/g)g(c/t)(a/t) or wrcy (a/t)(a/g)c(c/t) sequences. The similarity of the acquired asparagine compared to 
the original germline amino acid is based on three values; hydropathy, volume and physiochemical 
property of the amino acid. Dissimilar refers to two out of three values being different, and very dissimilar 
refers to all three values being different. The CDR3 located motif was not able to be analysed due to a lack 
of a comparative germline sequence.  N/A-not available.   
 
An extension cohort of twenty diagnostic samples (Supplementary Table 1.1) revealed 
that the majority of motifs occurred within the hypervariable regions, with 54% 
occurring in the CDR2 (Figure 3.3a). Although the framework regions maintain the 
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structure of the protein and are therefore more conserved, they are still prone to SHM, 
especially during prolonged GC expansion, as seen by the acquirement of motifs in FR3 
in four patients.  
Out of 30 samples, only nine V gene subgroups were used, highlighting an over-
representation of V genes in disease (Figure 3.3b). The most recurrently used genes 
included V3-48, V3-11 and V3-23. Interestingly, the germline amino acid sequence of 
these genes display motif ‘starter sequences’. These sequences can generate motifs with 
either one or two nucleotide substitutions in the first amino acid. For example, the CDR2 
region of V3-48 and V3-11, contains a ‘YIS’ amino acid sequence which is frequently 
substituted to ‘NIS’. V3-23 contains YIS, AIS and TIS in the CDR2, CDR2 and FR3 regions, 
respectively. As these starter sequences frequently give rise to motif sites in our cohort, 
this could explain the V gene bias observed in the disease.  
 
 
Figure 3.3: Analysis of IGHV gene in 30 diagnostic FL samples. a) Distribution of N-gly sites in variable 
region. Values are expressed for each region as a percentage of the total number of sites (n=39). b) Usage 
frequency of V gene subgroups. Values for each subgroup is expressed as a percentage of the total number 
of patients (n=30).  
 
3.4.2 Paired FL- tFL samples 
 
During the evolution of many malignancies, there is remodelling of the clonal repertoire 
due to selection pressures (e.g. therapy), leading to the outgrowth of clones which have 
a genetic advantage that progress the disease (McGranahan and Swanton, 2017). This is 
also observed in FL with the ongoing SHM process enabling us to track which subclones 
(based on IGHV sequences) gain dominance (Horn et al., 2016). Determining whether 
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motifs are conserved in the major clones of successive disease events despite an 
assumed change in their mutational profile can indicate their importance during 
progression.  
Genomic DNA from twelve paired FL-tFL samples was readily available. Clinical 
information regarding these patients is given below (Table 3.3). Patient 15 had three 
temporal samples. The median age of diagnosis was 47.5 years with a median time to 
transformation of 4.6 years, ranging from 0.6 years to 14.6 years. Therapy information 
was available for some patients.   
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Table 3.3: Clinical characteristics of patients included in paired sample analysis. Pt-patient, CHOP-cyclophosphamide, doxorubicin, vincristine, prednisolone; R-rituximab; 
RIC-SCT-reduced intensity conditioning stem cell transplantation.
Pt No. Gender 
Age at 
diagnosis 
Histological 
grade at 
diagnosis Sample types 
Time to 
transformation 
from diagnosis 
(months) 
No of lines of 
therapy before 
transformation Line of therapy 
11 F 45 1 Diagnosis/Transformation 40 1 
FL(diagnosis)-Radiotherapy (Jul 99) 
1st relapse- Chlorambucil 
Transformation- CHOP, then LD-56 trial, 
then Rituximab (Nov 02) 
12 F 30 1 FL relapse 7 /Transformation 174.9 13 NA 
13 M 29 4 Diagnosis/Transformation 7 0 
FL (diagnosis)-Expectant management (Jul 
11) 
Transformation-R-CHOP (Feb 12) 
14 M 45 2 FL relapse 1 /Transformation 44.9 7 
1st relapse- Cytarabine + Etoposide, followed 
by BEAM autograft (Jul 99) 
15 M 57 3 
Diagnosis/4th relapse/ 
/Transformation 
81 3 
FL(diagnosis)-Chlorambucil, then CHOP (April 
01) 
4th relapse-Velcade + Rituximab 
Transformation-R-CHOP + RIC-SCT (Jan 08) 
16 M 67 2 Progression/Transformation 35.7 1 NA 
17 F 42 1 Diagnosis/Transformation 39.5 0 NA 
18 F 32 NA FL Relapse 2 /Transformation 72.9 4 NA 
19 M 61 2 FL Relapse 2 /Transformation 22.8 3 NA 
20 F 47 1 Progression/Transformation 94.5 7 NA 
21 F 70 2 Progression/Transformation 27.5 0 NA 
22 M 45 1 Diagnosis/Transformation 18.2 2 NA 
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To ensure transformation was not de novo DLBCL, clonality between paired samples was 
verified through identical BCL2 breakpoints (Figure 3.4) and VDJ rearrangements. 
 
Figure 3.4: Shared BCL2-IGH breakpoints for 3 selected FL-tFL paired cases. Genomic DNA taken from 3 
patients at different disease event time points was used to amplify the BCL2-IGH breakpoint, using MBR 
and JH primers, with their sequences listed in Table 2.1. The breakpoints were identified by entering 
sequences into BLAST and comparing to reference sequences of BCL2 (Accession No. NC_000018.10) and 
IGH (Accession No. NC_000014.9). Shared breakpoints between paired samples indicates clonality.  
 
3.4.3 SHM in paired FL-tFL 
 
SHM patterns in the V gene region were also assessed between pairs, with all samples 
having a high number of shared mutations, further confirming a common clonal origin 
(Figure 3.5). Additional unique SHM sites also occurred in both FL and tFL biopsies, 
suggesting a divergent evolution from an earlier founder clone. This is supported by 
previous studies of SHM in FL progression (Carlotti et al., 2009). SHM resulted in several 
shared and unshared non-synonymous mutations that are highlighted in patients 11-13 
(Figure 3.6). 
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Figure 3.5: SHM within the heavy chain V gene of paired FL-tFL samples. SHM is defined as a variation in 
nucleotide sequence of the major clone V region from the germline V region sequence of closest 
homology. Shared mutations are identified (blue), in addition to disease-specific mutations occurring at 
unique sites within the V gene. For patient 15, the 4th relapse sample was omitted from the graph to 
compare SHM between the most temporally distant samples. 
 
 
Figure 3.6: Comparison of the V gene amino acid sequence for three FL-tFL paired cases. The top lines in 
the three cases represent the germline amino acid sequence of the V gene with the closest homology, as 
identified by IMGT-V-QUEST. Letters in bold represent distinct amino acids to the germline sequence in 
each disease event, a result of non-synonymous mutations introduced by SHM. Comparison of amino 
acids between paired samples shows shared and distinct SHM within each disease event. 
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3.4.4 N-glycosylation motifs during disease progression 
 
All patients with the exception of patient 20, contained N-glycosylation motifs across 
the variable region (n=11) (Table 3.4). Patients either had one or multiple N-gly motifs. 
The majority of sites occurred in the CDRs with additional sites in the FR2 and FR3. Non-
synonymous mutations lead to the acquisition of the asparagine residue in all patient 
samples, as revealed by comparison to the germline sequence. The serine/threonine 
amino acid of the motif was either a feature of the germline nucleotide sequence or 
gained through synonymous mutation or non-synonymous mutation. The extent of SHM 
within the acquired motif site is indicated in Table 3.5.  
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Table 3.4: N-glycosylation sites acquired through SHM in the VH gene of paired FL/t-FL cases. Identical V 
gene usage between the dominant clones in sequential samples highlights the clonal relationship between 
disease events. FL-1 indicates a first relapse. t-FL indicates a transformation. N-gly motifs which differ in 
amino acid composition between temporal samples are indicated in red. 
Patient FL Disease 
Event 
IGHV 
gene 
No. of 
acquired 
sites 
Region aa Motif 
11  FL  V4-34 1 CDR3 NST 
 t-FL(DLBCL) V4-34 1 CDR3 NST 
12 FL7 V3-15 1 CDR2 NIT 
 t-FL(DLBCL) V3-15 1 CDR2 NKS 
13  FL V3-23 1 CDR3 NFS 
 t-FL(DLBCL) V3-23 1 CDR3 NFS 
14  FL V4-59 1 CDR2 NVT 
 t-FL(DLBCL) V4-59 1 CDR2 NVT 
15  FL V3-7 4 CDR1, CDR1, CDR2, FR3 NFS, NYS, NET, NLS 
 FL4 V3-7 4 CDR1, CDR1, CDR2, FR3 NFS, NYS, NET, NLS 
 t-FL(DLBCL) V3-7 4 CDR1, CDR1, CDR2, FR3 NFS, NYS, NET, NLS 
16  FL1 V3-48 1 CDR3 NLS 
 t-FL(DLBCL) V3-48 1 CDR3 NLS 
17 FL V3-48 1 CDR2 NIT 
t-FL(DLBCL) V3-48 1 CDR2 NIT 
18 FL2 V3-48 1 FR2 NMT 
t-FL(DLBCL) V3-48 1 FR2 NMT 
19 FL2 V3-23 4 CDR1, CDR2, 
CDR2,CDR3  
NIT, NIS, NKT, NCT 
t-FL(DLBCL) V3-23 4 CDR1, CDR2, 
CDR2,CDR3 
NIT, NIS, NKT, NCT 
20 FL V3-23 0 - - 
t-FL(DLBCL) V3-23 0 - - 
21 FL V3-11 1 CDR1 NFS 
t-FL(DLBCL) V3-11 1 CDR1 NFS 
22 FL V3-30 1 CDR3 NFS 
t-FL(DLBCL) V3-30 1 CDR3 NVS 
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Table 3.5: Analysis of somatic mutations giving rise to N-gly sites. Red letters indicate a nucleotide 
replacement mutation.A refers to amino acid position 1, 2 and 3 of N-gly motif. Patients 11, 13, 16, 21 and 
the fourth motif site in patient 19 were excluded from analysis due to motifs being located in the CDR3 
region which does not have comparative germline sequence to determine somatic mutations at motif 
site. 
 
For patients 14, 15, 17, 18, 19 and 21, motif sites occurred in the FR1 to FR3 region and 
both site location and nucleotide sequence were conserved in progression and 
transformed samples (Figure 3.7). This conservation was not dependent on the number of 
motifs present in the earliest event, as seen in patients 15 and 19 which conserved all four 
sites. This conservation highlights that for these patients, motifs had arisen from shared 
SHM in a common ancestral cell that gives rise to the successive disease events. This 
common ancestral cell does not appear to be influenced by therapy as highlighted in 
patient 15 who had undergone several lines of therapy between biopsies (Table 3.3).  
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Figure 3.7: N-gly motif sites in two paired FL-tFL patient samples. Identical nucleotides between sequential 
samples indicate motifs have been acquired through shared SHM events in a common ancestral cell. IGHV 
PCR products used to sequence are shown on the right.     
 
N-gly motifs were also present in the CDR3 region of patients, 11, 13, 16, 19 (Figure 3.8). 
Although there is no germline CDR3 sequence to determine the origin of these motifs, 
their absence in the CDR3 region of healthy B cells is strong evidence that they were 
acquired through SHM, and similar to motifs in the FR1 to FR3 region, their conservation 
in temporal samples suggests they were acquired in a shared ancestral cell.  
 
Figure 3.8: Nucleotide sequences encoding for N-gly motifs in the CDR3 region of paired FL-tFL samples. 
Nucleotide composition is maintained as the disease progresses. Corresponding IGHV bands are indicated 
on the right.  
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3.4.5 SHM variation within N-gly motif sequence 
 
For patients 12 and 22, we observe a similar conservation of motif sites. Yet a distinction 
from the other patients lies in the difference in amino acid sequences between temporal 
samples (Table 3.4). For patient 12, the relapse and transformed motif amino acid 
sequence located in CDR2 were NIT and NKS, respectively. This suggests that the motifs 
seen in the different disease events are a result of unshared SHM. However, analysis of 
the codon giving rise to the asparagine residue of the motif reveals an identical 
nucleotide composition (aac) between the two samples (Figure 3.9), suggesting that this 
shared SHM event preceded the unshared mutations seen in the second and third codon 
as SHM is a stepwise process. If we relate this back to the germline (V3-15 gene) amino 
acid sequence which consists of SKT (serine, lysine and threonine), the shared SHM 
event would give rise to the N-gly motif, NKT. This indicates that temporal samples of 
patient 12 likely arose from a shared ancestral cell that displayed this motif. A 
divergence in evolution as evidenced by unshared SHM between events, then lead to 
the distinct motif compositions. As the unshared SHM maintained the motif site, we can 
infer a positive selection of motif containing clones during disease progression. 
 
 
Figure 3.9: Paired FL-tFL samples that have distinct SHM in the nucleotide sequences encoding for N-gly 
motifs. For patient 12, changes to the second and third codon in the transformed samples results in amino 
acid changes. For patient 22, a change to the second codon also result in an amino acid change. Despite 
changes to the first codon representing asparagine in patient 22, the amino acid is retained, maintaining 
the motif site. Differences in nucleotides between temporal samples are highlighted in orange.  
 
For patient 22, the CDR3-based motif in the diagnostic and transformed samples was 
NFS and NVS, respectively. Unlike patient 12, the codon giving rise to the asparagine 
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residue differed between samples; aac encoded for asparagine in the diagnostic sample 
and aat encoded for asparagine in the transformed sample (Figure 3.9). This 
nonsynonymous mutation could be due to ongoing SHM in the first codon, which is a 
valid viewpoint given the largely random nature of the SHM process. Yet the selection 
of a major clone which conserves the motif site, indicates that motif positive clones have 
an advantage during disease progression.   
 
3.4.6 Fate of germline encoded motifs compared to acquired motifs 
 
For patient 11, the germline V4-34 gene contains a naturally occurring motif site in the 
CDR2 region (NHS). However in both samples, a shared SHM (a>g) resulted in 
substitution of the asparagine residue to a serine, eliminating the motif from a shared 
ancestral cell (Figure 3.10). Acquisition of a new motif site in the CDR3 region was gained 
through shared SHM. The loss of the V4-34 natural motif site is seen in other studies 
(Zhu et al., 2002) (McCann et al., 2008) which suggest an irrelevance of sites to disease 
progression unlike those gained by SHM. This adds support to the claim that natural sites 
appear irrelevant to disease progression unlike those gained by SHM. This could be due 
to the differential glycosylation fates of natural versus acquired sites, with natural sites 
not found to be glycosylated. 
 
Figure 3.10: Analysis of germline and acquired N-gly motifs for patient 11’s temporal samples. V4-34 
contains a naturally occurring N-gly motif in the CDR2 region (NHS). IMGT analysis of experimental 
sequences reveals loss of this site and replacement by SHT (indicated in blue highlight). Identical 
nucleotide sequences highlight that loss was a result of shared SHM in a common ancestor. The acquired 
site was gained through shared SHM.  
128 
 
3.4.7 N-gly motifs in intraclonal variants 
 
Although the major clone makes up the bulk of the tumour, heterogeneity of disease is 
attributed by the unique subclones present as a result of ongoing SHM which may have 
distinctive mutational profiles. If a minor subclone gains an advantageous mutation, it 
can gain dominance, enabling the disease to evolve. This flux in clonal dynamics 
highlights the importance of evaluating subclones when considering disease 
progression.  
To determine whether motifs are a feature of intraconal variants, heteroduplex derived 
IGHV products from five paired FL-tFL samples underwent cloning. Up to 10 colonies 
were selected at random and subsequently sequenced following PCR amplification 
(Figure 3.11).  
 
Figure 3.11: IGHV bands derived from cloning. Nine white colonies were picked at random from the agar 
plate of patient 14, FL1 disease event, following the cloning method described in section 2.16. Each colony 
was amplified by PCR using the M13 forward and reverse primers (primer sequences detailed in section 
2.16). Each amplified colony is represented in this figure by a single band.    
 
The majority of amplified colonies contained an identical sequence to the major clone 
and were therefore discarded. Unique subclones were identified by having distinct 
sequences of ≥1 nucleotide between each other and the major clone. The number of 
subclones identified from the total number of colonies sequenced in the paired samples 
is given in Table 3.6. Subclones had a similar SHM rate to that of the major clone, with 
many shared SHMs. Despite also containing distinct SHMs, N-gly motifs identified in the 
major clone of the disease event were conserved in all clones (Table 3.6). This indicates 
motifs are a clonal SHM event and therefore occurred early in evolution. 
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Table 3.6: Conservation of N-gly motifs in distinct tumour related subclones. White colonies selected from 
the agar plates underwent IGHV amplification and sequencing to determine whether they represented 
unique subclones from that of the major clone and interrogate their N-gly status. The fourth column 
represents how many of the colonies sequenced were unique when compared to the major clone. The 
fifth column represents whether the unique subclones maintained the N-gly site present in the major 
clone.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
 
3.4.8 Patients undergoing NGS of IGHV  
 
Cloning only provides us with a snapshot of the vast clonal repertoire in FL. This is due 
to the limitations of the technique. Firstly, the number of unique subclones identified 
largely depends on which colonies are picked. This is because multiple colonies can 
contain an identical DNA insert which is influenced by the copy number of the original 
PCR products that are exposed to the plasmid vectors. To reduce this requires picking 
and sequencing a large number of colonies which can be labourious and time-
consuming. Other potential restriction to identifying unique clones includes how much 
of the transformed E.coli is spread on the agar plate and whether they contain a variety 
Patient FL disease event Motif in 
major clone 
No. of distinctive 
clones out of total 
colonies sequenced 
No. of distinctive 
clones with motif 
of major clone 
11  FL  NST 2/10 2/2 
 t-FL(DLBCL) NST 3/10 3/3 
12 FL7 NIT 2/10 2/2 
 t-FL(DLBCL) NKS 4/10 4/4 
13  FL NFS 3/8 3/3 
 t-FL(DLBCL) NFS 4/10 4/4 
14  FL1 NVS 3/9 3/3 
 t-FL(DLBCL) NVS 3/10 3/3 
15  FL NYS,NET,NLS 5/10 5/5 
 FL4 NYS,NET,NLS 4/10 4/4 
 t-FL(DLBCL) NYS,NET,NLS 3/10 3/3 
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of unique DNA inserts. To comprehensively analyse the IGHV subclonal repertoire, ultra-
deep sequencing of the PCR product was required.   
Three additional patients with paired FL-tFL samples were selected to undergo NGS 
sequencing. Samples had previously undergone somatic variant profiling by WGS or 
WES, which revealed a ‘sparse’ or ‘rich’ disease evolution pattern, based on genetic 
semblance between temporal samples (Okosun et al., 2014). We wanted to investigate 
whether there was a difference in N-gly dynamics in such mutationally distinct disease 
events. Patient’s 23 & 25 were categorised as ‘sparse’ and patient 24 categorised as 
‘rich’. Heteroduplex analysis identified the major clones, with all three patients 
displaying a VH3 gene family. Sequencing IGHV reads from three additional patients 
were available, generated from different sequencing platforms and configurations. 
Patient 26 and 27 sequencing reads were generated from the Roche 454 Life Sciences 
Genome Sequencer FLX (2x150bp) and patient 28 sequencing reads were generated 
from the Illumina Miseq platform (2x150bp). The Genewiz bioinformatics service report 
for patients 23-25 can be found in supplementary Tables 1.2 - 1.4, and supplementary 
Figures 1.1 and 1.2.  
Patient information is given in Table 3.7. The mean age at diagnosis was 49.8 years. All 
temporal samples excluding patients 27 and 28 were biopsied from the same anatomical 
site. By having temporal samples derived from distinct anatomical sites, enables us to 
analyse clonal populations within distinct microenvironments which may confer distinct 
selection pressures to tumour evolution.  
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                        Table 3.7. Additional clinical information regarding 6 patients who underwent IGHV targeted sequencing. 
Pt No Age at  Tumour Biopsy Site Histological  
Time from 
diagnosis Overall survival  Line of therapy 
diagnosis   grade years (months) years (months) 
23 N/A Diagnostic N/A N/A 0 
N/A N/A     Transformed FL N/A N/A 1(6) 
24 40 FL1 N/A N/A 0(5) 
4(2) 
Rituximab + BEAM autograft (Jul 
97) 
    FL3 N/A N/A 2(5) Bexxar (Jul 99) 
    Transformed FL N/A N/A 4 Methotrexate (Jun 00) 
25 48 FL2 Left axillary node N/A 12(3) 
N/A 
Expectant management (Aug 00)  
    FL3 N/A N/A 15(8) N/A 
    Transformed FL Left axillary node N/A 15(9) R-CHOP (Mar 04) 
26 43 FL Left inguinal node Grade 2 2(8) 14(7) 
CHOP, Fludarabine, Rituximab, 
Chlorambucil, Bortezomib 
    FL2   Grade 1 4 Interferon, MethylPrednisolone 
27 68 FL Right axilla Grade 3A 1(4) 
9(2) No treatment     FL2 Right femoral node Grade 1 1(9) 
28 50 Diagnostic FL Right cervical node Low grade 0 
N/A N/A     
Diagnostic 
DLBCL Right cervical node N/A 4(10) 
    Relapse DLBCL Retroperitoneal node N/A 6(9) 
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3.4.9 N-gly motifs in the major clones of temporal biopsies 
 
All patients had an IGH-VH3 rearranged gene. With the exception of patient 27, patients 
contained at least one acquired N-gly motif site in their major clone which was retained 
throughout temporal samples (Table 3.8), consistent with the previous FL-tFL study 
described above. 
 
 
Table 3.8. N-gly motifs identified in the major clone of six FL patients taken at different time points of 
disease. Italic red text refers to differences in the location or amino acid (aa) sequence of N-gly sites 
within the major clone across temporal samples. Major clones were determined through heteroduplex 
analysis following PCR amplification and verified from sequencing data, indicated by the highest count 
number. The multiple values in patient 24 and 26 relate to the multiple motifs observed. * Although 
temporal samples of patient 27 have different DJ rearrangements according to IMGT, when aligned they 
show highly similar CDR3 regions and share a t(14:18) breakpoint, indicating a clonal relationship. 
 
Patient 23 samples were taken at diagnosis and transformation (1.5 years after 
diagnosis). In the major clone, one N-glycosylation motif was observed in the CDR3 
region of the diagnostic sample, composed of the amino acid sequence NFS. The 
transformed major clone maintained the N-gly location in the CDR3 yet non-silent 
mutations within this region impacted the amino acid sequence (NFS>NVS). Samples for 
Patient 24 spanned the first relapse, second relapse and transformed disease events. In 
the major clone of the first relapse event, four N-gly motif sites were observed in several 
locations across the variable region, including CDR1 (NFS), FR2 (NMS), CDR2 (NIT) and 
Patient  Disease Event VDJ rearrangement Homology to V gene (%) Region in IGHV Motif aa sequence
Diagnosis 89.24 CDR3 NFS
Transformation 87.89 CDR3 NVS 
1st relapse 85.65 CDR1, FR2, CDR2, FR3 NFS, NMS, NIT, NNS
3rd relapse 86.1 CDR1, FR2, CDR2, FR3 NFS, NMS, NIT, NNS
Transformation 85.2 CDR1, FR2, CDR2, FR3 NFS, NMS, NIT, NNT
2nd relapse 79.82 CDR2 NIS
3rd relapse 79.82 CDR2 NIS
Transformation 79.55 CDR2 NIS
1st relapse 88.57 FR2, CDR3 NKS, NNS
2nd relapse 88.57 FR2, CDR3 NKS, NNS
1st relapse V3-23, D4-23, J6 89.11 CDR1 NFS
3rd relapse V3-23, D3-3*, J5* 83.47 FR3 NLT 
FL diagnosis N/A CDR3 NGS
DLBCL diagnosis N/A CDR3 NGS
DLBCL relapse N/A CDR3 NGS
V3-30,D3-16, J6
V3-11,D3-16, , J1
V3-48, D1-26, J4
V3-48, D3-10, J6
V3-23, D5-18, J628
23
24
25
26
27
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FR3 (NNS). All four sites were conserved in the 2nd relapse and transformed major 
clones, although the fourth site in the transformed sample had a different amino acid 
composition as a result of non-silent mutations (NNS>NNT). This conservation is despite 
the patient undergoing several lines of therapy in between biopsies (Table 3.7). Patient 
25 samples, taken at 2nd relapse, 3rd relapse and transformation had a conserved motif 
site and composition within the CDR2 region. Interestingly, the CDR3 length in the 
transformed sample major clone has a nine nucleotide deletion in the N1 region 
resulting in a shortened CDR3 length of 14 compared to the 2nd and 3rd relapse clones 
which had a CDR3 length of 17 (Figure 3.12). Although CDR3 length conservation is 
normally indicative of clonality, we were able to establish a clonal relationship by events 
sharing identical BCL2 breakpoints and VDJ rearrangements (Table 3.8 and Figure 3.13). 
 
 
Figure 3.12: Alignment of the major clone CDR3 region of Patient 25 disease events. The nine nucleotides 
highlighted in yellow refer to the nucleotides which are absent in the N1 region of the transformed major 
clone, resulting in a shorter CDR3 length of 14 instead of 17 (FL2 and FL3), as indicated by IMGT-V-QUEST. 
The CDR3 length seen in the major clone is conserved in the significant majority of subclones within the 
specific disease event. 
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Figure 3.13: BCL2 breakpoint of 3rd relapse and transformation events of patient 25. Identical breakpoint 
nucleotide sequence indicates clonality.  
 
For patient 26, the major clones of the 2nd and 3rd relapse samples contained two N-
gly sites NKS and NNS located in FR2 and CDR3, respectively.  
Patient 27 temporal samples were taken from different anatomical sites. 1st and 2nd 
relapse samples were taken from the right axillary node and right femoral node, 
respectively. Interestingly, the N-gly motif site observed in the 1st relapse major clone 
in the CDR1 region (NFS) was not found in the 2nd relapse major clone which contained 
a different motif site located in FR3 (NLT). 
The first two events for patient 28 were taken from the same anatomical site, yet the 
relapsed DLBCL was taken from a distinct site. Unlike patient 27, the motif site and 
amino acid sequence (NGS) in the CDR3 region was conserved throughout progression. 
Non-synonymous mutations lead to the acquisition of the asparagine residue in all 
patient samples, despite the presence of several germline encoded asparagines. The 
serine/threonine amino acid was either a feature of the germline or arose through 
synonymous or non-synonymous mutation (Table 3.9). The asparagine residue was 
generated through partial or complete codon substitution as highlighted in Patient 26, 
whereas across patients, the middle codon did not undergo variation except for in 
Patient 25. Samples with a C terminal serine were most commonly found in the germline 
and could be mutated to a threonine. Motifs located in the CDR3 region (as seen for 
patients 24, 28 and 26) were unable to be compared to a germline sequence, therefore 
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their origin from either synonymous or non-synonymous somatic mutations could not 
be established. 
 
Patient 
FL Disease 
Event AA Change  Bp mutation
A
 
    1 2 3 
24 
1st relapse 
TFS>NFS, YMS>NMS, 
YIS>NIT, KNS>NNS 
AAC, AAT, AAC, 
AAC 
TTC, ATG, ATT, 
AAC 
AGT, AGT, ACT, 
TCT 
3rd relapse 
TFS>NFS, YMS>NMS, 
YIS>NIT, KNS>NNS 
AAC, AAT, AAC, 
AAC 
TTC, ATG, ATT, 
AAC 
AGT, AGT, ACT, 
TCT 
Transformation 
TFS>NFS, YMS>NMS, 
YIS>NIT, KNS>NNT 
AAC, AAT, AAC, 
AAC 
TTC, ATG, ATT, 
AAC 
AGT, AGT, ACT, 
ACT 
25 
2nd relapse YIS>NIS AAC ATA AGT 
3rd relapse YIS>NIS AAC ATA AGT 
Transformation YIS>NIS AAC ATA AGT 
26 
1st relapse GKG>NKS AAT AAG AGT 
2nd relapse GKG>NKS AAT AAG AGC 
27 
1st relapse TFS>NFS AAC TTT AGC 
3rd relapse SLR>NLT AAC CTG ACA 
Table 3.9: Analysis of somatic mutations giving rise to N-gly sites. Red letters indicate a nucleotide 
replacement mutation.A refers to amino acid position 1, 2 and 3 of N-gly motif. Patients 1 and 6 were 
excluded from analysis due to motifs being located in the CDR3 region which does not have comparative 
germline sequence to determine somatic mutations at motif site. 
 
3.4.10 Distribution of SHM within the subclonal repertoire  
 
Figure 3.14 summarises the impact of somatic hypermutation across the variable region 
of Patients 23-25 by detailing the location and distribution of single nucleotide variants 
(SNV) in the subclonal repertoire, indicating the total numbers of non-synonymous 
versus synonymous mutations. Whilst there are shared distributions of specific 
transversion and transition mutations in certain regions across temporal samples, 
indicative of shared SHM in a common ancestral cell, there are also changes in 
distribution as the disease progresses as seen by the acquirement of new point 
mutations and absence of previous mutations. This is supportive of a divergent evolution 
between serial events.  
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Figure 3.14: Distribution of V gene nucleotide substitutions found in subclones across 
disease events for patients 23-25.  The CDR3 region has been excluded due to lack of a 
germline sequence. As the disease progresses, there are shifts in the mutation 
distribution. 
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Figure 3.14 also indicates how mutations are either silent or non-silent. BASELINe 
(Section 2.14) was used to determine whether the distribution of mutations in the 
immunoglobulin sequences the across the variable region was indicative to antigen-
driven selection, as calculated by the ratio of replacement/silent mutations in the CDRs 
and framework regions (Figure 3.15).  The 2nd relapse subclones of patient 25 showed 
positive selection of replacement mutations in their CDRs and negative selection of 
replacement mutations in their frameworks, which is typical of antigen-driven selection 
profile. This is because replacement mutations could potentially improve antigen affinity 
of the immunoglobulin and therefore are more likely to accumulate in the antigen 
binding associated CDRs. In contrast, replacement mutations in the framework regions 
could affect the structural integrity of the antigen-binding site of the immunoglobulin. 
In the subclone repertoire of successive disease events of patient 25 and in the temporal 
samples of all other patients, we did not observe positive selection in replacement 
mutations in the CDRs, as highlighted in Figure 3.15. Replacement mutations in the 
framework mutations were negatively selected in all temporal samples, which is 
expected as the surface immunoglobulin is constantly present and functional 
throughout FL disease. Comparatively, replacement mutations in the CDRs were more 
positively selected in all cases as indicated by negative PCDR/FR values. This finding 
highlights how subclones are selected based on structural integrity of the 
immunoglobulin but not by antigen, which is indicated in other studies. This infers an 
alternative selection pressure driving clonal evolution. 
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Figure 3.15: Representative BASELINe graphical output of subclones from temporal samples of three 
patients. BASELINe compares the frequency and location of replacement mutations against expected 
values from antigen-driven selection. Graphs highlight strong negative selection of replacement 
mutations in the framework regions but no positive selection in the CDRs (except for 2nd relapse subclones 
in patient 25, as indicated by a positive selection strength value). Negative PCDR/FR  indicates CDR 
replacement mutations are more positively selected than framework mutations.  
 
3.4.11 N-gly motif site conservation in subclone population 
 
To elucidate whether N-gly acquirement is a clonal event, I interrogated the subclone 
population. For patients containing one motif site in their major clone, ≥97% of the 
subclone population within and across disease events maintained the motif sites (Figure 
3.16). Strikingly, for Patients 24 and 26 which had multiple N-gly sites, no subclone with 
the complete absence of motifs was detected within and across disease events. For 
Patient 24, the 1st, 2nd and 3rd sites were conserved in >96% of subclones across 
events. The 4th site was conserved in 97.2% of clones in the 1st relapse sample and in 
81% and 85% of subclones in the 3rd relapse and transformation samples, respectively. 
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Interestingly, for all patients no further motifs accumulated within or across event 
subclones that were not found in the major clone.  
 
 
Figure 3.16: Comparison between % of tumour subclones with presence and absence of N-gly motif site in 
the heavy chain variable region across disease events. The motif location and sequence for each patient 
is detailed in Table 3.8. The majority of subclones across patients and disease events retain the N-gly site 
(p-0.0001). FL-diagnosis, FL1-1st relapse, FL2-2nd relapse, FL3-3rd relapse, tFL- transformation, DLBCL 
(diffuse large B cell lymphoma), rDLBCL (relapsed DLBCL). a-d  in Patient 24 refer to the four N-gly sites 
located in CDR2, FR2, CDR3, FR3, respectively. a&b in Patient 26 refer to the two N-gly sites located in FR2 
and CDR3. 
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3.4.12 Diversity within the N-gly motif site 
 
The majority of subclones present the identical nine nucleotides that encode for the N-
gly motif found in the major clone, indicating that the SHM that discriminates between 
these subclones lies within a different location of the variable region. However, for a 
relatively small proportion of subclones, there is diversity within nucleotide sequence 
encoding for the motif. This is expected as a consequence of the (largely) random 
process of SHM which does not differentiate between seemingly favourable and non-
favourable mutations. Table 3.10 highlights the % of total unique subclones with a 
different codon sequence to that of the major clone. The actual number of affected 
clones is also indicated. 
 
Patient FL Disease  
% of total subclones 
with different  
Clones with different codon sequence in N-gly 
region 
  Event 
codon sequence in N-
gly region 
Clones maintaining N-gly 
motif 
Clones without N-gly 
motif 
23 
Diagnosis 3.92 61 46 
Transformation 6.51 79 31 
24 
1st relapse 2.72, 3.2,58.41, 0.06 61, 78, 2022, 128 35, 35, 40, 98 
3rd relapse 4.78, 7.88, 32.39, 24.3 124, 142, 944, 186 21, 97, 38, 551 
Transformation 3.38, 3.73, 9.33, 18.84 76, 75, 1279, 150 58, 73, 91, 597 
25 
2nd relapse 0.85 281 104 
3rd relapse 8.7 136 43 
Transformation 28.5 426 29 
26 
1st relapse 34.57, 0 26, 0 2, 0 
2nd relapse 4.84, 0.004 9, 0 5, 1 
27 
1st relapse 15.71 18 4 
3rd relapse 5.66 18 3 
28 
Diagnosis 36.1 906 40 
DLBCL diagnosis 5.64 194 71 
DLBCL relapse 1.81 86 128 
Table 3.10. Analysis of subclones not sharing the identical codon sequence of the N-gly motif found in the 
major clone. % of the total tumour related subclones that do not contain the identical codon sequence 
seen in the major clone are highlighted on the right. The actual numbers of these subclones which do and 
do not encode for the N-gly motif are given on the right. The several values seen for Patient 24 and 26 are 
representative for the multiple N-gly sites seen for these patients. 
 
Interestingly, an average of 77% of affected clones were positive for the motif site 
because of either synonymous mutations of the asparagine or 
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synonymous/nonsynonymous mutations of the serine or threonine residue. Only 23% 
of subclones were absent for the site, indicating a positive selection of subclones that 
maintain the motif site. This is indirectly supported by motif negative subclones only 
making up ≤1% of the total count number in samples expressing only one motif site 
(Supplementary Table 1.5). 
The diversity within the nucleotide sequence encoding for the asparagine and serine or 
threonine residues in these positive subclones is shown for each disease event in Figure 
3.17. There are twenty possible nucleotide combinations that can give rise to N-gly 
motifs when considering the first and last amino acids only. As seen across patients, a 
variety of distinct motif encoding sequences arises in subclones through SHM, with the 
most diverse range of sequences seen for the 3rd motif site of patient 24.  
 
 
Figure 3.17: Diversity in the nucleotide sequence of the first and last amino acid of motif positive subclones. 
Subclones represented here did not display either the same asparagine or serine/threonine encoding 
nucleotide sequence as that of the major clone. The middle codon for all sequences was checked to ensure 
for the absence of proline as this middle amino acid would negatively affect the functionality of the N-gly 
motif.  
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3.4.13 Analysis of subclones with highest and lowest degree of SHM 
 
The range of SHM is indicated in Table 3.11, in which the least and most mutated 
subclones for each disease event were identified by the IMGT High V-QUEST program. 
The % difference in homology between the least and most mutated subclones ranged 
from 0.8 to 13.3, depending on the patient and disease event.  In some instances, the 
degree of SHM (indicated by these extreme subclones) does not increase as the disease 
progresses. This is reflected in patients 23-25, in which the least mutated transformed 
subclone has a greater semblance to the germline when compared to the least mutated 
subclone of the preceding FL events. The subclones highlight that evolution is not a 
linear process with the accumulation of SHM over time and supports the divergent 
pattern seen in other FL SHM studies (Carlotti et al., 2009, Carlotti et al., 2015).  
When we examine these extreme subclones (least and most mutated) collectively for 
each patient, we gain an insight into the point at which N-gly motifs were introduced. 
For example, in the transformed event for patient 24, we observe that the fourth motif 
site has been acquired in a subclone which has at least 93.2% homology to its germline, 
translating into just 17 nucleotide substitutions. However, further SHM is necessary for 
the acquirement of sites 1-3. For patients 23 and 26, motifs are acquired within their 
least mutated subclones, however, for patient 25 this isn’t the case. It suggests that the 
degree of SHM required for motif acquirement varies between patients and could be 
influenced by the V gene used. However, once acquired, single motifs are rarely lost 
despite a high level of ongoing SHM, as evidence in the most mutated subclones of 
patients 23, 25, 26 and 27. Although patient 24 has the loss of the 1st and 2nd motif sites 
as a result of ongoing SHM, they retain the 3rd and 4th site in their most mutated 
subclones.  
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  Patient 23 Patient 24 Patient 25 Patient 26 Patient 27 Patient 28 
Least mutated 
subclone FL tFL FL FL2 tFL FL2 FL3 tFL FL1 FL2 FL1 FL3 FL tFL tFL1 
% homology to 
G.L V gene 
sequence  89.23 89.6 87.6 87.1 93.2 78 79.8 89.2 89.4 88.6 98 89.1 97.8 93 92.3 
N-gly motif 
presence (Y/N) Y Y 
Y, Y, Y, 
Y Y, Y, Y, N N, N, N, Y Y Y N Y,Y Y, Y N Y (FL1 motif) Y Y Y 
Most mutated 
subclone                               
% homology to 
G.L V gene 
sequence  80.2 80.7 79.9 80.7 79.9 74.4 74 79.1 88.6 86.9 87.5 81.5 79.4 71.3 73.5 
N-gly motif 
presence (Y/N) Y Y 
N, N, Y, 
Y N, N, Y, Y N, N, Y, Y Y Y Y Y,Y Y,Y Y Y Y Y Y 
                                
% difference in 
homology 
between  
9.03 8.9 7.7 6.4 13.3 3.6 5.8 10.1 0.8 1.7 10.5 7.6 18.4 21.7 18.8 
least and most 
mutated 
subclones 
Table 3.11: N-gly motif status in most and least diverse subclone based on degree of SHM compared to V gene germline sequence.  Sequences were analysed for presence or 
absence of the N-gly motif site (s) found in the major clone. 
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3.4.14 Discordant SHM in distinct anatomical sites 
 
When comparing the subclones of patient 27, taken from two lymph nodes at distinct 
anatomical sites, we observe a clear discordance in the SHM pattern of the two 
populations and how this translates into a highly distinct amino acid sequence in the 
variable region of the major clones (Figure 3.18). This suggests an early divergence in 
the evolution of subclones giving rise to these two events. The presence of distinct 
motifs in each event (Table 3.8) infers that acquirement of motifs occurred after 
divergency in which event specific subclones underwent unique SHM processes. Despite 
this difference and the selection pressures imposed by microenvironmental difference, 
tumour subclones are universally reliant on N-gly motifs. 
 
 
 
Figure 3.18: Discordance in the SHM pattern of subclones identified in temporal samples from patient 27 
across the variable region. The V gene amino acid sequence of the major clones for the serial samples is 
given below. Major clone and germline amino acid sequences are indicated, with amino acid changes from 
the germline sequence highlighted in bold letters below. The discordant amino acid changes reflect the 
outcome of the distinct SHM pattern in the two events. Yet a clonal relationship was previously 
established between the two, indicating an early divergence in evolution (Carlotti et al., 2015). 
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3.4.15 Fate of motif negative subclones during progression 
 
The subclone population changes as the disease progresses, influenced by pressures 
that select for the outgrowth of subclones containing advantageous mutations that 
confer a survival advantage. These subclones may be present in the preceding event 
maintaining a background ‘role’ before acquirement of further genetic aberrations 
causes its proliferation and dominance. Therefore, the analysis of shared subclones 
across temporal samples can give us insight into the subclones important in driving 
disease progression. Subclone populations were merged across disease events to 
identify candidate clones (Figure 3.19). With the exception of Patient 25, a small number 
of subclones are shared across events.  These subclones are long-lived, as exampled in 
Patient 27 in which the two biopsies were taken 6.75 years apart (Table 3.7). It was 
interesting to observe that subclones were shared between distinct anatomical sites as 
seen in patient 27 and in patient 28, in which the relapsed DLBCL was biopsied from the 
retroperitoneal node in contrast to the first two events biopsied from the right cervical 
node. 
Analysis of the shared subclones revealed they were all motif positive, including those 
trafficked between anatomical sites. For patient 27, the subclones contained the motif 
of the second event. This indicates a trafficking ability of motif positive subclones. 
Patient 25 was an exception as 1.5% of the shared clones were negative (n=20). 
Interestingly, most of these negative clones have a higher relative count number in the 
successive disease event, suggesting that they confer an advantage (Supplementary 
Table 1.6). The lack of shared motif negative subclones in all other patients indicates 
that progression subclones are dependent on N-gly motifs. 
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Figure 3.19: Venn diagrams showing the number of shared and distinct subclones across disease events. 
Numbers inside circles reflect a number of subclones for the particular event with % of the total subclone 
repertoire across events indicated in brackets. For Patient 25, the transformation sample was omitted 
from analysis due to the difference in CDR3 length in comparison to the 1st and 2nd relapse.   
 
3.4.16 Lineage trees reveal origin and fate of N-gly negative subclones  
 
To investigate whether N-gly motifs are acquired early on in the disease, we investigated 
the evolution of subclones based on their IGHV sequences. The IgTree program is 
specifically designed for variable region immunoglobulin sequences and calculates the 
minimal and most probable mutational pathways separating subclones, highlighting 
intraclonal hierarchy (Barak et al., 2008) (Section 2.24). For Patients 26 and 27, the 
complete hierarchy can be visualised in lineage trees (Figures 3.20 and 3.21). Due to a 
the large number of subclones detected for Patients 23 and 25, only the negative 
subclones, their parent clone and their progenitor clones are depicted in Figure 3.22 to 
highlight their generation and contribution to the clonal repertoire within an event. As 
Patient 24 did not have any truly negative subclones, the analysis was omitted. 
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Figure 3.20: Lineage tree for the two disease events of Patient 26. The top panel represents the FL disease 
whereas the middle panel represents the second relapse, FL2. The bottom panel represents the zoomed 
in areas of FL2 (indicated in dotted box within second panel)  Orange circles:clones with both motif sites; 
purple circles:clones with only the first motif site; green circles: clones with only the second motif site; 
white circles: clones inferred to exist but not detected through 454 sequencing; grey circle: major clone 
containing both sites. Clones that have lost a motif  site in either the FR2 or CDR3 regions are able to 
regain the site following ongoing SHM (boxes in bottom panel). No new motif sites are acquired in clones. 
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Figure 3.21: Lineage tree for the two disease events of Patient 27. Top panel: FL disease event. Second 
panel: Second relapse event, FL2. Third and fourth panel: Zoomed in areas of FL2 (indicated in boxes 
within second panel) Orange circles: clones with motif site found in FL event; brown circles: clones with 
motif site found in FL2 event; red circles; clones without a motif site. Clones without motif do not give rise 
to further subclones and cannot regain motif sites unlike in multiple N-gly site tumour subclone 
populations (Patient 26). *Represents subclones containing the motif site of the preceding disease event.  
 
For patient 26, the earliest experimentally derived subclones (identified as filled circles 
closest to the germline Ig sequence at the top of the tree) are motif positive. While 
patient 26 does not have any truly negative subclones, several subclones lose at least 
one motif site. These subclones are observed to undergo further SHM and re-acquire 
the lost site (Figure 3.20), giving rise to several further clones. This is in contrast to 
patient 27 in which the loss of the single motif results in the subclone not undergoing 
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further diversification or expansion (Figure 3.21). As these clones are lost from 
progression samples, we can infer their elimination. All motif negative subclones in 
patient 27 were descendants of motif positive clones as a result of ongoing SHM and 
were not early events as suggested from their downstream positioning within the 
lineage trees.  
With greater numbers of motif negative subclones owing to an increase in overall 
subclones, Patients 23 and 25 lineage trees give a more comprehensive insight into the 
behaviour of negative clones in the tumour hierarchy (Figure 3.22). However, it is 
important to note that these negative subclones represent a minority within the 
heterogeneous population. For patient 23, negative clones represented 1.7% and 1.8% 
of the subclone population in diagnosis and transformation events, respectively. For 
patient 25, negative clones found in 2nd relapse, 3rd relapse and transformation 
represented 2.5%, 2.1% and 1.8% of the population, respectively. Motif negative clones 
were found to arise from either a positive or negative clone, through a single nucleotide 
variant. Several negative clones can arise from a shared positive ancestor, as depicted 
through the wide branching. Except for one clone in Patient 23, further SHM in these 
negative clones does not result in site re-acquirement or gain of new sites. However, 
these clones make up on average 0.01% of the total count in all patient samples. 
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Patient 23: Diagnosis 
 
 
Patient 23: Transformation 
 
 
Patient 25: 2nd relapse 
 
 
Patient 25: 3rd relapse 
 
 
Patient 25: Transformation 
 
Figure 3.22: Hierarchy of motif negative clones in relation to their direct ancestral clone for Patient 23 and 
25. This diagram represents part of the lineage trees as the majority of subclones (which are positive) are 
not shown and the interconnection between clones from a germline sequence is not depicted. Red clones 
represent motif negative clones. Orange clones represent motif positive clones derived from the 
sequencing platform. Clones in grey represent clones not detected by the sequencing platform but 
predicted to exist by the IgTree program. They are all assumed to contain the motif site due to a number 
of other experimentally detected progeny clones being motif positive. Numbers inside clones are 
generated through the IgTree program to numerate clones. 
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3.4.17 N-gly motifs in evolution of composite Hodgkin’s Lymphoma and FL 
 
We next wanted to investigate whether N-gly motifs were an early acquirement in other 
ancestral clones giving rise to more phenotypically and pathologically distinct disease 
events. Three cases of composite Hodgkin’s lymphoma (HL) and FL were analysed 
(Figure 3.23) which had previously been identified as originating from a common cell of 
origin through shared VDJ rearrangements and SHM patterns (Marafioti et al., 1999, 
Brauninger et al., 1999, Kuppers et al., 2001). For case 1, a 38 year old male was originally 
diagnosed with HL in the cervical lymph node. Following treatment, the patient 
developed FL in the same anatomical site two years later. For case 2, a biopsy of 
retroperitoneal nodes revealed composite FL and mixed cellularity HL with abundant 
Reed Sternberg cells (RSCs) in a 75 year old female. For case 3, a male was diagnosed 
with composite FL and HL in the splenic hilar lymph node. 
IGHV sequences for the HL cell and least mutated FL cell were obtained from the ENA 
website, as described in section 2.21. The least mutated FL sequences were used to 
minimise the evolutionary distance to the common cell of origin. Unlike FL, HL cells do 
not have intraclonal heterogeneity regarding their IGHV sequences and therefore the 
HL sequence used represented all HL tumour cells. 
 
 
Figure 3.23: Patients used in composite HL and FL IGHV analysis.  
 
For case 1, the FL and HL IGHV had one shared nucleotide substitutions, with the RSC 
and FL cell going on to gain an additional one and fifteen mutation(s), respectively 
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(Figure 3.24), indicating an early divergency between the two events. Through unshared 
SHM, the FL clone acquired two N-gly motifs NYS and NRS in the FR3 and CDR3 regions, 
respectively. However, RSC did not contain acquired motifs. Cases 2 and 3 had a greater 
number of shared SHMs compared to case 1, with 55 and 28 substitutions, respectively. 
In both cases, both the RSC and FL cells contained an identical N-gly motif, indicating 
acquirement occurred through shared SHM before divergency occurred to give rise to 
the distinct disease events. For case 2, the motif NMS was located in the CDR2 region 
and for case 3, the motif NIS was also found in the CDR2 region.  
 
 
Figure 3.24: Clonal relationship between composite HL and FL based on IGHV sequences. For case 1, 
divergency between clones specific for disease events occurred early, as indicated by the low number of 
shared SHM. For case 2 and 3, divergency occurred at a later time point as indicated by high numbers of 
shared SHM. All three FL cells contained an N-gly motif, however motif presence in the RSC was dependent 
on the time point of divergency. 
 
Although the distinct lymphomas are derived from the same germinal centre B cell, 
motifs are conserved only in patterns of late divergency, based on the relatively high 
number of shared IGHV mutations (Figure 3.25). 
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Figure 3.25: Evolution model of composite FL and HL cases based on IGHV sequences. 
 
3.5 Discussion 
 
FL patients undergo multiple cycles of relapse, eventually becoming refractory to 
therapy. This suggests that current therapies are not successfully targeting the early 
aberrations needed to propagate disease and as a result, the tumour can repopulate, 
gaining additional mutations that increase its complexity and reduce effective treatment 
options. Therefore, uncovering features of these ancestral cells and their 
microenvironmental interactions may offer durable outcomes for patients.   
96.7% of the diagnostic cohort contained at least one N-gly motif within the IGHV, 
supporting the high prevalence of motifs seen in disease. The remaining 3.3% were 
negative for motifs. Comparison to the germline sequence of closest homology revealed 
that motifs were acquired. Whilst CDR3 located motifs do not have a comparative 
germline sequence owing to the random nature of somatic recombination, the lack of 
CDR3 motifs in normal somatically mutated B cells is strong evidence of their 
acquirement through SHM. We observed bias in the V genes used across patients, with 
V3-48, V3-11 and V3-23 being the most recurrently used amongst patients. This has also 
been observed in other studies looking at V gene distribution amongst FL samples 
(Berget et al., 2015, Aarts et al., 2000). Interestingly these V genes contained ‘starter’ 
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sequences that in the majority of cases, gave rise to N-gly motif sites through one or two 
nucleotide substitutions, indicating a reason for such V gene bias in disease.  
Analysis of IGHV in paired FL/tFL samples revealed that motifs are conserved in the 
major clones of disease progression without additional sites being gained in transformed 
samples. Clonality of temporal events was confirmed by serial samples sharing identical 
V,D,J segments and t14;18 translocation breakpoints. For patients 12 and 22, the N-gly 
motifs were conserved in transformed samples despite unshared SHM occurring within 
the motif region as demonstrated by the change of amino acid sequences from NIT and 
NVS to NKS and NFS, respectively. The selection of a major clone which conserves the 
motif site indicates that motif positive clones have an advantage during disease 
progression. Conservation of motifs was despite patients undergoing therapy between 
biopsies, as highlighted in patient 15. We would expect therapy to exert a selection 
pressure on subclone in which those with advantageous mutations go on to dominate 
the clonal landscape. However, despite the assumed changes in the mutational profile 
of the major clones, conservation of sites is indicative of an ongoing reliance of the major 
clone on N-gly motifs.  
A few germline V genes have naturally occurring N-gly motifs, including V1-08, V4-34 
and V5a (Zhu et al., 2002). V4-34 has the motif NHS, which is found in the CDR2 region. 
Therefore, it is intriguing that we do not observe a bias towards these specific V genes 
in disease. In fact, the natural motif site of the V4-34 gene of patient 11 was found to be 
lost through shared SHM within our paired samples and a new site gained by shared 
SHM in the CDR3 region. This has been shown in other studies looking into SHM of FL 
cells (Zhu et al., 2002, McCann et al., 2008). Zhu et al observed six out of seven FL 
patients containing the V4-34 gene lost the natural site with acquisition of a new site in 
either the CDR1 or CDR2 regions. For the one patient who retained the site, a new site 
was acquired in the CDR1 region. McCann et al found that the V4-34 natural site was 
also lost in molecular clones derived from FL patients. Analysis of the variable region 
domain revealed that while acquired motifs were oligomannosylated, the natural site 
had no added sugars, suggesting differential glycosylation profiles of natural versus 
acquired motifs. This may explain as to why the natural site was lost in patient 11. 
Without mannoses binding, the FL cell cannot form interactions with lectins and 
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therefore the natural motif serves no functional relevance to the tumour cell and is 
eliminated. 
FL is a highly heterogeneous disease with thousands of subclones present based on 
either distinct IGHV sequence or distinct mutational profiles. A minor subclone can gain 
dominance in a successive disease event if it possesses or acquires an advantageous 
mutation and therefore analysis of subclones is essential with regards to the study of 
disease evolution. Sequencing of up to ten subclones derived from cloning enabled us 
to analyse N-gly motifs within intraclonal variants. We found motifs observed in the 
major clone were also conserved in the subclones. This alluded to the idea of motif 
acquirement being a clonal and early event in disease evolution.  However, to better 
address this required a comprehensive and ultra-deep analysis of the heterogeneous 
clonal landscape of disease which could only be assessed through next-generation 
sequencing. 
We report for the first time and in unparalleled depth, the behaviour of N-gly motifs 
during disease progression by analysing the clonal repertoire of temporal t(14:18) 
positive FL samples based on amplicon sequencing of the IGHV gene. Samples ranged 
from diagnosis to transformation and included a mixed patient cohort with variable 
clinical disease courses and therapeutic interventions, reflecting the heterogeneous 
nature of the disease. In support of the high prevalence of N-gly motifs in FL, all patients 
harboured at least one acquired site in their earliest disease event major clone. We 
found that these sites were a clonal feature as seen through significant conservation 
both in the heterogeneous subclonal population and the overall tumour mass. 
Sites are also retained in progression samples. These are seen in both progression 
exclusive subclones and shared subclones and although the acquirement of additional 
‘driver’ mutations through natural or therapy-related selection pressures may dampen 
the tumour’s microenvironment dependency, the motifs are suggested to retain an 
important functional significance at later stages of the disease, presumably mediated 
through the mannose-lectin interaction. This conservation occurred in both ‘rich’ and 
‘sparse’ temporal samples, suggesting that the motifs are acquired at an early disease 
time point, before genetic divergency occurred to give rise to distinct genetic subclones.   
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Not all sites are simply maintained during progression. Some, like in patient 24 and 26 
undergo SHM, resulting in changes to the nucleotide sequence (Table 3.9) which still 
encode for an N-gly site. This is similar to what we observed in patients 12 and 22 
temporal samples.   
The BASELINe program revealed that there was no positive selection in replacement 
mutations in the CDRs of any of the patient samples, except for the 2nd relapse sample 
of patient 25. For immunoglobulins that have undergone antigen-driven selection, 
replacement mutations in the CDRs could potentially improve antigen affinity, which is 
evidenced by the accumulation of mutations within these regions. However, all clonal 
populations did have strong negative selection against replacement mutations in the 
framework regions, providing strong evidence that subclones are selected based on 
structural integrity of the BCR but not by antigen recognition. This finding is supported 
by Hershberg et al and Zuckerman et al who also found strong negative selection against 
replacement mutations in the framework regions but no positive selection in the CDRs 
of FL variable regions (Hershberg et al., 2008, Zuckerman et al., 2010), inferring an 
alternative selection pressure driving clonal evolution. 
To ensure that N-gly motifs were not conserved due to a lack of further SHM within the 
site, we analysed diversity within the nine base pair region. Whilst the majority of 
subclones shared the identical nucleotides to that of the major clone, a minority of 
subclones had a different sequence, which is expected due to the (largely) random 
nature of SHM which does not discriminate been favourable and non-favourable 
mutations. Strikingly, an average of 77% of affected subclones maintained the motif site 
through multiple codon combinations, indicating a positive selection. 
Analysis of the least and most mutated subclones based on their homology to the 
germline V gene sequence gave us insight into the point at which N-gly motifs were 
acquired. In some cases, we were able to observe the motif within the earliest (least 
mutated) identified subclone whereas in others, this was not the case. This infers that 
the degree of SHM required for motif acquirement varies between patients and could 
be influenced by the V gene used and presence of so-called ‘starter’ sequences. 
However, once acquired, single motifs are rarely lost despite a high level of ongoing SHM 
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as evidenced in the most mutated subclones. Again this points to a selective advantage 
of tumour cells harbouring sites.  
Negative subclones made up only a minor population across patients and were not 
passed on to successive disease events, in contrast to motif positive subclones. Lineage 
trees enabled us to reveal how this rare population manifests. All negative clones are 
derived from a positive clone, suggesting acquirement of motifs is an early event. The 
presence of negative clones is an expected occurrence as SHM however they represent 
only a small % of the tumour population and bulk, and are likely to be outcompeted by 
motif positive clones, perhaps due to loss of the microenvironmental interaction 
provided via the added mannoses. The compact branching between negative clones 
suggests that even in the absence of motifs, clones can still undergo SHM but do not 
reacquire sites or gain new ones in their progeny. However, it’s important to take note 
that SHM does not indicate longevity of these subclones; they are separated by a single 
SHM event, suggesting they can arise within a short time frame of each other (e.g. hours 
or days). Indeed their absence from subsequent samples suggests they are short-lived, 
having adequate time for a single SHM event to give rise to a progeny subclone.  
Patient 27 provided an interesting case for two reasons; the different anatomical sites 
for the two events and the discordant SHM within the IGHV between the two clonal 
populations. This discordance suggests an early divergence, where an ancestral cell with 
limited SHM, migrated from one site to another where selection pressures drove the 
outward growth of subclones with a specific SHM pattern. However, despite IGHV 
sequence heterogeneity, the acquirement of motifs within each population at different 
locations illustrates that motifs are an essential feature of FL, regardless of 
microenvironment differences. The sharing of two subclones with the motif of the 
diagnostic sample (Figure 3.19) highlights the trafficking ability of motif positive 
subclones, not just across disease episodes but between anatomical sites. The trafficking 
of only motif positive subclones between sites suggests a dynamic mannose-lectin 
interaction enabling GC exit and migration. This exclusive trafficking of motif positive 
subclones was also seen in patient 28 in which sampling of the diagnostic FL and 
sequential relapsed DLBCL occurred at distinct anatomical sites. However, for patient 
28, SHM patterns between events were highly similar and the CDR3 N-gly site was 
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conserved throughout suggesting a late divergency between events from a shared 
ancestral cell. 
Finally, we explored whether N-gly motifs were acquired within the common ancestral 
cell of disease events which are phenotypically distinct. Composite lymphomas are 
defined by either the simultaneous or sequential presence of two distinct lymphomas in 
a patient (Jaffe et al., 1994). Through their analysis, we can discriminate the events 
leading to lymphomagenesis in general and the events giving rise to each particular 
disease. We analysed the IGHV sequences of three cases of composite FL and HL. HL is 
characterised by occurrence of rare RSCs embedded in a mixed cellular infiltrate (Farrell 
and Jarrett, 2011). RSCs have a very different profile to FL cells including a large cell size, 
frequent multinuclearity, prominent eosinophilic nucleoli, loss of surface 
immunoglobulin expression and loss of B cell markers CD10, BCL-6 and CD20 (Kuppers 
et al., 2003). We found that in two of our cases, identical N-gly motifs were found in the 
RSC and FL cells, arising as an event of shared SHM and therefore a feature of a shared 
common ancestral cell. For case 1, only the FL cell acquired N-gly motifs, indicating N-
gly motifs were not a shared event of the common ancestral cell. This is likely due to 
transforming genetic events leading to HL manifestation occurring early in evolution as 
indicated by the relatively low level of SHM seen within the RSC. Due to the lack of 
surface immunoglobulin expression on RSCs, it is unlikely that the N-gly motifs seen in 
case 2 and 3 have a functional and beneficial role within these cells. Instead, they are 
more likely to be an ‘imprint’ of a long duration of the common ancestral cell within the 
GC before transforming mutations were acquired. 
The conservation of motifs in and across FL disease events and the lack of accumulation 
during ongoing SHM suggests they are an early and stable event in FL pathogenesis. Early 
events are usually determined through their conservation within temporal samples and 
for patients 23-25, WGS/WES had previously identified key genetic aberrations within a 
putative ancestral cell, known as the common progenitor cell (CPC). For all three 
patients this included mutations in CREBBP, KMT2D and TNFRSF14. Patients 23 and 25 
had a ‘sparse’ CPC due to the lack of shared genetic aberrations across temporal 
samples, suggesting an early divergency with episodes arising from more genetically 
independent pathways. However, despite this mutational heterogeneity between 
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events, motif sites are conserved, identifying an important and rare feature of the CPC. 
This is an important finding as the CPC is believed to be the reservoir pool from which 
successive disease events arise, accounting for the high relapse rates experienced by the 
majority of patients (Okosun et al., 2014). The longest interval between the first and last 
events is seen in patient 28 with an interval of 6.75 years, suggesting an N-gly motif 
encoding CPC able to remain dormant for many years before a mutational event leads 
to a selective advantage and emergence of a new disease episode. The mannose-lectin 
interaction may enable tumour retention and survival of the CPC permitting the 
accumulation of genetic events that lead to overt disease, suggesting a critical priming 
event in FL manifestation. Although epigenetic deregulation is a considered CPC event 
as evidenced in the previous genetic profiling of Patient’s 23-25 samples, our data imply 
that it is not solely sufficient for ‘driving’ the disease. Instead, the N-gly motif profile 
determines which clones are able to expand and survive during disease progression, 
irrespective of the genetic profile of the subclones which are believed to harbour such 
‘driver’ mutations. Analysis of the genetic profile of motif negative subclones will 
determine the validity of this hypothesis. 
Although the t14;18 translocation can be found in healthy B cells which do not go on to 
become malignant, N-gly sites in the variable region are restricted to GC derived 
lymphomas indicating an attractive and tumour specific therapeutic target which may 
lead to the loss of a critical CPC-microenvironmental interaction and reduce the 
frequency of relapse. The presence of N-gly motifs in the presumed FL precursor lesion, 
ISFN, supports the theory of N-gly motifs occurring at an early stage of pathogenesis 
(Kosmidis et al., 2017, Mamessier et al., 2015), being acquired even before disease 
manifestation. Figure 3.26 summarises how N-gly motifs impact the evolution of the 
disease. 
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Figure 3.26: Simplified model of FL evolution and progression based on N-gly motifs. The model is based 
on the high throughput sequencing of the IGHV gene. Following the t14;18 translocation during a likely 
error in VDJ recombination in the bone marrow, the B cell migrates to the germinal centre where it 
undergoes SHM. N-gly motif sites are acquired early on in the process (purple figure), in the presumed 
precursor lesion, ISFN. As FL-like B cells are believed to represent the circulating counterparts of ISFN, N-
gly motifs may be retained in these cells also. Precursor cells which do not acquire sites through SHM 
undergo apoptosis, assumed by the low frequency of motif negative subclones in the clonal repertoire. 
Clones maintain conservation of motifs during tumour evolution through ongoing SHM and gain of 
additional mutations, leading to an ancestral cell pool population, the CPC. The CPC provides a reservoir 
from which distinct disease events arise from, all of which retain the motif site. At each stage of evolution, 
SHM results in the emergence of lost motif clones, due to the largely random nature of the process that 
does not distinguish between favourable and non-favourable mutations. However, these represent only 
a minor mass of the heterogeneous tumour population and cannot traffic between events, indicating their 
insignificance in propagating progression and their likely loss from the clonal repertoire through death 
pathways. PFL-partial involvement by FL.   
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Chapter 4: DC-SIGN AND MR EXPRESSION IN FL 
MICROENVIRONMENT 
 
 
4.1 Introduction 
 
There is now substantial evidence to suggest that FL cells are able to manipulate and 
influence their microenvironment to ensure their survival (Ame-Thomas and Tarte, 
2014). Compared to healthy follicles, neoplastic GCs have upregulated T cell subsets, 
such as TFH cells and TRegs cells that were shown to dampen the antitumor response 
through attenuation of CD8+ cells (Yang et al., 2006a, Yang et al., 2006b). The increase 
of Tregs is likely due to the ability of FL cells to secrete the cytokine CCL22 which is 
involved in the chemotaxis and migration of TRegs from their interfollicular location into 
the neoplastic follicle (Yang et al., 2006a).  
As previously mentioned, FL cells reside in the GC surrounded by a plethora of non-
malignant immune cells, including follicular dendritic cells, and macrophages. A pivotal 
study by Dave et al., in which the gene expression of non-malignant immune cells was 
analysed, elucidated how important the immune system, irrespective of tumour 
genetics, is in determining clinical outcome (Dave et al., 2004). Enrichment for genes 
expressed in T cells was found to be associated with a favourable prognosis, whereas 
genes expressed in macrophages and follicular dendritic cells were strongly associated 
with poor clinical prognosis. Given the highly variable clinical outcome in FL, there is an 
urgent need to validate these findings to improve patient risk stratification and more 
importantly, offer the possibility of identifying new targets for future drug design. Using 
real time PCR and immunohistochemical analysis, Byers et al demonstrated that high 
numbers of CD68+ macrophages and CCR1, the marker of monocyte activation, were 
associated with shorter survival (Byers et al., 2008). This was supported by Farinha et al 
who also found CD68+ macrophages predicted a worse outcome through 
immunostaining of FL TMAs (Farinha et al., 2005). The macrophage marker, CD163 that 
is predominantly found on M2-skewed macrophages (Buechler et al., 2000), has also 
been associated with poor prognosis and increased angiogenic sprouting in follicular 
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lymphoma (Clear et al., 2010). While these studies supported those of Dave et al, other 
groups investigating how the number and arrangement of immune cells impacts 
prognosis has been highly variable, likely due to the lack of conformity regarding 
treatment and immunohistochemistry scoring techniques (Carreras et al., 2009, de Jong 
et al., 2009, Lee et al., 2006). Therefore, improved assessment of the microenvironment 
regarding prognosis is required.  
FL cells are believed to interact with their microenvironment through the mannose-
lectin interaction, as described in the Introduction. To briefly recap, >90% of FL cases 
display unusual sites for N-linked glycosylation within their immunoglobulin variable 
regions that are acceptor sites for high mannose terminating glycans (McCann et al., 
2008). Oligomannoses are able to interact with C-type lectins that bind carbohydrate 
structures in a calcium dependent manner. C-type lectins act as pattern recognition 
receptors that bind to pathogens and activate immunity (McGreal et al., 2004). Two C-
type lectins with specificity for high mannoses are DC-SIGN and MR that are expressed 
on immune cells including macrophages and dendritic cells (Robinson et al., 2006). 
These two lectins were shown to bind to oligomannoses expressed on FL surface 
immunoglobulin and activate BCR signalling, inferring a novel antigen-independent, but 
cell contact dependent survival pathway for tumour cells. 
Interestingly, DC-SIGN and MR have been shown to interact with other cancer-
associated glycoproteins, inducing an immune ‘dampening’ response through 
upregulation of anti-inflammatory and downregulation of pro-inflammatory cytokines 
produced by the lectin-expressing cell. Cross-linking of MR on immature dendritic cells 
with anti-MR antibody was shown to activate DC maturation and induce the secretion 
of anti-inflammatory cytokines and Th2 attracting chemokines, leading to negative 
regulation of Th1 polarised responses (Chieppa et al., 2003). Interestingly, similar 
responses are seen when the receptor is engaged with cancer-derived glycoproteins. For 
example, ligation of MR with the ovarian cancer derived glycoprotein TAG-72 on TAMs 
lead to increased IL-10 production and decreased CCL3 (Allavena et al., 2010), the Th1 
attracting chemokine. This immune dampening response is also seen when DC-SIGN is 
engaged with colon cancer derived glycoproteins, leading to an increased IL-10 
expression (Nonaka et al., 2008). IL-10 production promotes polarisation of M2 
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macrophages (Allavena et al., 2010), the phenotype displayed by FL derived TAMs. MR 
is highly expressed on TAMs and DC-SIGN strongly expressed on M2 macrophages (Amin 
et al., 2015), suggesting that these lectins play a role in polarising the immune cells to 
create a pro tumour, immune suppressive microenvironment. Therefore, the mannose-
lectin interaction may have a double effect for FL tumourigenesis; through BCR 
activation and the remodelling of the microenvironment.  
DC-SIGN expression has been investigated in situ and found to be localised to 
paracortical lymphatic sinuses and scattered in perifollicular regions (Amin et al., 2015, 
Linley et al., 2015). Expression was also found on CD68+ mononuclear cells that were 
shown to be in direct contact with CD20+ FL cells, indicating the feasibility of the 
mannose-lectin interaction in vivo. These studies were performed on fresh frozen tissue 
sections with either immunofluorescence or immunohistochemistry used to detect 
antigen expression. Whilst frozen tissue sections provide an excellent source for antigen 
analysis, information regarding co-expression and spatial relationships between cells is 
difficult to assess in this type of section, owing to the limitation of multiplex IHC in which 
a maximum of three antigens can be visualised in a section. A unique technique 
developed within our department (Ball et al., 2017), has expanded on the multiplex IHC 
principle by enabling up to seven cellular markers to be explored in a single section, 
including those which are co-localised through the sequential stripping and re-probing 
method, described in section 2.27. This offers a more comprehensive and in-depth 
characterisation of the microenvironment. Stripping and re-probing is performed on 
formalin fixed paraffin embedded (FFPE) sections. The long-term storage potential of 
paraffin-embedded tissues provides a wealth of archival samples in which to perform 
retrospective analysis, often with long-term clinical follow-up available. Furthermore, 
formalin fixation leads to better preservation of tissue morphology through formation 
of cross-links between proteins, ensuring observed cellular interactions and tissue 
location is comparative to that seen in vivo. 
The quantity of DC-SIGN and MR positive cells in FFPE-derived FL sections has not been 
investigated, nor their localisation and distribution on different immune cell populations 
and whether this has any prognostic implications.  
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4.2 Objectives 
 
We utilised a novel, multiplex, sequential phenotyping strategy to examine the 
expression and location of DC-SIGN and MR on immune cells of the microenvironment 
in diagnostic FL biopsies. FL biopsies were taken from two groups at the extremes of 
overall survival (<5 years and >15 years) to evaluate any prognostic significance. Results 
were also compared to normal reactive lymph nodes (LNs), in which N-gly motifs are 
rarely observed in the IGHV to determine any correlations between DC-SIGN/MR 
expression and presence of N-gly motifs.  
 
4.3 Method 
 
4.3.1 Patient samples 
 
Lymph node blocks derived from patients diagnosed with FL at St Bartholomew’s 
Hospital (London, UK) between 1977-2006 were used for this study. 3 µm thick whole 
sections were cut from paraffin-embedded tissue blocks using a microtome and 
mounted onto glass slides. Sections were made for nine patients whose survival was >15 
years and seven patients whose survival was <5 years. All sections were from diagnostic 
biopsies. As reactive follicles are considered the healthy counterpart to neoplastic 
follicles, nine cases of reactive lymph nodes were also sectioned and mounted to be 
used as a control group. Whole sections were favoured over tissue microarrays (TMAs) 
to account for the morphologic heterogeneity of FL which can be missed in the 
‘snapshot’ provided by tissue cores consisting of a diameter of 1mm. Clinical data from 
the extreme survival cases is found in section 4.4.1 
 
4.3.2 DNA extraction 
 
Cores (1mm width by 4mm depth) were taken from follicle rich sites from the extreme 
survival tissue blocks to obtain tumour cell DNA. DNA was extracted from the paraffin 
by using the QIAamp DNA FFPE Tissue Kit (Qiagen) and following the protocol. Briefly, 
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paraffin is first removed from the tissue using xylene followed by removal of the xylene 
by 100% ethanol which rehydrates the tissue. Proteinase K is a serine protease that was 
then incubated with the sample to lyse and remove contaminating proteins, including 
DNAses that degrade DNA and therefore impact integrity. It achieves this by cleaving 
the peptide bond next to the carboxyl group of hydrophobic amino acid residues. A 90⁰C 
incubation reverse formalin crosslinking of nucleic acids before the sample is transferred 
to the QIAamp MinElute column where DNA binds to the column followed by a series of 
washes to remove contaminants and is finally eluted. DNA concentration and 
contaminants were assessed using the Nanodrop Spectrophotometer.  
 
4.3.3 IGHV amplification 
 
Eluted genomic DNA then proceeded to IGHV amplification as described in Section 3.3.3. 
 
4.3.4 IHC 
All slides were first stained for DC-SIGN simultaneously to avoid ‘batch effects’ with 
regards to staining intensity. The staining procedure was performed as described in 
section 2.25. Following coverslipping, slides were incubated overnight in a fume 
cupboard to ensure complete drying of the DPX mountant. Slides were then scanned 
using the Pannoramic 250 High Throughput scanner to produce high quality brightfield 
images. The quality of scanned slides were checked on the Pannoramic Viewer program 
(Version 1.15.4). 
Slides were placed overnight in xylene to remove coverslips before proceeding to 
stripping and reprobing with the next antibody, as described in section 2.27. Slides were 
reprobed with antibodies in the following order; CD10, CD163, MR, CD68 and CD21.  
 
4.3.5 Visiopharm 
 
The digital image files were uploaded into the Visiopharm software and the six images 
for each case were automatically aligned using TissueAlign, followed by manual 
corrections. The cells of the aligned images underwent analysis for the six markers to 
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identify cell phenotype. Readouts included csv files documenting the number of single 
or multi-stained cells with regards to known cell markers CD21 (follicular dendritic cell), 
CD68 (macrophage), CD163 (M2 macrophage), their location (GC or interfollicular 
regions) and the mean intensity of DC-SIGN and MR staining in each of these cells. This 
was performed by the two Visiopharm APPs described in section 2.28.  
4.3.6 Statistics 
 
Statistical analyses were performed using GraphPad Prism version 5.4 (GraphPad 
Software Inc., La Jolla, CA, USA). Statistical analysis was used to compare the different 
extreme survival groups (<5 year and >15 year) and control group (reactive lymph node). 
One-way ANOVA without assumption of Gaussian distribution was performed to 
determine if the differences between the group means were greater than you'd expect 
to see by chance. Two-way ANOVA was used to determine if the differences between 
DC-SIGN and MR staining within each group was greater than you’d expect to see by 
chance. Statistic tests were considered significant at P ≤ 0.05 (*). A p-value of ≤0.01 was 
identified by two asterisks (**) and a p-value of ≤0.001 was identified by three asterisks 
(***). 
 
4.4 Results 
 
 
4.4.1 N-gly motifs status of different groups  
 
Clinical information regarding our cohort is provided in Table 4.1. The average overall 
survival of patients within the <5 year survival group was 1.91 years, whereas the overall 
survival in the >15 year survival group was 22.49 years. The average age of the <5 year 
survival group was 61 years whereas the average age of the >15 year survival group was 
50.5 years. Upon diagnosis, patients underwent either watchful waiting, single 
chemotherapy or radiotherapy. No clinical information could be gained on the reactive 
lymph node group except for their absence of a lymphoma diagnosis. 
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  Patient 
No. 
Sex Age FLIPI Score Initial 
management 
Overall survival 
(years)   
<5 year 
survival 
29 F 54 3-High Observation 1.38  
30 F 31 
2-
Intermediate Observation 2.60  
31 M 72 1-Low Observation 0.80  
32 F 80 n/a Observation 3.70  
33 M 73 3-High n/a 0.43  
34 M 56 n/a Observation 3.62  
35 F n/a 3-High 
Single 
chemotherapy 0.88  
>15 year 
survival 
36 F 53 1-Low Radiotherapy 15.27  
37 F 51 1-Low n/a 25.19  
38 M 37 1-Low 
Single 
chemotherapy 30.54  
39 M 47 1-Low n/a 25.60  
40 M 62 
2-
Intermediate Observation 27.35  
41 M 63 
2-
Intermediate n/a 16.25  
42 M 40 3-High 
Single 
chemotherapy 19.01  
43 F 39 1-Low Radiotherapy 22.55  
44 F 63 3-High n/a 20.68  
Table 4.1: Clinical information regarding extreme survival patients. 
 
To determine N-gly motif status within our cohort, IGHV amplification and heteroduplex 
analysis were performed on cores. In 48.5% of cases, I was unable to successfully amplify 
the IGHV gene. 100ng of genomic DNA from these cases was run on a 1.8% agarose gel 
at 100V to evaluate DNA integrity (Figure 4.1). The lack of distinctive heavy bands and 
presence of smears was indicative of poor quality, fragmented DNA. To determine 
whether fragments were similar in size to the IGHV product, the housekeeping gene 
GAPDH and GATA2 were utilised as controls, as they are 200bp and 440bp in length, 
respectively. Whilst the majority of samples were able to amplify GADPH, GATA2 was 
not amplified in any cases (Figure 4.1), suggesting the FFPE derived DNA fragments were 
too short to successfully amplify IGHV.  
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Figure 4.1: Representative agarose gels highlighting DNA integrity from two extreme FFPE samples. Left; 
smear of DNA is indicative of poor quality DNA extracted from two FFPE cases. Middle; DNA extracted 
from two tonsil biopsies was compared with DNA extracted from FFPE. IGHV was successfully amplified 
in tonsil samples whereas the two FFPE failed amplification. Successful amplification of GAPDH (200bp) in 
both samples is indicative of intact DNA of a certain fragment size. Right; amplification of GATA2, which 
is a 440bp long product was unsuccessful in patient 36, indicative of DNA fragments being <440bp long. 
This observation was reproduced in all other samples which failed IGHV amplification. 
 
Despite this, the IGHV in a number of cases from each group was successfully amplified 
(Table 4.2). Reactive cases were all N-gly motif negative, keeping in line with the low 
occurrence seen in normal somatically mutated B cells (~9%) (Alcoceba et al., 2012). The 
extreme survival groups were all motif positive.  
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Table 4.2: N-gly status in the IGHV of samples undergoing multiplex immunohistochemistry. n/a 
indicates cases that failed IGHV amplification. 
 
4.4.2 Distribution of immune cells in FL lymph node 
 
Three markers were used to identify three distinct cell types. CD21 is a marker of FDCs, 
CD68 is a pan macrophage marker and CD163+ is widely seen as a phenotypic marker of 
M2 macrophages. Usually M2 macrophages are both CD68+ and CD163+, however our 
analysis revealed that a large population of CD163+ cells were not also positive for CD68. 
Therefore CD68+CD163+ cells were treated as distinct from CD163+ cells, which were 
defined as M2 macrophages. Cells which were absent for all three markers but positive 
for MR or DC-SIGN were labelled ‘CD68-CD163CD21-’. The numbers of each cell type 
were quantified in both the GC and interfollicular regions (termed ‘tissue’ in the graphs), 
with actual numbers given in supplementary Table 1.7.   
Patient No. N-gly motif Region 
A no site
B no site
C no site
D n/a
E no site
F n/a
G no site
H no site
I no site
29 NIT CDR3
30 n/a
31 NMT CDR1
32 n/a
33 NFS CDR2
34 n/a
35 n/a
36 n/a
37 NNT CDR2
38 n/a
39 NMS CDR2
40 NFS CDR2
41 n/a
42 NFS CDR3
43 n/a
44 n/a
45 no site
46 n/a
47 n/a
48 no site
49 n/a
50 n/a
51 no site
52 n/a
Reactive
<5yr survival group
>15yr survival group
PTFL
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CD21+ cells within the GC were the predominant cell type in the reactive and extreme 
FL groups. The number of CD21+ cells was significantly lower in the tissue for each group, 
supporting CD21+ as a robust follicular dendritic cell marker. This was further evidenced 
by the morphology of CD21+ cells that produced a classical meshwork pattern (Figure 
4.2).   
 
 
Figure 4.2: Meshwork pattern of follicular dendritic cells identified by CD21 marker in patient 32. Scalebar 
(top-left) represents a distance of 100μm. Magnification: x19.59. 
  
GC derived CD21+ cells made up 32.01% of the overall cell population in the reactive 
group (Figure 4.3).  GC CD21+ cells of the <5 year and >15 year cases were in higher 
numbers, making up 46.6% and 34.7% of the cell population, respectively. The number 
of CD68+ in the GC was lowest in the reactive group, making up 0.15% of the overall cell 
population. <5 year and >15 year groups had comparatively higher CD68+ numbers of 
1.4% and 1.77%, respectively. The interfollicular region CD68+ count was highest in the 
<5 year group. In the GC, the extreme survival groups both had a greater proportion of 
CD163+ cells compared to the reactive, in contrast to their interfollicular counterparts, 
in which all three groups had similar cell counts. CD68+CD163+ cell numbers were 
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slightly raised in the interfollicular regions compared to the GC in all three groups. The 
reactive group had an increased number of CD68+CD163+ cells in the interfollicular 
regions compared to the FL groups.  
The CD163-CD68-CD21- population within the interfollicular region was the 
predominant cell type in the reactive and extreme FL groups. This cell group made up 
31.9%, 13.4% and 23.5% of the total cell population in the reactive, <5 year and >15 year 
survival groups, respectively. The reactive LN group had a significantly higher number of 
these cells compared to the <5 year survival group (p-0.05), with a similar trend 
observed between the reactive and >15 year survival group. 
 
 
Figure 4.3: Distribution of cell types in GC and interfollicular regions across all three groups. The visiopharm 
software identified positive cells for each marker through staining intensity. The number of positive cells 
for each marker was divided by the total number of cells identified to give the % values. Total numbers 
are shown in supplementary Table 1.7. Reactive LN (n=9), < 5 year survival (n=7), > 15 year survival (n=9). 
* p-0.05. 
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4.4.3 Mean intensity of DC-SIGN and MR  
 
To ensure DC-SIGN and MR staining were specific, I checked by eye the location and 
distribution of DC-SIGN+ and MR+ cells throughout samples. In FL samples, both stains 
had a similar distribution pattern within the perifollicular zone and sinusoid, matching 
what has been reported by Amin et al and Linley et al in frozen tissue sections (Linley et 
al., 2015, Amin et al., 2015) (Figure 4.4). 
 
 
Figure 4.4: Specific DC-SIGN and MR staining in patient 38. As reported in literature, positive cells were 
mostly located to the perifollicular zone. Magnification of DC-SIGN stain: x6.03. Magnification of MR 
stain: x15. 
 
DC-SIGN and MR staining was assessed for each cell population within each group by 
calculating mean intensity scores. This was to determine whether DC-SIGN and MR 
staining differed between specific cell populations (Figure 4.5). DC-SIGN staining was 
lower than MR staining in both GC and interfollicular regions for all groups. The mean 
DC-SIGN intensity in GC derived CD21+ cells was significantly higher in the reactive LN 
group compared to the >15 year survival group (p-0.01). <5 year survival also had a lower 
DC-SIGN intensity compared to the reactive LN group, but without achieving statistical 
significance. Differences were also seen between the reactive LN group and the FL 
groups for GC located CD163+ cells and CD68+CD163+ cells, in which the reactive LN 
group had significantly higher DC-SIGN staining. In contrast, no difference in mean MR 
intensity was seen in any GC located cell types. Similarly to the GC, DC-SIGN staining of 
the interfollicular region was greater in the reactive group CD68+ population compared 
to the >15 year survival group (p-0.05), with similar trends seen for the <5 year survival 
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group. DC-SIGN staining was also greater in the CD163+ population of the reactive group 
compared to <5 year (p-0.01) and >15 year (p-0.001) survival groups. MR staining was 
similar across groups and cell types, excluding CD163+ cells, in which the reactive LN 
staining was significantly greater than the <5 year FL group (p-0.05) and >15 year FL 
group (p-0.001). This is in contrast to DC-SIGN staining in which there are several 
significant distinctions between the reactive LN and FL groups (described above).  
 
 
Figure 4.5: Mean intensity of DC-SIGN and MR across cell types and disease groups. For each cell within a 
cell type group, a DC-SIGN and MR intensity value was given. The mean intensity value for all cells within a 
cell type group was calculated and plotted.  
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4.4.4 DC-SIGN and MR markers in GC-located cell populations 
 
Individual cells within the GC were assessed for DC-SIGN and MR positivity by comparing 
their individual intensity values to the median DC-SIGN and MR intensities calculated 
across all cell types. This was done on an individual case basis to determine inter-patient 
heterogeneity. Cells with intensity greater than the median value were termed positive 
whereas cells with intensity lower than the median value were termed negative. This 
was performed in Excel (Microsoft) using the COUNTIF function. The results for CD21, 
CD68 and CD163 positive cells in the individual cases can be seen in Figure 4.6. 
CD68+CD163+ and CD68-CD163-CD21- were omitted from analysis due to these cell 
types not being identified in some patients. From Figure 4.6, we can observe the 
heterogeneity of DC-SIGN and MR expression across different cell types, along with 
intra-group heterogeneity of expression.   
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Figure 4.6: Distribution of immune cells with DC-SIGN and MR positive and negative phenotypes within 
individual cases. Top panel: % of CD21+ cells across groups. Middle panel: % of CD68+ cells across groups. 
Bottom panel: % of CD163+ cells across groups. Proportion of double positive (DC-SIGN+MR+) cells are 
represented in black, proportion of single DC-SIGN positive cells are represented in brown                                         
(DC-SIGN+MR-), proportion of single MR positive cell are represented in blue (DC-SIGN-MR+) and the 
proportion of double negative (DC-SIGN-MR-) are represented in red. These bar charts highlight inter and 
intra-group patient heterogeneity.  
 
I then compared whether there was any distinction between DC-SIGN and MR 
expression within cell populations of different groups (Figure 4.7). A larger proportion 
of CD21+ cells in the <5 year survival were double positive compared to the reactive 
group (p-0.01). This was also the case for DC-SIGN expressing CD21+ cells. The double 
negative population was significantly lower in the <5 year group compared to the 
reactive group.  The phenotype of CD21+ cells in the >15 year also showed a similar 
trend to that of the <5 year group but to a lesser degree. For MR positive cells, the FL 
groups all had greater proportions compared to the reactive group. 
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Figure 4.7: % of GC located cell types expressing DC-SIGN and MR positive and negative phenotypes across 
disease groups. This figure is a re-representation of the data in Figure 4.6, with the mean values for each 
group plotted. * p-0.05, **p-0.01. 
 
For the FL groups, the double positive phenotype made up the largest proportion of 
CD68+ cells whereas for the reactive group, this phenotype was the least represented 
phenotype, in contrast to its tissue counterpart. Indeed there was a significant 
difference between the reactive LN and <5 year survival group (p-0.01) with similar 
trends observed for the other FL groups. Similarly, to CD21+ cells, the double negative 
population was lower in the FL groups compared to the reactive LN group in which this 
cell population represented the predominant phenotype of CD68+ cells.  
For the CD163+ population, the FL groups had a greater proportion of double positive 
cells compared to the reactive, with the biggest proportions seen in the <5 year group. 
The DC-SIGN population was greatest in the reactive group compared to the FL groups. 
177 
 
For the double negative group, the reactive and >15 year groups had similar proportions 
whereas the <5 year group was lower. However the FL groups having a greater 
proportion of MR+ cells, with the difference most obvious between the reactive and >15 
year survival groups (p-0.05). 
 
4.4.5 DC-SIGN and MR markers in interfollicular-located cell populations 
 
DC-SIGN and MR positivity was then assessed in cell populations within the 
interfollicular region. Figure 4.8 shows the % of different cell types in the tissue which 
were either double positive for DC-SIGN and MR, single positive for either DC-SIGN or 
MR, or negative for both markers. Similarly to the GC, the predominant phenotype of 
CD21+ cells across groups was double negative. For CD21+ cells, a greater proportion of 
cells were double negative in the reactive LN group compared to the three FL groups, in 
contrast to the % of MR+ cells which was lower in the reactive LN group compared to 
the FL groups (Figure 4.8). % of double positive cells was higher in the FL groups, with 
similar trends seen for DC-SIGN positive cells, although findings were not significant. The 
double negative was the dominant phenotype of CD21+ cells across groups in the tissue. 
This is in contrast to the CD68+ population, in which the dominant phenotype was 
double positive followed by MR+ cells. DC-SIGN+ and double negative phenotypes made 
up the lowest % of CD68+ cells. Compared to CD68+ cells in the GC, there was a lower 
proportion of DC-SIGN positive and double negative GC located CD68+ cells across all 
groups.  
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Figure 4.8: % of interfollicular located cell types expressing DC-SIGN and MR positive and negative 
phenotypes across disease groups. The mean values for each group is plotted. * p-0.05, *** p-0.001. 
 
For CD163+ cells, the double positive phenotype was dominant across groups, with 
reactive LN having relatively high cell counts compared to <5 year and >15 year survival 
groups. Reactive LN group had a significantly lower expression of double negative 
CD163+ cells compared to the two extreme survival groups (p-0.05). Similar to the trend 
seen in the GC counterpart, the DC-SIGN population was greatest in the reactive group 
compared to the FL groups 
The proportion of MR+ cells was significantly higher in the >15 year group (p-0.001) with 
the 5 year survival also showing an upward trend (Figure 4.8). 
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4.5 Discussion 
 
To our knowledge, this is the first study that has utilised a unique and in-depth 
sequential multiplex procedure to comprehensively analyse the FL microenvironment of 
extreme survival cases to determine prognostic impact. So far, traditional multiplex IHC 
studies regarding the assessment of the tumour landscape have been limited by the 
restricted number of antigens assessed within a section due to antibody cross reactivity 
(detailed in section 2.26) along with the inability to identify antigen co-localisation. 
Through a stripping and reprobing method on single FFPE whole sections, we have been 
able to; 1) assess the number and localisation of several immune cells within the FL LN, 
2) determine and quantify immune cells expressing DC-SIGN and MR, and 3) assess 
microenvironment  distinctions between healthy and disease states as well as the  
differences within extreme FL survival groups.  
Reactive LNs were used as a control group as they represent the healthy counterparts 
of neoplastic follicles. Furthermore, as normal somatically mutated B cells rarely express 
N-gly motifs in their IGHV, they offered the benefit of determining whether any 
differences observed regarding DC-SIGN and MR expression between healthy and 
disease tissue could be correlated to N-gly status. To determine N-gly status, we 
extracted genomic DNA derived from the FFPE samples and amplified the IGHV gene. In 
44% of cases, we were unable to successfully amplify the gene. This was likely due to 
the quality of the DNA as indicated in Figure 4.1. DNA extraction from FFPE is associated 
with a number of challenges, mainly due to formalin fixation that results in cross-links 
between proteins and DNA. This causes the DNA to be significantly degraded and 
fragmented. The degree of fragmentation is also influenced by the age of the sample 
and as the majority of our extreme survival group biopsies were taken during the 1970s 
and 1980s, this may be a valid reason for the PCR failure (Figure 4.1). Despite this, the 
IGHV was successfully amplified in a number of cases across the groups. The reactive LN 
cases were motif negative whilst our extreme survival groups were positive, supporting 
previous findings (McCann et al., 2008, Alcoceba et al., 2012).  
Following multiple IHC and identification of different cell types, I assessed the 
distribution of cell types across the GC and interfollicular regions. Usually M2 
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macrophages are both CD68+ and CD163+, however our analysis revealed that a large 
population of CD163+ cells were not positive for CD68. This could be due to a weaker 
staining by CD68, which has been noted in other studies (Kridel et al., 2015b, Tan et al., 
2012, Klein et al., 2014). Therefore CD68+CD163+ cells were treated as distinct from 
CD163+ cells, which were considered M2 macrophages. 
FDCs (CD21+) made up the largest proportion of cells within the GC across groups, with 
the <5 year group having the highest number, followed by the >15 year group. FDC 
associated genes were shown to correlate with a poor outcome by Dave et al, which 
supports our findings (Dave et al., 2004).  In the interfollicular region, M2 macrophages 
made up the largest proportion of cells for the FL groups, with similar counts seen for 
the reactive LN.  However, when we compared M2 macrophages in the GC, the FL groups 
had a higher number compared to the reactive group, indicative of tumour-associated 
macrophages (TAMs). The prognostic implications of the CD163 marker has been 
explored by Kridel et al. Analysis of two studies revealed that CD163 was predictive of 
outcome in FL but was dependent on the type of treatment patients had received (Kridel 
et al., 2015b). PRIMA trial patients treated with rituximab, cyclophosphamide, 
doxorubicin, vincristine, and prednisone, and randomized to rituximab maintenance or 
observation, had favourable outcome with high CD163+ counts. In contrast, high 
CD163+ counts in patients treated with first-line systemic treatment including rituximab, 
cyclophosphamide, vincristine, and prednisone were predicted to have an adverse 
outcome. No studies have so far looked at CD163 count in diagnostic samples before 
treatment and therefore our data gives a unique insight into the ‘natural’ 
microenvironmental landscape and how this translates to OS. The >15 year survival 
group had a higher CD163+ count in the GC compared to the <5 year, suggesting a 
favourable outcome of higher CD163+ counts in disease, however the difference in 
count between the two was not significant. 
The mean intensity of DC-SIGN and MR was assessed between groups. This was first 
assessed across all cell types. In all groups, MR intensity was significantly higher than 
DC-SIGN intensity. This could be indicative of a greater expression of MR compared to 
DC-SIGN within the lymph node or a comparatively weaker signal of DC-SIGN expression 
due to the antibody. MR intensities were similar between groups except for the 
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interfollicular located M2 population, in which the mean intensity for the reactive group 
was significantly higher than the >15 year group. For DC-SIGN, there was intergroup 
variability in GC located follicular dendritic cells, M2 macrophages and CD68+CD163+ 
cell populations in which the reactive LN group had a significantly higher mean intensity.  
This was also true for DC-SIGN staining of the macrophage and M2 populations in the 
tissue, suggestive of greater DC-SIGN expression in the reactive group compared to the 
disease groups. However, the extreme survival tissue blocks were considerably older 
than the reactive LN blocks, which could have influenced staining intensity. Indeed Grillo 
et al found that membrane antigens presented reduced staining intensity in older blocks 
(Grillo et al., 2017). Therefore, it was important to determine on a case-specific basis, 
the degree of staining of DC-SIGN and MR to determine the number of cells that were 
either DC-SIGN or MR positive, double positive or double negative. This was achieved by 
calculating the median DC-SIGN and MR intensity values and grouping individual cells 
into either positive or negative categories based on whether they exceeded or fell below 
the median values.  
DC-SIGN and MR were expressed on a proportion of macrophages, M2 macrophages 
and FDCs across groups, which is an expected finding given their normal expression on 
these cells types. They have a variety of roles as pattern recognition receptors, including 
phagocytosis/antigen presentation of pathogens and mediation of endogenous cell-cell 
interaction during the innate immune response (Dambuza and Brown, 2015, 
Geijtenbeek and Gringhuis, 2009). DC-SIGN+MR+ was the predominant phenotype of 
both macrophages and M2 macrophages of the interfollicular region in all groups.  
In the GC, the phenotype of macrophages and M2 macrophages was more evenly 
distributed. However, the <5 year survival group had a significantly greater proportion 
of double positive macrophages compared to the reactive LN group (p-0.01). The >15 
year survival group also had a higher proportion of double positive macrophages 
compared to the reactive group, but did not reach significance. A similar trend for both 
FL groups was seen in the other cell types, regarding higher numbers of double positive 
cells compared to the reactive group.  In the FDC compartment, <5 year survival group 
had a significantly higher number of double positive cells (p-0.01). These differences 
between disease and reactive groups were not seen in the interfollicular region cell 
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counterparts, indicative of skewing of GC-specific macrophages, M2 macrophages and 
FDCs to display both DC-SIGN and MR. These higher numbers inversely correlated to 
fewer double negative cells compared to the reactive LN group, with a significant 
difference seen with the <5 year survival group (p-0.01), suggesting a skewing of 
immune cells to the other three phenotypes in disease.  
M2 macrophages derived from the >15 year survival group had significantly higher 
numbers of the MR positive phenotype compared to the reactive group in both the GC 
(p-0.05) and interfollicular region (p-0.001), with the <5 year survival group showing a 
similar trend without significance. The higher count of MR positive M2 cells in the 
interfollicular region may indicate that these calls can exert pathological effects without 
being in direct contact with tumour cells. 
Compared to the reactive group, the extreme survival groups in general shared similar 
trends concerning the DC-SIGN and MR phenotype of immune cells. Between the two 
groups, no significant difference was reached. However, this was a small cohort and 
therefore analysis of more patients is needed to validate DC-SIGN or MR expression as 
predictive markers of outcome. Studies by Dave et al and others have revealed the 
impact of immune cells in patient outcome, with CD68+ macrophages predictive of a 
worse outcome (Dave et al., 2004, Farinha et al., 2005, Byers et al., 2008). CD163+ M2 
macrophages have also been associated with a poorer clinical outcome, however Kridel 
et al demonstrated that this prediction is heavily impacted by treatment (Kridel et al., 
2015b). Therefore going forward, we would ideally perform analysis on extreme survival 
cases that have all undergone the same therapy, to ensure intrinsic biological 
heterogeneity of the disease is the cause of distinctive clinical outcomes and is not down 
to treatment heterogeneity. It would also prove interesting to explore lectin expression 
in histologically and clinically distinct FL subtypes, such as PTFL. These patients usually 
presenting with localised stage one lymphadenopathy which has a good response rate 
to local excision or minimal chemotherapy (Araf and Fitzgibbon, 2016). Compared to 
adult FL, it is genetically ‘light’, with fewer recurrent mutations and lack of epigenetic 
mutations, indicative of a distinct pathogenesis pathway (Louissaint et al., 2016). 
Interestingly a group recently observed that a further distinction between adult FL and 
PTFL was a lack of N-gly motifs in the IGHV gene (unpublished data), suggesting that 
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PTFL does not utilise the mannose-lectin interaction. As we have access to PTFL sections 
from our collaborators in Germany, Tubingen, this will form part of our future 
investigation. 
The distinctions between reactive and FL LNs suggests that presence of N-gly motifs in 
the IGHV are associated with a skewing of immune cells to express lectins that are 
implicated to be involved in the mannose-lectin interaction. Indeed, the majority of 
increased DC-SIGN and MR cells are seen in the GC compartment, where FL cells reside. 
Therefore, we can infer that through this interaction, lymphoma cells can remodel their 
microenvironment by influencing the lectin-expressing cells. DC-SIGN and MR 
interaction with other cancer derived glycoproteins has been shown to contribute to a 
pro-tumour microenvironment (as discussed at the beginning of this chapter), indicating 
the feasibility of this model. A greater proportion of lectin-expressing cells may ensure 
sustained BCR activation and survival of the tumour cell within the GC.  
This study has shown an in-depth characterisation of the FL microenvironment and has 
revealed several significant differences between the expression of DC-SIGN and MR on 
immune cells within disease and healthy reactive LNs. These preliminary findings 
support further in-depth analysis using greater cohort numbers. Whilst we have 
demonstrated the promise of sequential multiplex IHC in analysing the 
microenvironment at a single cell level, mass cytometry imaging is an exciting new 
method of contextualising the landscape. Up to 37 antigens can be visualised at once, 
giving unprecedented insight into the microenvironment. This will be advantageous in 
exploring the precise spatial arrangement of lectin-expressing cells in the interfollicular 
and GC regions and their interaction with FL cells and immune cells, including T cells to 
provide a comprehensive view of the mannose-lectin interaction in situ. 
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Chapter 5: DISCUSSION 
 
 
FL is the most prevalent indolent NHL in western countries. The introduction of the anti-
CD20 monoclonal antibody rituximab revolutionised FL treatment by increasing 
response rates and significantly improving PFS and OS (Hiddemann et al., 2005, Marcus 
et al., 2005). Patients now have a median survival of 15 years (Tan et al., 2013, Czuczman 
et al., 2004). Despite this significant breakthrough, and patients responding well to initial 
treatment, the disease remains incurable with patients undergoing frequent relapses 
with each remission free period becoming progressively shorter before patients become 
refractory to treatment or transform to an aggressive lymphoma. The clinical burden 
due to the protracted relapse-remitting course is significant and therefore better 
understanding of key pathogenic pathways is required to develop targeted therapies.  
A significant challenge to deciphering this is the heterogeneity of FL disease, both 
clinically and biologically.  The majority of patients achieve a high response rate to first-
line therapy and usually follow an indolent disease course. However, in up to 25% of 
patients, progression occurs within 2 years of treatment or the disease transforms to a 
high-grade lymphoma (Casulo et al., 2015, Casulo, 2016). For these patients, prognostic 
outlook is relatively very poor and predicting which patients would fall into this high-risk 
group remains an ongoing area of research (Huet et al., 2018b) as it would identify 
patients most likely to benefit from clinical trials. The biological heterogeneity of FL has 
been exemplified by NGS that has revealed a complex and variable genetic landscape. 
Recurrent mutations in specific genes have been identified, indicating biological 
pathways perturbed in disease, including epigenetic regulation (Okosun et al., 2014, Araf 
et al., 2016). However, these mutations are not found within all patients and vary in clonal 
dominance, not just between patients but also in spatially separated biopsies from 
individual cases (Araf et al., 2018). Targeting a mutation in a clonal population may, 
therefore, enable a minor subclone to gain dominance, leading to relapse. This 
heterogeneity of subclones and their genetics compromises the approach of precision 
medicine. Targeting early events in pathogenesis which are conserved clonally would 
likely have the most beneficial impact on sustained remission, which is why 
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characterising events of the putative CPC compartment is an important new area of 
research in FL. Genetic changes in the CPC are being investigated and characterised 
(Okosun et al., 2014), yet CPC-microenvironment interactions remain unexplored 
despite our extensive knowledge on the importance of microenvironment-tumour cell 
interactions in pathogenesis.  
We implemented a NGS approach to identify and catalogue N-gly motifs in the IGHV of 
unique subclones that contribute to the heterogeneous clonal repertoire of disease. A 
longitudinal profiling strategy using paired FL and tFL samples enabled the delineation 
of the clonal IGHV repertoire throughout a patient’s disease course, giving insight into 
the importance of motifs during disease evolution, expanding our views on the ontogeny 
and pathogenesis of FL. The inclusion of a clinically and biologically variable patient 
cohort ensured findings were representative of the heterogeneous disease. A striking 
finding was that >97% of subclones within a disease event shared the same motif site as 
that identified in the major clone, indicating N-gly motifs as a feature of the clonal 
repertoire. These motif sites were conserved in the clonal population of successive 
disease events, including relapse and transformation, indicating that motifs were 
acquired at an early time point of disease evolution in an ancestral cell population from 
which disease events arise from, the CPC. This is an important finding, as the CPC is 
believed to be currently resistant to therapy as highlighted by the high relapse rates 
seen for patients, indicating the therapeutic promise of targeting specific characteristics 
within this compartment. We’ve shown motifs to be important in both ‘rich’ and ‘sparse’ 
evolutionary models, suggesting that targeting of these motifs may have universal 
benefit to all FL patients, regardless of genetic heterogeneity amongst tumour clones. 
These findings were not restricted to our own experimental data, but also IGHV 
sequencing data generated from different platforms and research institutes, indicating 
the validity and reproducibility of our data. 
The early acquirement of N-gly motifs has previously been demonstrated in study of 
ISFN cells, believed to represent malignant precursor cells (Kosmidis et al., 2017, 
Mamessier et al., 2015). Having a functional mannose-lectin interaction at this early 
stage in disease development may explain how precursor cells are able to survive in the 
hostile GC without the need for high-affinity BCRs, enabling accumulation of genetic hits 
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required for malignant transformation. Whether or not motifs are functional within tFL 
disease is questionable. Following transformation, the disease changes dramatically and 
becomes aggressive with acquirement of new mutations such as MYC. Therefore 
microenvironmental interactions before transformation may become obsolete and 
therefore the presence of motifs within subclones specific to this disease event may, in 
fact, be an ‘imprint’ of the ancestral cell from which they’re derived. However, the 
striking finding regarding the lack of motif negative subclones passed onto successive 
disease events, including transformed events, is a strong argument that subclones have 
an ongoing reliance on motif presentation as the disease progresses. The fate of 
subclones is determined by N-gly motif status, regardless of the genetic profile of the 
clone, highlighting the importance of microenvironmental interactions in disease 
progression. Targeting motifs or the mannose-lectin interaction may lead to significant 
disruption of the microenvironment and tumour cell death. As a feature of the putative 
CPC, therapeutic targeting may also lead to longer remission periods and even cure by 
disrupting the reservoir pool that propagates the disease. Determining the genetic 
profile of these motif negative clones may provide us with insight into the relationship 
between genetics and the microenvironment that determines clone fate during disease 
progression and thereby piece together the profile of progression-associated subclones. 
It could also give an indication into true FL ‘driver’ mutations. ‘Driver’ mutations in this 
context represent critical mutations that are critical for malignant transformation and 
disease progression, in contrast to so-called ‘passenger’ mutations that are assumed to 
be biologically neutral and simply carried along with the drivers (Stratton et al., 2009). 
Examples of driver mutations in other haematological diseases include MYC in Burkitt’s 
lymphoma and BCL-ABL1 in chronic myeloid leukaemia (Koschmieder et al., 2005, 
Schmitz et al., 2014). The t14;18 translocation is considered a ‘driver’ mutation in FL with 
the bcl2 mouse models developing follicular hyperplasia (McDonnell and Korsmeyer, 
1991, Egle et al., 2004). However, the inability of these models to faithfully emulate the 
exact indolent nature of the disease and the presence of t14;18 positive cells in healthy 
people (Limpens et al., 1995, Dolken et al., 1996, Schuler et al., 2009), suggest additional 
‘driver’ mutations are required for malignant transformation.  Okosun et al revealed 
through WGS of paired FL-tFL samples, that CREBBP and KMT2D mutations are likely to 
be early ‘driver’ events due to their clonal dominance across temporal samples and 
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recurrence across patients (Okosun et al., 2014). The ‘driver’ potential of these 
mutations is currently undergoing investigation in transgenic mouse models to 
determine their role in disease initiation. Patients 23-25 were included in this study, with 
both epigenetic genes considered early ‘driver’ events. However, the role of these 
mutations in ‘driving’ disease progression has been challenged by our study. If these 
mutations were considered truly clonal, we would assume each subclone to contain the 
aberrations. The disappearance of motif negative subclones in subsequent samples, 
with new motif negative subclones maintaining an extremely low count in progression 
events, implies that subclone survival is more weighted by microenvironmental 
interactions rather than these ‘driver’ mutations. Alternatively, it could be the result of 
motif negative subclones being outcompeted by motif positive subclones due to the 
advantages of additional microenvironmental support, mediated by the mannose-lectin 
interaction. However, we also cannot rule out that these motif negative clones have a 
different genetic profile to motif positive subclones in which driver mutations are 
absent. As 10% of FL cases are negative for N-gly motifs, it would be highly valuable to 
determine and compare their genetic profiles with motif positive cases to identify true 
‘driver’ mutations that seemingly make the putative mannose-lectin interaction 
redundant for disease initiation and progression. The collaboration between two 
distinct yet interconnected disciplines of FL research could lead to a comprehensive and 
well-rounded understanding of the intricate pathobiology of FL.  
We next utilised a novel multiplex, sequential phenotyping of FFPE sections derived 
from extreme survival cases of FL (Ball et al., 2017). We were able to look at six different 
immune cell markers to determine the expression of DC-SIGN and MR on immune cells 
of the tumour microenvironment and whether this correlated to prognostic outcome. 
To our knowledge, this is the first study of its kind giving novel insight and 
characterisation of the microenvironment at unrivalled depth due to a unique stripping 
and re-probing protocol. We observed a significant deviation in the tumour 
microenvironment, characterised by a higher proportion of follicular dendritic cells, 
macrophages and M2 macrophages displaying a MR+ and DC-SIGN+MR+ phenotype 
compared to the immune cells of reactive LNs, suggesting a pathogenic-derived cause 
to increased lectin expression within these cells. As reactive LNs were motif negative, 
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this increase could be attributed to the mannose-lectin interaction that may result in 
polarisation of interacting immune cells to express these phenotypes. Although there 
were no significant differences between the extreme survival groups, this data provides 
the rationale for conducting analysis in larger cohorts to validate the prognostic 
implications of DC-SIGN and MR expression and provide insight into whether targeting 
such immune changes can divert the FL microenvironment from one that is tumour 
supportive to one that is tumour suppressive. It also warrants further investigation into 
the mannose-lectin interaction in situ, which we will explore through high-throughput 
multiplexing platforms, including mass cytometry imaging.  
The knowledge that FL is a significantly heterogeneous disease warrants research into 
finding key pathogenic events that are universally perturbed in all patients to ensure 
maximal and widespread benefit. This project has contributed to this aim by 
determining N-gly motifs in the IGHV are an early event in disease evolution of the 
majority of FL patients irrespective of the genetic and biological heterogeneity of 
disease. This finding supports the hypothesis of the mannose-lectin interaction 
operating a critical survival-signalling pathway in FL cells and provides strong rationale 
for future investigations into translating this finding into improving the outcome for FL 
patients. 
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Supplementary Tables 
 
Table 1.1: Incidence of novel N-glycosylation sites in extension cohort of diagnostic FL samples.  
 
 
 
 
 
Sample ID V gene Homology (%) No. of sites Region aa Motif 
A V3-11 89.8 1 CDR2 NIS 
B V3-48 87.3 1 CDR2 NIS 
C V3-23 90.1 1 CDR1 NIT 
D V3-15 87 2 CDR1, CDR3 NFS, NIT 
E V3-15 86.7 1 CDR2 NIS 
F V3-11 82.11 1 CDR2 NIS 
G V3-11 89.5 1 CDR3 NFS 
H V3-15 92.5 1 CDR2 NKS 
I V3-48 87 1 CDR2 NMS 
J V4-59 85.5 1 CDR2 NIS 
K V3-48 89 1 CDR1 NIS 
L V3-30 89.3 1 CDR2 NVS 
M V3-23 88.2 1 CDR3 NIS 
N V3-30 89.7 1 CDR2 NKS 
O V3-11 90 1 CDR2 NIT 
P V3-23 90.2 2 CDR1, CDR2 NFS, 
NVS 
Q V3-11 90.7 1 CDR2 NIS 
R V3-23 84.8 2 CDR2, FR3 NST, NIS 
S V3-23 87.6 2 CDR1, FR3 NFS, NIS 
T V3-11 88.9 1 CDR3 NIS 
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Table 1.2: Summary of NGS data generated for each patient sample.  
 
 
 
Table 1.3: Summary of merged reads for each patient sample. 
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Sample PF Clusters Amplicon Size Estimated Coverage  
Patient 24- 1
st
 
relapse 
1,320,495 300 2,200,825 
Patient 23-
Diagnosis 1,319,287 300 2,198,812 
Patient 25-2
nd
 
relapse 
1,188,214 300 1,980,357 
Patient 25-3
rd
 
relapse 944,471 300 1,574,118 
Patient 25-
Transformation 1,546,380 300 2,577,300 
Patient 24-3
rd
 
relapse 929,244 300 1,548,740 
Patient 24-
Transformation 1,224,512 300 2,040,853 
Patient 23-
Transformation 1,365,431 300 2,275,718 
Table 1.4: Estimated coverage for each sample. Values are based on the assumption of an 
amplicon size of 300bp. 
 
 
Table 1.5: Total count numbers for disease event for Patients 23-25. High % of counts containing 
motifs reflect how they are a significant feature of the tumour bulk.  * For Patient 24, the values 
take into account only clones where all four sites are present or clones where ≥1 motif are absent. 
Patient 26, 27 and 28 were excluded due to lack of available information regarding count numbers. 
 
 
 
 
 
Patient Disease 
% of tumour related 
counts with all N-gly motif 
sites present 
% of tumour related counts 
without all N-gly motif sites 
present 
23 
Diagnosis 99.32 0.68 
Transformation 99.42 0.58 
24 
1st relapse 94.7 5.3* 
3rd relapse 94.8 5.2* 
Transformation 86.7 13.3* 
25 
2nd relapse 99.15 0.85 
3rd relapse 99.01 1 
Transformation 99.3 0.7 
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Shared negative 
clone 
% of total tumour 
count in FL2 
% of total tumour 
count in FL3 
1 0.042152 0.037872 
2 0.040614 0.056808 
3 0.034152 0.067460 
4 0.034152 0.035505 
5 0.031383 0.031955 
6 0.030153 0.056808 
7 0.027999 0.018936 
8 0.027383 0.027221 
9 0.019999 0.036689 
10 0.016615 0.024854 
11 0.013846 0.015386 
12 0.010153 0.021303 
13 0.008307 0.040239 
14 0.008307 0.026037 
15 0.007384 0.020120 
16 0.007077 0.014202 
17 0.006461 0.014202 
18 0.006461 0.023670 
19 0.006154 0.023670 
20 0.004923 0.017753 
Table 1.6: % of total tumour count for the negative shared subclones of Patient 25. 
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Table 1.7: Count numbers for each cell type identified by the Visiopharm software. 
CD21 GC CD21 Tissue CD68+ GC CD68+ Tissue CD163+ GC CD163+ Tissue CD68+ CD163+GC CD68+CD163+Tissue CD68-CD163-CD21- GC CD68-CD163-CD21- Tissue
Patient 1 3022 584 10 77 201 4664 24 2116 888 4262
Patient 2 14729 1392 167 2277 529 7853 242 10316 2477 18217
Patient 3 3778 8078 29 56 211 17868 4 993 340 21181
Patient 4 25335 9852 84 119 135 2722 7 32 1842 17937
Patient 5 37371 709 34 172 709 2358 10 28 3026 31112
Patient 6 7194 718 31 51 1089 6589 46 214 6033 15314
Patient 7 10204 1640 239 496 308 11741 141 1911 2096 16990
Patient 8 26656 1069 109 473 1820 6582 89 2804 4605 15937
Patient 9 3919 202 0 0 294 1251 13 99 215 820
Total 132208 24244 703 3721 5296 61628 576 18513 21522 141770
Patient 1 1489 2201 202 2148 0 201 11 426 132 5052
Patient 2 4153 895 131 617 137 1765 4 193 133 1719
Patient 3 15802 3082 1456 1361 3327 3122 1101 1523 746 1060
Patient 4 37824 388 1134 582 516 7619 171 1563 240 478
Patient 5 22863 3088 26 60 3708 22541 84 425 1461 9448
Patient 6 2507 1284 2 4 2320 1514 0 0 1064 751
Patient 7 33120 2273 4 38 82 305 1 1 369 2591
Total 117758 13211 2955 4810 10090 37067 1372 4131 4145 21099
Patient 1 18338 5463 510 385 4071 7610 82 368 3294 7747
Patient 2 3094 933 84 577 124 2647 71 660 594 7322
Patient 3 3426 72 465 506 161 3689 8 179 1368 4654
Patient 4 65607 159 4736 921 9839 15652 1569 2014 7496 2586
Patient 5 28 0 1165 333 10769 7169 115 29 1321 1687
Patient 6 22767 425 380 281 2452 11046 2 13 1296 9291
Patient 7 10239 1754 93 672 146 396 0 110 953 4518
Patient 8 3132 73 10 1 402 3412 0 0 674 6869
Patient 9 10690 1026 89 58 1223 4051 7 1 1019 3896
Total 137321 9905 7532 3734 29187 55672 1854 3374 18015 48570
Reactive LN
5 yr
15 yr
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Supplementary Figures 
 
 
Figure 1.1: Q-Score distribution of NGS samples (Patients 23-25) after trimming. X-axis, the position 
of sequence. Y-axis, average Q scores. 
 
 
Figure 1.2: Distribution of GC-content in all samples after trimming. X-axis, relative GC-content of 
a sequence in percentage. Y-axis, number of sequences featuring particular GC-percentages 
normalized to the total number of sequences. 
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